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Summary 
 
Various invasive and non-invasive cranial monitoring techniques can be applied 
clinically to describe the extent to which cerebral hemodynamics and subsequently, 
patient outcome, have been impacted following acute brain injury (ABI).  
This Ph.D. thesis examines both prospective and retrospective patient data in both 
neurocritical and general intensive care patients. Thirty neurotrauma patients and forty 
general intensive care patients with neurological complications were prospectively 
monitored after ABI. Retrospective patient data was harvested from a database of 1,023 
traumatic brain injury (TBI) patients with invasive intracranial pressure (ICP), arterial 
blood pressure (ABP), and transcranial Doppler ultrasonography (TCD) recordings. 
Data analysis focused on ICP microsensor accuracy, compensatory reserve, the 
pulsatility of brain signals (ICP and TCD), and cerebral arterial blood volume (CaBV) 
based on TCD. The main results are summarized below: 
I. Intracranial hypertension has a profound negative influence on cerebrovascular 
parameters and patient outcome. 
II. ICP microsensor accuracy is limited, with an average error of approximately ± 
6.0 mm Hg. 
III. ICP weighted with the compensatory reserve better predicts outcome than 
mean ICP alone. 
IV. ICP and TCD pulsatility are functions of mean ICP and cerebral perfusion 
pressure (CPP). 
V. Continuous blood flow forward (CFF) and pulsatile blood flow forward (PFF) 
models can approximate CaBV with derived TCD signals; CFF best models TCD 
pulsatility. 
VI. The pressure reactivity index (PRx) and the pulse amplitude index (PAx) can be 
estimated non-invasively using slow waves of TCD estimated by CaBV with 
similar outcome-predictive power. 
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VII. Multi-parametric TCD-based monitoring of general intensive care patients is 
clinically feasible; the joint estimation of autoregulation, dysautonomia, non-
invasive ICP, and critical closing pressure is possible. 
 
The culmination of these projects should have an impact on current monitoring 
practices in ABI patients, emphasizing the continued validation and refinement of TCD 
methodology in clinical neurosciences. 
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Chapter 1 
 
Working Hypotheses 
 
The preservation of cerebral autoregulation is of critical interest to patients suffering 
from traumatic brain injury (TBI). TBI affects the balanced relationship between 
cerebral pressures and flows, often leading to complications such as intracranial 
hypertension or cerebral ischemia that may prove fatal if left untreated. Non-invasive 
cranial monitoring techniques can be applied clinically to describe the extent to which 
the injury has impacted cerebral hemodynamics and subsequently, patient outcome. 
  Transcranial Doppler ultrasonography (TCD) is considered to be a reliable 
“stethoscope” for the brain that is uniquely suitable to monitor cerebral hemodynamics 
in both acute vascular conditions and neurological disorders. Although TCD data is 
classically associated with the estimation of cerebral blood flow velocity, it can be 
further analyzed and adapted with the aid of dedicated neuromonitoring software to 
provide additional derived parameters that are of immediate clinical value in the 
prediction of patient mortality. Among these, five groups of parameters are of particular 
interest within the scope of this Ph.D. thesis: 1) cerebral autoregulation as described by 
the pressure reactivity index and the mean flow index, PRx and Mx, respectively; 2) non-
invasive estimators of intracranial pressure (ICP) and cerebral perfusion pressure (CPP); 
3) cerebral arterial blood volume (CaBV); 4) spectral pulsatility index (sPI); and 5) 
critical closing pressure (CrCP), wall tension (WT), and the diastolic closing margin 
(DCM).  
Each of the above parameters expresses the likelihood of mortality following TBI, 
but their outcome-predictive power increases exponentially when used in conjunction 
to create a more complete cerebral hemodynamic profile for each patient. The body of 
this Ph.D. thesis applies a continuous multi-parametric approach to TCD monitoring in 
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neurocritical care, with a focus on the continued validation and refinement of this 
methodology in clinical neurosciences.  
The three major aims of this thesis form the backbone of each of the three 
chapters outlining results (Chapters 4-6): 
 
1. Describe the clinical indications of elevated intracranial pressure after 
traumatic brain injury. 
2. Develop and understand new mathematical models that explore pulsatile 
cerebral hemodynamics in terms of cerebrovascular resistance and 
cerebral blood volume in both the time and frequency domains. 
3. Apply non-invasive neuromonitoring techniques such as transcranial 
Doppler ultrasonography to both create alternatives to invasive 
monitoring and expand neuromonitoring principles to broader patient 
populations. 
 
A review of contemporary literature is presented in Chapter 2, followed by an outline of 
the methodologies (Chapter 3) common to each of the seven studies relating to the aims 
of this thesis (Chapters 4-6). The final chapter (Chapter 7) provides a summary of the 
previous results chapters and identifies future directions for the research in this field.  
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1.1.        Clinical Consequences of Elevated ICP  
Intracranial pressure (ICP) monitoring is a crucial informative tool in neurocritical care. 
ICP is a reference pressure for cerebral blood flow (CBF). Intracranial hypertension and 
adequacy of brain blood flow are two main concerns following traumatic brain injury 
(TBI) It is well documented that elevated ICP (>20 mm Hg) after TBI increases the risk 
of poor outcome, independent of low cerebral perfusion pressure (CPP) or the severity 
of primary injury. However, all ICP sensors, irrespective of design, are subject to 
systematic and random measurement inaccuracies that can affect patient care if 
overlooked or disregarded. “Compensatory-reserve-weighted intracranial pressure 
(ICP)”, named “weightedICP” for brevity, is introduced as a variable that may better 
describe changes leading to mortality after TBI over the standard mean ICP displayed 
by traditional sensors.  
 
  Hypotheses  
 
• Elevated ICP affects cerebral autoregulation as assessed by both the 
pressure reactivity (PRx) and mean flow (Mx) indices. Elevated ICP will 
associate with a higher risk of mortality, as it exposes the brain to ischemic 
insults whenever CPP falls. 
• All ICP sensors will be subject to measurement inaccuracies. In theory, 
the sensors with the most “acceptable” long-term measurement errors will 
be the ones incorporated into routine ICP management protocols. 
• “WeightedICP” will be significantly associated with mortality after TBI, 
perhaps more so than mean ICP. This variable will be sensitive to both the 
rising absolute ICP and to the critical deterioration of pressure-volume 
compensation.  
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1.2.  Modeling Pulsatile Cerebral Hemodynamics   
The pulsatility index (PI) is suggested to describe various hemodynamic mechanisms, 
such as ICP and CPP modulation, as a function of cerebrovascular resistance. The 
determination of relationships between the TCD-based spectral pulsatility index (sPI) 
and pulse amplitude (AMP) of intracranial pressure in severe TBI patients exhibiting 
extreme physiology will support a previously-proposed model of TCD-based 
pulsatility. Mathematical modeling can further explain the underlying pulsatile 
component of cerebral arterial blood volume (CaBV). Data can be analyzed with either 
the continuous flow forward (CFF, moderately pulsatile blood inflow and steady blood 
outflow) or pulsatile flow forward through regulating arterioles (PFF, both blood inflow 
and outflow are pulsatile) modeling approaches to estimate the pulse component of 
CaBV. This way, clinical monitoring of changes in cerebral compartmental compliances 
becomes possible.  
 
  Hypotheses  
 
• sPI will closely approximate both ICP and AMP, and will also signal to 
clinicians when a patient’s CPP is approaching the lower limit of 
autoregulation. The sPI equation can be applied with confidence to 
extreme physiological conditions such as ICP plateau waves and unstable 
mean arterial pressure (MAP). 
• TCD-based estimation of CaBV pulsations will appear feasible when 
employing the CFF modeling approach. Optimal CaBV estimation will 
properly outline the blood volume component of ICP, which may allow 
the implementation of targeted therapies for particular intracranial 
components contributing to elevated ICP. 
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1.3.  Non-Invasive Neuromonitoring Applications 
The advancement of non-invasive approximations of “traditional” invasive estimators of 
cerebral autoregulation (i.e. nPRx and PRx, nICP and ICP, nCPP and CPP, etc.) offers 
the potential to expand continuous neuromonitoring both within and outside of 
neurocritical care. These parameters can be calculated in real time on the basis of non-
invasive TCD waveform analysis to predict patient outcome. TCD can also be utilized 
in conjunction with routine electroencephalography (EEG); joint consideration of 
cerebral electrical and circulatory activity is presumed to provide more thorough insight 
into brain health than isolated monitoring modalities. Multi-modal monitoring can 
potentially detect and track the evolution of secondary complications in a large variety 
of patients.  
 
  Hypotheses  
 
• CaBV modeling principles can be expanded to the derivation of non-
invasive equivalents of the outcome-predictive pressure reactivity index 
(PRx) and the pulse amplitude index PAx with slow waves of mean CaBV 
and its pulse amplitude (yielding nPRx and nPAx models). 
• TCD-based monitoring analyses will return information about ICP 
(calculated non-invasively) and CPP that would otherwise be unavailable. 
For example, the application of Mx_a to general intensive care patients 
will generate models of cerebral autoregulation and outcome prediction 
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Chapter 2 
 
A Practical Introduction to Neuromonitoring 
Following Acute TBI 
 
 
Cerebral autoregulation is considered to be the vascular self-regulatory mechanism that 
maintains a constant balance between cerebral blood flow and variations in blood 
pressure. Governed by interactions between various biophysical processes, 
autoregulation functions as a shield from the potential damages caused by unexpected 
fluctuations in pressures and/or flows. Autoregulation may be compromised following 
acute or traumatic brain injuries (ABI or TBI), potentially leading to an unfavorable 
outcome for the patient if left untreated. 
Despite its complexity, autoregulation can be quantified non-invasively with the 
aid of transcranial Doppler ultrasonography (TCD) or interpreted as mathematically- 
 
The following publications formed the basis of this chapter: 
❖ Calviello LA, Donnelly J, Zeiler FA, Thelin EP, Smielewski P, Czosnyka M. Cerebral 
autoregulation monitoring in acute traumatic brain injury: what's the evidence? 
Minerva Anestesiologica. 2017 Aug;83(8):844. 
❖ Calviello LA and Czosnyka M. Neurocritical Care Monitoring in ICU: 
Measurement of the Cerebral Autoregulation by TCD. NESCC Project. 2018 
September. 
 
❖ Calviello LA, Zeiler FA, Donnelly J, Smielewski P, Czigler A, Lavinio A, Hutchinson 
PJ, and Czosnyka M. Cerebrovascular Consequences of Elevated Intracranial 
Pressure after Traumatic Brain Injury. Neurocritical Care. In Review. 
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derived indices based on commonly-monitored input signals such as arterial blood 
pressure (ABP) and intracranial pressure (ICP) that yield outcome-predictive indices 
such as the pressure reactivity index (PRx). Although these autoregulatory indices are 
primarily surrogate markers of cerebral hemodynamic activity, they have been robustly 
correlated with patient outcomes. 
This chapter seeks to explain the methodology behind the calculations of various 
measures of autoregulation, and how these indices affect clinical outcome prediction 
modeling. A comparison of relevant methods of the assessment of autoregulation and 
their respective relationships with outcome are listed in Table 2.1, with:  PRx, mean flow 
index (Mx), NIRS-based spatially-resolved indices, and brain tissue oxygenation (PbtO2) 
-based oxygen reactivity index (ORx) highlighted. Finally, the advantages and 
disadvantages of each parent monitoring device are outlined in Table 2.2.  
 
2.1.     Overview of Cerebral Autoregulation 
Cerebral autoregulation is the inherent capability of the brain to regulate cerebral blood 
flow across a range of blood pressures within the cranial cavity(1). It is a protective 
mechanism for the brain that enables it to withstand dynamic changes; however, TBI 
often disrupts this process and leaves the brain in a state of “dysautoregulation” that can 
prove fatal if left untreated(2).TBI is commonly attributed to events such as blunt force, 
falls, or motor vehicle accidents that result in a decrease or loss in consciousness, 
memory deficit, or neurological and/or mental state alterations such as weakness or 
disorientation(3). However, the appearance of injury severity is not the decisive factor in 
determining the ability of the brain to recover its disposition towards this protective 
mechanism(1). Moderate to severe TBI cases (i.e. cerebral hemorrhages or contusions) 
are generally easier to diagnose with imaging techniques such as magnetic resonance 
imaging (MRI) and computed tomography (CT) than are mild TBI cases, but standard 
scoring criteria for both cannot be determined as absolute predictors of the damage 
sustained by the cerebral autoregulatory reserve following the initial insult(4). 
 
11 
Chapter 2 – A Practical Introduction to Neuromonitoring Following Acute TBI 
 
2.1.1.   Physiological Drivers of Cerebral Autoregulation 
The loss of autoregulation is theorized to be a multifactorial event process. Cerebral 
structural integrity can be compromised by injury, leading to the scrambled 
communication between metabolic demand and delivery pathways to the brain via 
blood vessels, or this can occur in the reverse order(1). Autoregulation has previously 
been described as a delicate balancing act between vasoconstriction and vasodilation as 
the resistance of the cerebrovascular bed adapts(5,6) to both sudden and slow dynamic 
changes in cerebral perfusion pressure (CPP), a product of the difference between ABP 
and ICP. 
 
Arterial Blood Pressure 
Cerebrovascular tone has long been observed to fluctuate along with changes in 
ABP; cerebral vessels constrict as ABP rises, and dilate when ABP drops(7). The quantity 
of blood flowing through the cerebral arteries is thus directly affected by any changes 
in ABP. In acute brain injury, the homeostatic mechanism governing cerebral 
autoregulation can become disturbed. In order for cerebral autoregulation to be 
considered “intact”, ABP must be independent of the cerebral circulation and at a value 
that is neither too high (predisposing the patient to edema or hemorrhage) nor too low 
(predisposing the patient to cerebral ischemia)(8,9). In Figure 2.1 (below), autoregulation 
is preserved at mean arterial pressures (MAP) of 50-150 mm Hg, and CBF at about 50 
ml/100 g brain tissue/minute(8). In hypertensive patients, this range moves towards 
higher values, with the placement of the curve shifting towards the right, whereas the 
converse occurs in hypotensive patients(10). A passive relationship between ABP and 
cerebral blood flow (CBF) is indicative of poor prognosis. 
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Figure 2.1. Autoregulation of Cerebral Blood Flow. Cerebral autoregulation is 
preserved at (MAP) or 50-150 mm Hg, and CBF at about 50 ml/100 g brain tissue/minute. 
 
Intracranial Pressure 
Perhaps the greatest risk factor for poor patient outcome is sustained, high values 
of intracranial pressure (ICP), which dangerously strain cranial volumetric capacity and 
can produce irreversible damage(11). According to the Monro-Kellie doctrine, ICP is 
comprised of four separate components: arterial blood inflow and venous blood outflow 
(both of which contribute to cerebral blood volume, CBV), cerebrospinal fluid (CSF), 
and a fixed brain volume(12); in a healthy system, when one component increases, the 
others should decrease to accommodate for this change in order to maintain a constant 
value. In TBI patients, ICP is often abnormally elevated, requiring aggressive clinical 
intervention to maintain perfusion and prevent brain herniation. These interventions 
include the use of sedative agents and vasopressors, head positioning, CSF drainage,  
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osmotherapy, surgical evacuation or decompression, and targeted temperature 
management(11).  
Intracranial compliance is characteristically reduced in patients with intracranial 
hypertension, meaning that patients with elevated ICP are at risk of further significant 
spikes in ICP even in response to minor volume changes of intracranial blood and CSF 
or brain swelling.  Low CPP inversely correlates with increased ICP, predisposing the 
injured brain to hypoxia until it triggers the ultimately deadly trifecta of “mechanical 
compression, displacement, and herniation of brain tissue”(13). Invasive ICP monitors are 
essential to the diagnosis and treatment of high ICP; however, initial values of ICP 
(determined on admission) are poor predictors of outcome, particularly in those with 
mass lesions(14). There is a bilateral, causal relationship between brain damage and high 
ICP. Intracranial hypertension (sustained values of ICP >20 mm Hg) unfolding over a 
period of days can progressively alter the brain’s ability to adapt its cerebral structural 
and volumetric reserves(15) to maintain a reasonable degree of function. In survivors, the 
long-term effects of persistent neuroinflammation and chronic structural degeneration 
can dramatically increase the risks of depression, susceptibility to cognitive loss and 
dementia, or accelerated rates of brain atrophy(3). 
 
2.1.2.   Systemic Regulation of Vessel Caliber  
Additionally, metabolic, endothelial, myogenic, and neurogenic factors have each been 
theorized to lead the regulation of vessel caliber. To date, it is unclear which of these 
mechanisms predominate in the control of cerebral arterial vessel caliber(16). The 
metabolic theory postulates that byproducts of cerebral metabolism lead to alterations 
in vessel diameter.  However, the changes in extra-cellular metabolic byproducts is 
relatively slow in relation to the rapid response of the cerebral vasculature, thus it may 
not be integral in autoregulatory control(16).  
Endothelial factors, such as nitric oxide synthase (NOS) and endothelin (ET), are 
expressed as a function of the flow-related stresses encountered by the endothelium. It  
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is plausible to consider these endothelial mediators as potential key players in preserved 
and deranged autoregulatory states(16).  
 
Myogenic autoregulatory theories revolve around the concept of flow-related 
stress on the vascular smooth muscle, leading to reflexive changes in vessel diameter  
secondary to varied smooth muscle tone(16). Both myogenic and endothelial 
mechanisms probably overlap, forming one reflex, known as autoregulation: CBF 
remaining independent despite changes in cerebral perfusion pressure(1). 
Finally, the neurogenic hypothesis focuses on neurotransmitter-mediated 
changes in vascular tone, which are believed to stem from fluctuations in sympathetic 
or parasympathetic output to the tunica media(16). One or more of these mechanisms 
may be the driver(s) of autoregulatory control, and are likely subject to derangements 
depending on the individual host response to injury during various neuropathologic 
conditions(1,16). 
 
2.2.    Clinical Applications of Cerebral Autoregulation  
To provide the greatest and the most reliable amount of clinical information, 
neurocritical care professionals have increasingly been focusing their attention on non-
invasive, bedside multi-modal brain monitoring in conjunction with traditional imaging 
techniques. Prediction of patient outcome in adult TBI is difficult; primarily 
correlational assessment methods of surrogate markers are relied upon for investigation 
into autoregulation (i.e., pressure reactivity index (PRx), mean flow velocity (Mx), 
oxygen pressure reactivity index (ORx), etc.). One of, if not the most, popular methods 
of non-invasively assessing cerebral autoregulation comes in the form of TCD, which 
can detect irregularities in cerebral blood flow(2), providing diagnostic value for 
secondary insults like cerebral vasospasm. TCD is applied to the middle cerebral artery 
(MCA), which is considered the primary conduit for the cerebral circulatory system and 
is assumed to have a constant diameter(1). Ultrasonic penetration of the MCA returns a 
pulse wave spectrum that can be immediately visually classified as either normal or  
 
15 
Chapter 2 – A Practical Introduction to Neuromonitoring Following Acute TBI 
 
abnormal (i.e. vasospastic(17), and can be further analyzed to provide more in-depth 
information about the state of cerebral autoregulation. 
Residual autoregulatory capacity is then described by TCD as “either the speed 
or the direction of changes” of flow velocity in the face of fluctuations in arterial blood  
pressure(17). Figures 2.2A and 2.2B demonstrate the effects of variable ABP and ICP on 
blood flow velocity in animal models using TCD(11,18). 
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Figure 2.2. Graphs over time highlighting (top to bottom) pressure-passivity of 
the cerebrovascular bed in animal models. A) FVx, ABP, ICP and CPP over a 20-
minute recording period in New Zealand white rabbits being subjected to intracranial 
hypertension. There is a robust correlation (R=0.96) between FVx and CPP below the 
lower limit of autoregulation(11); B) Doppler flow, ABP, ICP, and CPP during a 2-hour 
recording period in piglets with induced arterial hypotension. ICP and ABP are strongly-
correlated below the lower limit of autoregulation (R=0.70), again demonstrating 
pressure-passivity with decreasing ABP accompanied by decreasing ICP(19). 
 
FVx: middle cerebral arterial flow velocity; ABP: arterial blood pressure; ICP: intracranial 
pressure; CPP: cerebral perfusion pressure; mm Hg: millimeters of Mercury. 
 
2.2.1.    Transcranial Doppler as a Technique 
TCD is the most-validated technique for non-invasively measuring the velocity of the 
blood flowing through cerebral arteries; Doppler ultrasonography reflects the rate of 
change in the frequency of sound waves perceived by an observer moving relative to the 
wave source (1,20–27). The “traditional” TCD instrument used in neurocritical care centers 
(such as the Multi Dop X4, DWL Elektronische Systeme, Sipplingen, Germany) features 
a headframe that is inserted into the patient’s ears, supporting bilateral 2 MHz probes 
that are fixed onto the temporal window (located above the zygomatic arch) in order to 
insonate the MCA(28) (Figure 2.3). Once in place, a high-frequency ultrasonic beam is 
transmitted that penetrates the skull, commonly at a depth of 50-60 mm, to return the 
Doppler spectra from the artery on accompanying software(29) (Figure 2.3). This 
waveform demonstrates the systolic, mean, and diastolic values of the cerebral blood 
flow velocity (FV), which can be further examined individually in detailed studies of 
outcome prediction(27). FV in healthy subjects has been previously determined to 
perfuse at a rate of 62 ± 12 cm/s, and was found to be nearly symmetrical between the 
left and the right branches of the MCA(29).  
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Figure 2.3. Transcranial Doppler Device Operation. Diagram of the area (dotted line) 
where Doppler signals from intracranial arteries were obtained(29). The zygomatic arch 
is indicated. The most likely location to obtain signals is shown by the position of the 
probe. 
             
 
 
Figure 2.4. Transcranial Doppler Signal Acquisition. The transcranial Doppler 
waveform showing [the] middle cerebral artery, identified by the characteristic tracing 
in [the] upward direction(30). 
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TCD can be highly instrumental in the prediction of secondary insults and/or 
complications of TBI. For example, TCD-based FV can be indicative of vasospasm (the 
narrowing of a vessel accompanied by MCA flow >120 cm/s) following subarachnoid 
hemorrhage (SAH)(17). Routine monitoring sessions are undertaken daily for an average 
duration of about 30 minutes. TCD devices can be connected to bedside monitors that 
provide invasively-quantified clinical information, such as ABP, ICP, and CPP. 
Employing dedicated neuromonitoring software such as ICM+TM (Cambridge 
Enterprise, Ltd.), day-to-day comparisons of FV are often utilized alongside these 
parameters to assess both short- and long-term trends with respect to the patient's 
autoregulatory status (Figure 2.4)(1,2). 
 
2.2.2.    Transcranial Doppler as a Clinical Informant 
In addition to FV, TCD yields several descriptive parameters that paint a broader picture 
of cerebral autoregulation. The pulsatility index (PI), a measure of distal cerebrovascular 
resistance to flow(28), can be calculated as the difference between systolic and diastolic 
FV divided by mean FV over one cardiac cycle. TCD-based FV can also be compared 
against readily-available clinical information from bedside monitors (i.e. ABP, ICP, CPP, 
etc.) to provide distinctive correlational assessments of surrogate markers of cerebral 
autoregulation, such as the pressure reactivity index (PRx) or the mean flow index (Mx) 
within ICM+TM (Figure 2.5, below)(1). The dynamic autoregulation index (ARI) 
demonstrates the interactions between non-invasive TCD and standard invasively-
quantified measurements to produce a graded score of cerebral autoregulation. 
Analyses of these parameters are increasingly becoming a part of clinical practice and 
represent the patient's autoregulatory reserve at any observed timepoint (2).  
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Figure 2.5. Dynamic Changes in Flow Velocity and Cerebral Perfusion Pressure. 
Captured during a transcranial Doppler recording for a single TBI patient over 5 
minutes. Cerebral autoregulation can be approximated by a calculation of Mx from the 
correlation coefficient between mean FV and CPP, here the Mx value is positive (0.73), 
denoting disturbed autoregulation).  
 
MCA: middle cerebral artery; FV: flow velocity; CPP: cerebral perfusion pressure; Mx: 
mean flow index; mmHg: millimeters of Mercury.  
 
 
Autoregulation Index (ARI) 
The concept of creating a holistic TCD-based autoregulatory index was first 
developed by Aaslid et al.(32)  to assess the dynamic changes in cerebral autoregulation 
that occur following step-changes in CPP. By manipulating ABP in decrements of 20 
mm Hg via thigh-cuff deflation, the rapid physiological response (or lack thereof) of the 
cerebral blood supply to these fluctuations in ABP is examined as a predictor of 
autoregulatory capacity. This experimental setup was revisited by Tiecks et al.(33), who 
collected FV and ABP values following the thigh-cuff release to calculate a graded 
reference index (ARI – the index of autoregulation) that would describe the  
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cerebrovascular resistance (CVR) as a function of ABP. ARI effectively answers the 
question of whether cerebral blood flow moderates itself appropriately when ABP  
 
varies(2). Plotting FV against the elapsed time from the initial thigh-cuff release, a series 
of 10 best-fit template models is generated through transfer function analysis(34,35); 
increased steepness in these curves highlights a greater reservoir of cerebral 
autoregulation, where an ARI of 0 indicates pressure-passivity and an ARI of 9 indicates 
optimal autoregulation (Figure 2.6). In patients suffering from TBI or other 
cerebrovascular diseases such as stroke, ARI is lower than it would be in a healthy 
population (ARI <5)(35).However, this primarily visual assessment method is susceptible 
to bias, as strict observer standards are not in place and the quality of curve-fitting can 
vary(34). 
The validity of ARI to mirror dynamic changes in cerebral autoregulation was 
further examined by Panerai et al.(34) via Monte Carlo simulations that mimed random 
input and output signals of both FV and ABP over a 5-minute interval. As transfer 
function analysis is crucial to the calculation of ARI, the strength of the index is tied to 
its spectral components(34,36). ARI’s utility to gauge patient outcome is limited if the 
recorded signals have a low signal-to-noise ratio. For each harmonic, the amount of 
output power that can be linearly explained by the input power is expressed by the 
squared coherence function. A coherence of 1 for pure, univariate systems is indicative 
of a high signal-to-noise ratio, whereas a coherence at or near 0 represents the latter(34,36) 
The phase shift between the Fourier components of both the input and the output 
signals reflects the "interdependence" of FV and ABP, with a positive phase shift 
(optimally 90°) revealing the presence of an intact, non-passive autoregulatory 
reserve(36–38). When applied to the Glasgow Outcome Score (GOS), a lower ARI is 
compatible with GOS 1 or 2 (unfavorable outcome), whereas a higher ARI implies the 
converse, GOS 3-5 (favorable outcome)(36). However, ARI is less sensitive when 
discriminating scores along the lower end of its 0-9 scale, and is largely dependent on 
how accurately the template model(33,39) matches the individual physiological events 
captured by TCD and ABP monitors.  
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Figure 2.6. Tiecks’ Model of Autoregulation. An example(36) of Tiecks’ model, 
demonstrating the ARI curves scaled from 0-9. An ARI score of 9 is indicative of optimal 
cerebral autoregulation.  
 
 
Mean Flow Index (Mx) 
The mean flow index (Mx) is derived from the linear correlation coefficient 
between mean FV and CPP(40,41); this marker of cerebral autoregulation is fundamentally 
dependent on non-invasive TCD monitoring data as opposed to invasive parameters 
(i.e. ABP and ICP). A central tenet to the success of Mx as a surrogate for the 
autoregulatory reserve is the assumption that the diameter of the MCA remains 
constant, which has yet to be either proven or disproven(41). As the first 48 hours of 
admission are crucial to the recovery of autoregulation after TBI(1), TCD and  
 
 
 
22 
Chapter 2 – A Practical Introduction to Neuromonitoring Following Acute TBI 
 
subsequently Mx can assess this rather easily; values of Mx less than or equal to 0 are 
representative of an intact autoregulatory reserve in which FV actively responds to  
changes in CPP, whereas positive Mx trends state the opposite(40). Overall patient 
outcome (dichotomized into “favorable” and “unfavorable” outcomes) appeared to be 
largely affected by positive values of Mx within this timeframe, regardless of whether 
Mx “recovered” to negative values during the patient’s course of stay. Figure 2.5, above, 
provides an example of a patient with disturbed autoregulation, as assessed with Mx. 
Lang et al.(26) used Mx with TCD to gauge autoregulation in a cohort of TBI 
patients. Recalling that Mx is a continuous measure of slow, spontaneous changes in 
CPP and cerebral blood flow volume (CBFV) applied for the examination of MCA blood 
flow regularity(26), this research group attempted to produce the same results with Mx 
values derived from each of the separate input signals of ABP and CPP. Despite revealing 
a non-significant difference between the discriminatory powers of these two input 
signals, Lang et al.(26) cautioned that Mx as a function of CPP necessitates invasive ICP 
data collection to produce CPP calculations, whereas Mx as a function of ABP does not. 
As non-invasive measures of autoregulatory status are prioritized, it seems much more 
likely for Mx derived from ABP as the input to become a routine TCD index than would 
its counterpart when invasive monitoring is undesirable. However, in a more recent 
study in a larger cohort of patients (n=288), Liu et al.(36) compared Mx derived from both 
ABP and CPP in outcome prediction, finding CPP to be the superior input signal. 
However, the time-domain calculation of Mx itself does not rely entirely on non-
invasive data collection to express autoregulatory reserve; once again, CPP is the 
difference between ABP and ICP, making Mx somewhat dependent on ICP fluctuations 
as a result. Lang et al.(26) attempted to attain Mx with two separate input signals: CPP 
and ABP, the latter rendering the parameter to be quantifiable with non-invasive 
measures. Although possible to use, Mx determined from ABP is not as sensitive as Mx 
determined from CPP(36). Continuing the search for an entirely non-invasive Mx 
function, Budohoski et al.(27) cited correlations between the systolic (Sx), diastolic (Dx), 
and mean (Mx) components of the FV waveform when using the input signals of either 
ABP or CPP. Separate analyses yielded the same result: Mx calculated with CPP is the 
superior predictor of functional patient outcome(1,27).  
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2.2.3.    Benefits and Limitations of Transcranial 
Doppler 
TCD is an important tool to have in neuro-critical care units. It is inexpensive, portable, 
and relatively simple to use once trained in how to do so. TCD examinations are as 
accurate as magnetic resonance imaging (MRI) when assessing vascular pathology(42) 
and do not require patients to be moved to imaging suites. Additionally, TCD devices 
can be paired with clinical monitoring software such as ICM+TM (Cambridge Enterprise, 
Ltd.) to return pertinent information about a TBI patient that cannot be gleaned from 
bedside monitors. Without TCD and dedicated analytical platforms such as ICM+TM, 
mortality and functional outcome could not be determined on the basis of one or two 
functions (ARI is a more robust predictor of mortality than Mx, but the latter is more 
sensitive to functional outcome(36,40,43)). The benefit of both ARI and Mx is that they 
assign scalar value to cerebral autoregulation to the “weighted spatial averages as seen 
from the aspect of the MCA”(44) when employing the TCD monitoring technique. 
Additionally, although PRx and Mx have both been used to describe different 
components of the autoregulatory mechanism and it has been suggested that Mx is a 
better predictor of functional outcome than of mortality(43,45), PRx is more 
discriminatory for survival versus mortality); however, both demonstrate U-shaped 
curves when plotted against CPP and are directly responsive to alterations of ICP(46).  
High values of Mx and PRx insinuate the inability of the cerebral vasculature to regulate 
cerebral blood flow as measured by either of these parameters(47).  
Although there is a shortage of “autoregulation markers”(20), the above surrogates 
(ARI, Mx, PRx) can technically be monitored continuously, as their respective values 
can be repeatedly calculated over any specified time period during the patient’s neuro-
intensive care stay. The utility of TCD was further affirmed by Panerai et al.(42), who 
compared the quality of the measurement to the sensitivity of gradient-echo MRI 
sequences as a marker of blood flow velocity changes attributable to injury and  
pathology in patients suffering from acute ischemic stroke. Therefore, they can be 
reported in the same fashion as ABP and ICP.  
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            Despite this important point, TCD, and thus its derived parameters, are only 
intermittently affixed to the patients (<1 hour) due to the relative “clumsiness” and 
potential disruptiveness of the instrument to routine nursing interventions (i.e. turning 
the patient, preparing the patient for an x-ray or scan, etc.). TCD is primarily viewed as 
a research tool and is treated as an accessory to the patient; for example, it is nearly 
impossible to retain a stable probe position if a patient is being re-positioned or 
examined, as nurses are not obligated to be vigilant over the TCD recording session 
itself. TCD’s time dependence only permits clinicians to receive “snapshots” of cerebral 
hemodynamic activity1. Another drawback of TCD is its reliance on operator validity(25); 
even experienced technicians may not agree on the probe placement, depth of the MCA, 
etc. The relative strengths and limitations of TCD-based assessments are detailed 
further in Table 2.2. If the diameter of the MCA was ever to be proven variant, the core 
of TCD monitoring technology and thus its credibility would be undermined.  
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2.2.4.      Invasive Alternative Techniques to TCD 
PRx, and subsequently, outcome, is affected by interrelationships between such 
parameters as MAP, ICP, and CPP(46) that cannot be described non-invasively with TCD. 
These components need to be controlled to drive minimal values of PRx, as appropriate 
vessel diameter modifications spurred by vascular smooth muscle cells ensure the 
protection of the brain(45,47). However, emerging evidence indicates that PRx may be 
affected by many other factors including red blood cell transfusion(48), alterations in 
temperature(49), or arterial glucose concentration(50). 
           In addition to PRx, near-infrared spectroscopy (NIRS) and brain tissue 
oxygenation (PbtO2) are common alternatives to operator and time-dependent TCD 
recordings. Although invasive in nature, these techniques can be utilized outside of 
dedicated research environments, and thus are perhaps more likely to become 
clinically-accepted descriptors of cerebral autoregulation. 
 
Pressure Reactivity Index (PRx)  
The PRx is calculated as the moving linear correlation coefficient between MAP 
and ICP, from 30 consecutive samples binned into 10-second data windows(40). PRx 
values at or below 0 reflect intact autoregulatory reserves. PRx values above 0 indicate 
the increasing passivity of the cerebrovascular bed, in which variations in arterial blood 
pressure directly influence increases or decreases in ICP. This inability of the brain to 
discriminate the ABP and ICP input, and to mediate vasoconstriction or vasodilation 
accordingly, is a predictor of poor outcome. Ideally, in the attempt to preserve cerebral 
autoregulation, these indices  
should not be co-dependent, as cerebrovascular passivity intimates a global 
autoregulatory disturbance. The utilization of computerized ABP and ICP monitoring 
to produce the PRx as a correlation coefficient has shown to be a robust predictor of 
outcome following rises in ICP. Sorrentino et al.(21) described critical values of PRx that 
maximized the difference between patients who died (PRx =0.25) and those with a more 
favorable outcome (PRx =0.05).   
 
26 
Chapter 2 – A Practical Introduction to Neuromonitoring Following Acute TBI 
 
The inherent capacity for this neuroprotective mechanism deteriorates with 
age(51), but is especially compounded by TBI(40). The age of patients may serve as a 
predisposition to secondary insults, with natural aging processes affecting the reactivity 
of the cerebrovascular bed(51). The impaired state of the brain after injury makes it even 
more vulnerable to and uncompromising with sudden changes in ICP and CPP(52). For 
example, large reductions in CPP lead to arteriolar dilations, which in turn decrease 
cerebrovascular resistance, and vice versa(53). Therefore, the elderly TBI population may 
be more vulnerable to secondary brain injuries caused by reductions in CPP. 
 
Interactions of PRx with Cerebral Metabolic Factors 
In combination with CPP, PbtO2 is theorized to act as a surrogate marker of 
cerebral blood flow, taking tissue oxygenation pressure into account(54). Disturbances 
in cerebral blood flow after severe head injury directly contribute to the brain’s inability 
to adjust vessel diameter in response to transmural pressure demands. Microdialysis 
can aid in the detection of TBI-mediated cerebral metabolic changes. Common markers 
include glucose, lactate, pyruvate, glutamate, glycerol, and the lactate/pyruvate ratio. 
The relative concentrations of these parameters are associated with outcome. For 
instance, Timofeev et al.(55) quantified the lactate/pyruvate ratio as a surrogate marker 
of cerebral metabolism, showing that higher values (>25) reflect an independent 
association with patient mortality attributable to either mitochondrial dysfunction or a 
lack of oxygen supply in the brain.  
Further assessment of these additional factors’ effects on PRx can be useful in 
outcome prediction. Steiner et al.(56) questioned the role of cerebral metabolic 
dysfunction in suboptimal PRx, and subsequently, outcome. The global cerebral 
metabolic rate of oxygen (CMRO2) was hypothesized to play a role in the incidence of 
dysautoregulation explained by PRx that could prime patients for secondary insults to 
the brain (i.e. ischemia, hyperemia, etc.). Ang et al.(57), posited similar oxygen 
disturbances in lesioned tissue as evidence of autoregulatory failure. An inverse 
relationship between CMRO2 and PRx was determined, but the effects of the two could 
not pinpoint the underlying causes of poor  
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outcome, or the dynamics and concentrations of blood in the lesioned part of the brain. 
Autoregulatory status is important for neuro-intensive care management. 
Autoregulation depends on CPP to balance cerebral blood flow and cerebral 
metabolism(56). Elevated CPP can predispose patients to cerebral metabolic failure 
(demonstrated by decreased CMRO2), and thus can potentially drive autoregulatory 
failure. However, there is currently no data available to firmly suggest that changing 
local metabolics would lead to improved autoregulation, although support for the 
theory that metabolic derangements are associated with unfavorable PRx is leant by the 
work of Timofeev et al.(55). It remains to be proven that cerebral metabolic alterations 
will influence patient outcome; for example, CMRO2 signal decreases may be a 
downstream consequence of autoregulatory failure (56). 
 
Application of PRx toThe Monitoring of Optimal Cerebral Perfusion Pressure (CPPOPT) 
The autoregulatory response to CPP changes has been demonstrated within the 
physiological boundaries of 50-100 mm Hg, with some studies showing evidence of CPP 
values above this upper bound(22,58). Drastic CPP variations after TBI can greatly affect a 
patient’s chances of survival, and additionally, functional outcome(5). The progressive 
failure of autoregulation with falling CPP can predict the incidence of secondary, 
potentially intractable insults to the brain such as delayed cerebral ischemia, 
vasospasm, etc. However, increasing CPP past a “safe” range could lead to hyper-
perfusion (current guidelines stipulate that CPP should rest between 60-70 mm Hg) 
which has been associated  
with risk of edema or leakages through the blood-brain barrier, as well as potential 
cardiac or respiratory distress(59). 
To simplify cerebral vasoreactivity as a direct measure of pressure and flow, it is 
perhaps best to explain it by its relationship with CPP(60). PRx is the regression between 
ICP and MAP, and CPP is the difference between arterial blood pressure and ICP. PRx 
has been used to derive an optimal CPP (CPPOPT) in traumatic brain-injured patients(5). 
CPPOPT is determined from the lowest PRx value plotted against all of the CPP values  
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within a recorded period (usually 4 hours). This often results in a simple-to-
comprehend U-shaped curve in which CPPOPT is the minimum value found at the base 
of the curve (Figure 2.7). On the further suggestion of Steiner et al.(61) with CPPOPT 
determined as the lowest-measured plotted average of PRx trends, it may be sensible to 
continually direct patient management towards 0 or negative values in accordance with 
CPPOPT treatment protocols based on pressure autoregulatory capacity(53,54,62). 
Yet, individualized CPPOPT values may not be contained within the boundaries 
of 60-70 mm Hg, as evidenced by Figure 2.7, which features a CPPOPT value at 91.14 mm 
Hg.  Some patients may achieve a more stable PRx at CPPOPT above or below the advised 
“safe” range, an observation which has led research to examine the benefits of CPPOPT 
therapies that are separately tailored to each patient, to reduce incidences of secondary 
injuries across the board(17,23,53,56). A recent systematic review conducted by Needham et 
al.(5) reaffirms the importance of safeguarding against mortality by treating each patient 
in accordance with his or her individually-determined target CPPOPT to maximize 
cerebrovascular reactivity. 
 
 
Figure 2.7. Determination of CPPOPT. An example(1) of CPP derived from PRx obtained 
from a single patient over a monitoring period of approximately 4 hours. The green, 
yellow, orange, and red bars of PRx respectively represent a spectrum of favorable to 
unfavorable PRx during the observation. These values of PRx are plotted against CPP, 
with the minimum value of the curve declared CPPOPT. In this particular patient, CPPOPT 
is equivalent to 91.14 mm Hg. 
PRx: Pressure Reactivity Index; CPP: cerebral perfusion pressure; mm Hg: millimeters of 
Mercury. 
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Criticisms of PRx 
The original definition of PRx functions as a descriptor of “graded loss of 
autoregulation”(61), raising the question of whether it is possible to incorporate PRx into 
CPP management protocols, yielding an autoregulatory therapy (perhaps indexed as 
PRxOPT). Steiner et al.(61) assessed the effect of time on PRx and posited that disturbed 
PRx (reported as PRx >0.2) for a period of six hours was a strong predictor of patient 
mortality. Corresponding CPP values during these observations were analyzed for 
deviations from calculated CPPOPT, however, CPPOPT was unable to be defined in some 
cases, demonstrating that autoregulation-oriented therapy is difficult to implement 
because it is nearly impossible to guarantee the consistency of curve-fitting between 
surrogate measures of autoregulation. CPPOPT fundamentally requires an index of 
vascular reactivity for its calculation, in addition to high-frequency data examined every 
four hours to create time points(63). Table 2.2 provides an in-depth description of the 
strengths and limitations of PRx and other continuous autoregulatory indices.  
Aries et al.(64) similarly found an obstacle to the design of PRx-guided therapy, 
stating that the fundamental calculation of PRx as a function of arterial blood pressure 
and intracranial pressure assumes that the vacillations of cerebrovascular resistance are 
coupled with those of cerebral blood volume, inducing the direction of ICP towards 
higher values when intracranial compliance is low, and vice versa. The necessity of this 
pairing is problematic for independent models of PRx-guided therapy protocols, as PRx 
is a “noisy” derived index requiring a higher signal-to-noise ratio and time-domain 
analysis(64). To counter this, Aries et al.(64) put forth the proposition of PAx (the index of 
the intracranial pressure waveform amplitude) as a modification of PRx that is 
“potentially independent” of ICP fluxes that could affect the validity of PRx as a true 
measure of autoregulation(65).  
Finally, the plot showing the distribution of PRx along various CPP values 
contains many intrinsic calculations. It is PRx: the correlation of ABP and ICP, versus 
the difference:  ABP minus ICP. It may be possible that the U-shape of this relationship 
may be derived from the nature of mathematical transformations, rather than a 
physiological relationship(66). 
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Near-Infrared Spectroscopy (NIRS) 
 Near-infrared spectroscopy (NIRS) provides a continuous, dynamic measure of 
cerebral autoregulation through the calculation of the tissue oxygenation index TOx 
(used interchangeably with the cerebral oximetry index, COx(67)), the moving 
correlation coefficient between invasive ABP and regional oxygen saturation (rSO2) over 
30 consecutive samples averaged over 10 seconds(68). Cerebral oxygenation is obtained 
non-invasively by affixing optodes to a patient’s forehead, which capture the light 
emitted from a single laser diode in the near-infrared spectrum that penetrates the 
superficial cerebral tissues(67). rSO2 is displayed by NIRS as the tissue oxygenation index, 
a compilation of the concentrations of oxygenated, deoxygenated, and total hemoglobin 
in region, parameters which can be further dissociated by their absorption spectra(69–71). 
NIRS has been verified as an alternative technique through which to describe 
autoregulation in TBI patients when ICP monitors are declared unfeasible by the nature 
of pathology. Additionally, NIRS is not operator-dependent like TCD, which makes it 
more accessible to clinicians. However, NIRS can be confounded by factors such as the 
presence of frontal contusions, which can complicate optode placement(69).  
TOx is invasive, requiring an arterial catheter for the ABP input signal(68). Similar 
to the acquisition of CPPOPT by PRx, recorded ABP values can be plotted against TOx, 
producing a curve-fitted “ABPOPT” as the lowest-associated TOx(68,69). Highton et al.(72) 
applied ICP, TCD, and NIRS to compare the agreements between PRx, Mx, and TOx in 
predicting autoregulatory failure. They found that both PRx and Mx were significantly 
correlated with TOx, although there was incomplete agreement between the reactivity 
indices(72).  The NIRS-derived total hemoglobin reactivity index (THx), the correlation 
coefficient between the total hemoglobin index (THI = oxygenated + deoxygenated 
blood) and ABP, has been suggested as analogous to PRx(73). THI used in this calculation 
is described by Diedler et al.(73) as “a normalized measure of [total] hemoglobin 
concentration and thereby provides a tracer of cerebral blood volume”. NIRS-based THx 
has been suggested as a non-invasive substitute for PRx, supporting the PRx-THx 
association reported by Zweifel et al.(69), who posited that ABP can provide a “reasonable 
approximation” of CPP. Later work by Dias et al.(74) examined the calculation of CPPOPT  
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with TOx instead of PRx, although the results of that single-center study have yet to be 
confirmed as evidence of the influence of NIRS for CPPOPT determination. Further 
details on the relative strengths and limitations of the application of NIRS for 
autoregulatory assessment are available in Table 2.2. 
 
Oxygen Reactivity Index (ORx) 
Collating analog MAP, ICP, CPP, and PbtO2 data from double-lumen skull bolts 
(Licox IM2, Integra NeuroSciences Inc.)  inserted in the right frontal region of the brain, 
Jaeger et al.(75) calculated the oxygen pressure reactivity index (ORx) as a moving 
correlation coefficient between CPP and the invasively-quantified PbtO2. They 
discovered parallels between the scoring of ORx and that of PRx to measure whether a 
patient is capable of autoregulating. (Table 2.2 compares ORx to PRx as has been 
documented within the existing body of literature). Similar to PRx, ORx values range 
between -1 and 1, with a positive, passive relationship between PbtO2 and CPP indicating 
impaired autoregulation. Figure 2.8 describes this relationship. 
 
 
 
Figure 2.8. Comparison of ORx and PRx. A) An example(1) of a 50-minute time-trend 
of ORx derived from PbtO2 plotted against PRx obtained from a single patient to 
demonstrate the similarities in scoring between the indices; B) Although this ORx-PRx 
plot suggests a robust correlation between ORx and PRx (R=0.68), it should be noted 
that PbtO2 can be mechanically altered, whereas ICP is only subject to natural 
fluctuations within the brain - therefore, PRx values cannot change while ABP or ICP 
remain the same.  
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ORx: Oxygen Pressure Reactivity Index; PbtO2: brain tissue oxygenation; PRx: pressure 
reactivity index; CPP: cerebral perfusion pressure; ICP: intracranial pressure; mm Hg: 
millimeters of Mercury.  
 
2.3.1.      Factual Tables Based on Literature 
Cerebral autoregulation is not fully elucidated, but it is widely agreed-upon that 
disturbed autoregulation directly influences outcome following TBI. This selective 
review of the existing body of literature confirms that the concept of autoregulation is 
difficult to model, and even more so to mediate. Intricate relationships between blood 
flow and blood pressure govern calculations of derived indices of autoregulation, such 
as that of PRx and Mx, which are suitable for continuous monitoring. Assessments of 
autoregulation, heavily reliant on non-invasive transcranial Doppler analysis of blood 
flow within the middle cerebral artery, can provide deeper insight into autoregulation, 
although this notion is challenged by both mechanical and data-driven criticism of TCD 
monitoring. Near-infrared spectroscopy can be considered as promising technology, but 
is still awaiting strong proofs. Despite the absence of a true marker of autoregulatory 
capacity, the control of this mechanism is a central feature of neuro-critical care 
management plans, whether treating patients in accordance with either ICP- or CPP-
oriented protocols. 
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Table 2.1. Autoregulation Index Characteristics and Summary of Available Core Literature in TBI. AMP = fundamental amplitude of ICP, 
Dx = diastolic flow index, CPP = cerebral perfusion pressure, FVm = mean flow velocity, FVd = diastolic flow velocity, FVs = systolic flow 
velocity, GOS = Glasgow Outcome Scale, ICP = intracranial pressure, MAP = mean arterial pressure, MCA = middle cerebral artery, NIRS 
= near infrared spectroscopy, ORx = oxygen reactivity index, PbtO2 = brain tissue oxygenation, PAx = pulse amplitude index,  PRx = pressure 
reactivity index, Sx = systolic flow index, TCD = transcranial Doppler, THI = total hemoglobin index, TOI = total oxygenation index. *This 
total number of patients for PRx and Mx studies is inflated given many studies have arisen from a small number of centers, yielding overlap 
between patient populations reported in various studies.  Thus, the total number of unique patients reported is substantially less. **Only 
spatially resolved signals and indices are described, given the design of spatially resolved NIRS is to remove signal contamination from skin 
based extra-cranial circulation.  Many “other” non-spatially resolved indices exist and are not covered in this table. 
 
Parent 
Signal 
Acquisition 
Commonly 
Derived 
Autoregulatory 
Indices 
Calculation Technique Approximate # of 
Papers in the 
Literature 
Number of 
Patients 
Described 
Core Evidence Summary of 
Evidence 
Invasive ICP 
monitoring 
1. PRx – 
correlation 
between ICP 
and MAP 
 
2. PAx – 
correlation 
between AMP 
and MAP 
 
-Pearson correlation 
coefficients between 10- 
second averaged signals 
(ICP, AMP, MAP) over a 
5-minute window. 
 
-Typically updated every 
60 seconds 
1. PRx - 28 with 
core focus on 
patient 
outcome 
 
2. Many more 
documenting 
relationships 
between PRx 
and other 
indices (ie. PAx, 
etc.) and other 
physiologic 
signals 
 
Outcome Studies 
-4690 total 
(mean 168 per 
study)* 
 
 
1. PRx is more 
positive in those 
patients with fatal 
outcome 
(p<0.0002)(76,77)  
 
2. PRx threshold for 
mortality 
prediction at 
6months is 
~+0.25.(21)  
 
3. PRx threshold for 
morbidity 
prediction at 6-
1. Positive PRx is 
positively 
correlated to 
mortality and 
poor functional 
outcome at 6 
months. 
 
2. PRx above 
+0.25 is 
positively 
correlated with 
mortality.  
 
3. PRx above 0.05 
is positively 
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months is 
~0.05.(21)  
 
4. PRx tends to 
display positive 
correlations with 
Mx (r=0.58; 
p<0.001)(47). 
  
5. PRx and PAx 
display positive 
correlations 
(r=0.68; p<0.001); 
with PAx 
potentially being 
a better predictor 
of outcome in 
those with low 
ICP (ie. 15 mm Hg 
or less)(64). 
correlated with 
morbidity. 
 
4. Unclear if PAx 
(or other ICP 
derived indices) 
may prove 
superior in 
outcome 
prediction for 
certain 
subpopulations 
of TBI patients. 
TCD flow 
velocity 
derived - from 
MCA 
(typically) 
1. Mx – correlation 
between FVm 
and mean CPP 
 
2. Sx – correlation 
between FVs 
and mean CPP 
 
3. Dx – correlation 
between FVd 
and mean CPP 
 
-Pearson correlation 
coefficients between 10-
second averaged signals 
(FVm, FVs, FVd, 
CPP/MAP) over a 5-
minute window. 
 
-Typically updated every 
60 seconds. 
1. Mx – 17 main 
studies (with 50 or 
more patients) 
documenting 
association with 
patient outcome. 
 
2. Many more 
smaller studies 
evaluating 
Mx/Sx/Dx and 
patient outcome or 
Outcome studies 
(>50 
patients/study) – 
3606 total (mean 
212 
patients/study)* 
1. Mx is negatively 
correlated with 
mortality and 
morbidity at 6 
months (p=0.018 
and p=0.002)(78). 
 
2. Mx is superior to 
Mx_a (and 
Sx_a/Dx_a) in 
outcome 
prediction(19,79).  
 
1. Positive Mx 
values are 
correlated to 
morbidity and 
mortality at 6 
months. 
 
2. A threshold for 
poor outcome 
may be +0.3 for 
Mx. 
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*Note: Mx/Sx/Dx 
can be derived non-
invasively from 
MAP, instead of 
CPP.  These “MAP” 
versions are 
denoted in 
literature with “-a” 
suffix typically. 
 
physiologic 
outcomes. 
 
 
3. A threshold of 
+0.3 for Mx is 
associated with 
mortality and 
morbidity(21). 
NIRS derived 
– bifrontal 
signal 
acquisition**  
 
1. TOx (also 
known as COx)– 
correlation 
between TOI 
and CPP 
 
2. THx (also 
known as HVx) 
– correlation 
between THI 
and CPP 
 
*Note: TOx/THx 
can be derived non-
invasively from 
MAP, instead of 
CPP.  These “MAP” 
versions are 
denoted with “-a” 
suffix typically. 
 
-Pearson correlation 
coefficients between 10- 
second averaged signals 
(TOI, THI, CPP/MAP) 
over a 5-minute window. 
 
-Typically updated every 
60 seconds. 
9 main studies 
documenting NIRS 
based moving 
correlation 
coefficient for 
autoregulatory 
assessment 
Total of 187 
patients (mean 21 
patients/study) 
1. THx and TOx are 
positively 
correlated with 
PRx (r=0.63 and 
r=0.40 
respectively; 
p<0.05)(72). 
 
2. Non-spatially 
resolved indices 
may be influence 
by skin-related 
artifacts, thus are 
not strongly 
correlated with 
PRx(70).  
 
3. Mx appear to be 
more correlated 
with TOx (r=0.61, 
p=0.004) than 
THx (r=0.26, 
p=0.28)(72). 
1. Spatially-
resolved TOx 
and THx are 
moderately 
correlated with 
PRx. 
 
2. Varying degrees 
of correlation 
between 
TOx/THx exist 
with Mx. 
 
3. Non-spatially 
derived indices 
may be subject 
to skin blood 
flow 
contamination 
and should be 
interpreted 
with caution. 
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Brain Tissue 
Oxygen 
(PbtO2) 
derived 
1. ORx – 
correlation 
between the 
PbtO2 signal and 
CPP 
Varied calculation 
methods: 
 
-Strongest evidence from 
Jaeger et al. in TBI31 
 
-Typically 30-second 
signal averages (PbtO2 
and CPP) 
 
-Pearson coefficient 
calculated over various 
windows: 30 minutes, 60 
minutes, 120 minutes. 
 
-updated every 60 
seconds 
 
*Note: other variations 
within the literature 
exist. 
 
10 studies in the 
literature describe 
ORx calculation 
Total of 159 
patients (mean: 
18 patient/study) 
1. ORx and PRx are 
positively 
correlated 
(r=0.55, 
p<0.01)(75).  
 
2. ORx displays a 
negative 
correlation with 
6-month GOS 
(r=-0.62, 
p<0.01)(75). 
 
3. ORx does not 
appear to rapidly 
respond to 
extreme 
physiologic 
conditions, such 
as plateau 
waves(80).  
1. ORx displays a 
positive 
correlation with 
PRx. 
 
2. High ORx 
values are 
correlated with 
worse 6-month 
outcome. 
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Table 2.2. Advantages and Disadvantages of Continuous Autoregulatory Indices. ABP = arterial blood pressure, AMP = fundamental 
amplitude of ICP, CBF = cerebral blood flow, CBFV = cerebral blood flow velocity, CBV = cerebral blood volume, Dx = diastolic flow index, 
FiO2 = fraction of inspired oxygen, ICP = intra-cranial pressure, ICU = intensive care unit, MAP = mean arterial pressure, MCA = middle 
cerebral artery, Mx = mean flow index, NIRS = near infrared spectroscopy, ORx = oxygen reactivity index, PAx = index derived from 
correlation between AMP and MAP, PbtO2 = brain tissue oxygen, PRx = pressure reactivity index, TCD = transcranial Doppler, THI = 
total hemoglobin index, TOI = total oxygenation index. 
 
Monitoring Device Invasiveness of 
Monitor 
Autoregulatory 
Indices Derived 
Advantages Disadvantages 
ICP monitor  
 
(Parenchymal based 
strain-gauge/fiber-
optic OR 
ventriculostomy based) 
 
Invasive 1. PRx 
 
2. PAx 
1. Based on commonly 
measured physiological 
variables in the ICU (ICP 
and MAP). 
 
2. Many studies documenting 
association with patient 
outcome. 
 
3. Thresholds for outcome 
prediction available for PRx. 
 
4. Responsive during extremes 
of physiology (ie. plateau 
waves and ABP 
fluctuations). 
 
1. Invasive ICP monitoring required 
 
2. Subject to signal “noise” and changes in 
parent signal phase shift - impacting the 
correlation coefficient.  Thus, averaging of 
PRx values over 30 minutes of steady state is 
recommended. 
 
3. PRx may be unreliable post craniectomy 
 
 
4. PRx and PAx are “global” assessments of 
autoregulatory capacity, thus symmetry of 
autoregulation cannot be commented on. 
 
 
TCD Invasive OR 
Non-invasive  
1. Mx 
 
2. Sx 
 
1. Can be conducted 
completely non-invasively 
(ie. using MAP in the 
calculation) 
1. Operator dependent on acquisition of MCA 
flow velocities. 
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3. Dx 
 
*And MAP 
derivatives: (Mx-
a, Sx-a, Dx-a) 
 
 
2. Studies documenting 
association with patient 
outcome. 
 
3. Thresholds for outcome 
prediction are available for 
Mx. 
 
4. Can use the technique for 
non-invasive follow-up on 
ward or in clinic. 
 
5. Asymmetry in 
autoregulation can be 
assessed via bilateral CBFV 
acquisition. 
 
 
2. Limited duration of signal acquisition (ie. as 
long as the probe can be held in position). 
 
3. Labor intensive for acquisition of long 
recordings in large populations. 
 
4. Non-invasive indices (Mx_a, Sx_a, Dx_a) are 
not as strongly associated with patient 
outcome as the CPP-derived ones. 
 
5. Limited data on Sx and Dx. 
NIRS (Spatially 
Resolved)  
 
(Obtained via 
transcutaneous 
bifrontal optode) 
Invasive OR 
Non-invasive 
1. TOx 
 
2. THx 
 
*And MAP 
derivatives: (TOx-
a, THx-a) 
 
1. Ease of application of 
bifrontal adherent optode. 
 
2. Long recording possible. 
 
3. Can obtain non-invasive 
version of indices (ie. using 
MAP in the calculation). 
 
4. Can be used in follow-up on 
the ward or in clinic. 
 
5. Spatially resolved NIRS 
signals (TOI and THI) 
1. Non-spatially resolved NIRS signals are 
subject to contamination of extracranial 
blood flow within the skin. 
 
2. NIRS signals are not pulse responsive 
waveforms, thus linking to pulsatile signals 
such as ICP and ABP can be difficult. 
 
3. Unclear aspect of cerebral physiology 
measured by NIRS.  Thought to stem from 
cortical CBF/CBV, signals may represent 
more of the venous component of the 
cerebral vascular system. 
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theoretically have skin 
based extra-cranial blood 
flow contamination 
removed. 
 
6. Theoretically can assess 
symmetry of autoregulation, 
given bifrontal signal 
acquisition. 
4. NIRS based oxy-/deoxy-hemoglobin signals 
may be influenced by systemic factors (ie. 
cardiorespiratory complications, hemoglobin 
levels and oxygen carrying capacity) 
 
5. Available literature for NIRS based 
autoregulatory indices is limited.  With 
mixed correlations with ICP and TCD 
derived indices. 
 
6. Association between NIRS indices and 
patient outcome is currently not clear. 
 
Brain Tissue 
Oxygenation 
(PbtO2) 
Invasive 1. ORx 1. Provides unique physiologic 
variable (local brain tissue 
oxygenation). 
 
2. Once the PbtO2 probe is 
placed, it can obtain 
continuous measures of 
local oxygen levels. 
 
3. Some data to suggest 
association of ORx with 
patient outcome. 
 
4. Some data to suggest 
moderate correlation with 
PRx. 
1. Invasive parenchymal monitor. 
 
2. PbtO2 signal is slowly responsive, hence ORx 
indices need to be derived over long period 
of recording (ie. 30 min up to 2 hours; or 
longer). 
 
3. PbtO2 signal is influenced by many factors 
(ie. FiO2, cardiovascular status, pulmonary 
gas exchange, hemoglobin level, cerebral 
capillary oxygen diffusion, etc.). 
 
4. PbtO2 signal may be influenced by probe 
location, with intra-/peri-contusional 
location yielding different results from 
“healthy”/non-lesional locations. 
 
5. Given the PbtO2 signal is focally obtained 
from the parenchyma surrounding the probe 
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tip, it is unclear if ORx is a focal versus 
global measure of autoregulatory capacity. 
 
6. Cannot comment on symmetry of 
autoregulation, given focal nature of PbtO2 
probe. 
 
7. ORx literature is very limited. 
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Chapter 3 
 
Methodology 
 
There are substantial similarities among the methodological aspects of the seven studies 
presented in this thesis. Five of the seven studies retrospectively examined an 
established database of adult TBI patients to provide novel insight related to: 1) the 
consequences of intracranial hypertension, 2) the cerebral compensatory reserve and 
ICP, 3) the spectral pulsatility index, 4) mathematical modeling of cerebral arterial 
blood volume, and 5) non-invasive estimators of PRx and the pulse amplitude index 
(PAx).  One prospective study applied TCD monitoring for the first time to a population 
of adult general intensive care patients, and the final study was performed as a topical 
literature review on ICP measurement accuracy. Common methods across the six adult 
patient studies are described below; additionally, each study is detailed separately 
within its respective chapter (Table 3.1, below). 
 
3.1        Patients 
Retrospective Data 
 
The retrospectively-collected data that was utilized in five of the studies 
comprising this thesis was harvested in subsections from a database of 1,023 adult TBI 
patients admitted to the Addenbrooke’s Hospital Neurosciences Critical Care Unit 
(NCCU) between 1992 and 2013. Each patient exhibited a clinical need for ICP 
monitoring; ICP and additional computerized bedside signal recordings are contained 
within this database, the collection of which was reviewed and approved by the local 
and institutional ethics committee at Addenbrooke’s Hospital (NHS Trust, Cambridge, 
United Kingdom), the University of Cambridge and the NCCU Users’ Group (30 REC 
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97/291). Inclusion criteria for these studies were: adult TBI, at least 12 hours of invasive 
ICP and ABP monitoring, the availability of admission Glasgow Coma Scale (GCS) score, 
and an inverted six-month Glasgow Outcome Score (GOS) outcome data (1= dead, 2= 
vegetative state, 3= severe disability, 4= moderate disability, and 5=good recovery). 
 All patients were sedated with a mixture of propofol, fentanyl, and midazolam 
before being intubated and mechanically ventilated. Prior to 1994, TBI patients were 
managed by the Department of Neurosurgery and general Intensive Care Unit (ICU) if 
they required further ventilatory or organ support. The present NCCU was first opened 
in 1994 with 12 beds, and fully expanded in 2011 into a 23-bed major trauma unit. During 
this timeframe, patients were treated in accordance with a protocol aiming to maintain 
ICP below 20 mm Hg and CPP above 70 mm Hg. In particular, ICP was controlled using 
a step-wise approach of positioning, sedation, ventriculostomy drainage, hypothermia, 
and finally barbiturate-induced burst suppression of electroencephalography (EEG) and 
decompressive craniectomy as rescue therapies. CPP was modulated by intravenous 
fluids, inotropes, and vasopressors.  
Later, additional monitoring modalities (cerebral autoregulation as assessed by 
PRx (1999), microdialysis (2002), and brain tissue oxygenation (PbtO2, 2004) were 
introduced into patient care standards.  By 2003, CPP thresholds had been modified to 
a value above 60 mm Hg (previously 70 mm Hg), with additional restrictions on 
hyperventilation put in place (acceptable end-tidal carbon dioxide (EtCO2) becoming 
scaled from 4.5-5 kPa instead of 4-4.5 kPa). Since 2012, individualized CPP targets based 
on autoregulation have become available to clinicians seeking to optimize patient 
management.  
 
Prospective Data 
  
The prospectively-collected data that was utilized and presented in this thesis is 
part of a new database of 40 adult patients who were admitted to either the NCCU at 
Addenbrooke’s Hospital or the John Farman Intensive Care Unit (JFICU), also located 
at Addenbrooke’s Hospital, between March 2017 and March 2019. Patients who failed to 
awaken appropriately after resuscitation from cardiac arrest, meningitis, seizure, sepsis, 
metabolic encephalopathies, overdose, or organ failure/transplant were referred by staff 
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members for inclusion in this study (IRAS Project ID: 165207). All patients received 
invasive ABP and non-invasive TCD (Rimed Digi- LiteTM, Rimed Ltd., Israel).  and EEG 
recordings (Nihon Kohden CerebAir, Shinjuku, Japan). Six-month outcome data (GOS) 
was also collected for each patient.  
Patients were excluded from the study if they were: under the age of 18, lacking 
pre-existing mental capacity to consent, expressing wishes to not participate in 
research, or were unable to safely undergo transcutaneous monitoring due to skin 
infections, known allergies, etc. Prior to study enrollment, informed consent was 
obtained following consultation with the patients’ next of kin/legal representative or 
professional clinical consultee. 
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Table 3.1. Description of Clinical Thesis Material. CPC – Cerebral Performance Category 
(CPC 1: normal cerebral function and normal living; CPC 2: cerebral disability but 
sufficient function for activities of daily living; CPC 3: severe disability, limited cognition, 
inability to carry out independent existence; CPC 4: coma; CPC 5: brain death), GCS – 
Glasgow Coma Scale, GOS - Glasgow Outcome Score (1= dead, 2= vegetative state, 3= 
severe disability, 4= moderate disability, and 5=good recovery). 
 
Chapter  Full Title of Study Patient 
Demographics 
Condition 
Studied 
Retrospective or 
Prospective 
4 Cerebrovascular 
Consequences of Elevated 
Intracranial Pressure after 
Traumatic Brain Injury 
1023 patients 
(Age Range:  18.5-
56.2 years; 
Admission GCS: 
3.3-10.4; Median 
GOS: 1-4). 
TBI Retrospective 
4 Measurement Accuracy 
for Intracranial Pressure 
Monitoring 
Variable TBI Literature Review 
 
4 Compensatory-Reserve-
Weighted Intracranial 
Pressure and its 
Association with Outcome 
after Traumatic Brain 
Injury 
1023 patients 
(Age Range:  15.0-
85.0 years; 
Admission GCS: 
4-9; Median 
GOS: 1-5). 
TBI Retrospective 
5 Relationship Between 
Brain Pulsatility and 
Cerebral Perfusion 
Pressure 
20 patients (Age 
Range: 15.0-60.0 
years; GCS: 3-7; 
Median GOS: 2-
5).  
TBI Retrospective 
 
 
5 Estimation of Pulsatile 
Cerebral Arterial Blood 
Volume based on 
52 patients (Age 
Range: 17.0-70.0 
years; GCS: 1-12; 
TBI Retrospective 
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Transcranial Doppler 
Signals 
Median GOS: 1-
5). 
6 Validation of Non-
Invasive Cerebrovascular 
Pressure Reactivity and 
Pulse Amplitude 
Reactivity Indices in 
Traumatic Brain Injury 
273 patients (Age 
Range: 3.0-77.0 
years; GCS: 1-15; 
Median GOS: 1-
5).  
TBI Retrospective 
6 Feasibility of Non-Invasive 
Multimodal Brain 
Monitoring in Intensive 
Care Patients 
40 patients (Age 
Range: 20.4-69.73 
years, Median 
CPC: 1-5). 
Cardiac arrest, 
meningitis, 
seizure, sepsis, 
metabolic 
encephalopathies, 
overdose, or 
organ 
failure/transplant 
 
Prospective 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 – Methodology   46 
 
3.2        Data Acquisition and Processing 
ABP was continuously monitored invasively [from the either the radial or the femoral 
artery using a pressure monitoring kit (Baxter Healthcare C.A., U.S.A.; Sidcup, U.K.)] in 
both the retrospective and prospective studies. In the five subsets of TBI patients, ICP 
was monitored using an intraparenchymal probe with strain gauge sensors (Codman & 
Shurtleff, M.A., U.S.A. or Camino Laboratories, C.A., U.S.A.). Prior to 1996, one-minute 
data time averages were collected by computerized software that was developed in-
house. From 1996-2002, all data trends were sampled at 100 Hz and stored as one-
minute trends with the dedicated monitoring software system ICM. From 2002 onward, 
all data trends were collected and integrated with ICM+© software (licensed by 
Cambridge Enterprise, Cambridge, U.K.: http://www.neurosurg.cam.ac.uk/icmplus). 
Cerebral autoregulation as expressed by PRx was calculated as the linear Pearson 
correlation coefficient between 30 consecutive 10-second averaged values of ABP and 
ICP (continuous PRx values were generated by a 300-second moving window). CPP was 
calculated as the difference between ABP and ICP. Post-processing, minute-by-minute 
data for each patient was exported into comma-separated-value (CSV) files for later 
analysis in Microsoft Excel, Statgraphics (Statpoint Technologies, Inc., V.A., U.S.A.), 
IBM SPSS Statistics 23, or R software (R Core Team [2017]; R: a language and 
environment for statistical computing. R Foundation for Statistical Computing, Vienna, 
Austria. URL https://www.R-project.org/). 
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Table 3.2. Neuromonitoring Modalities Utilized for Data Capture and Analysis. ABP – arterial blood pressure, AMP – amplitude of the 
ICP waveform, CaBV – cerebral arterial blood volume, CrCP – critical closing pressure, CPP – cerebral perfusion pressure (ABP-ICP), 
DCM – diastolic closing margin, FV – cerebral blood flow velocity, ICP – intracranial pressure, Mx – mean flow index (correlation 
between FV and CPP), Mx_a – mean flow index calculated with ABP, PAx – pulse amplitude index (correlation between AMP and mean 
ABP), PI – pulsatility index, PRx – pressure reactivity index (correlation between ABP and ICP), RAP – resistance area product (linear 
regression analysis of ABP and FV waveforms over one cardiac cycle), and sPI – spectral pulsatility index.  
 
Modality Invasive or Non-Invasive Transducer Monitoring Software Secondary 
Parameters 
Intracranial 
Pressure 
Invasive Codman 
MICROSENSOR 
intraparenchymal 
probe  
(Codman & 
Shurtleff, M.A., 
U.S.A.) 
GE Marquette 
Solar System 
(GE 
Healthcare, 
Chicago, I.L., 
U.S.A.) 
ICM+TM Mean ICP 
CPP 
AMP 
PRx 
RAP 
PAx 
Cerebral 
Blood Flow 
Velocity 
Non-Invasive Rimed 2 MHz probe 
(Rimed Digi- 
LiteTM, Rimed Ltd., 
Israel), DWL 2MHz 
None ICM+TM Mean FV 
Mx 
Pulsatile CaBV 
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probe (Multi Dop 
X4, DWL 
Elektronische 
Systeme, 
Sipplingen, 
Germany) 
PI 
sPI 
CrCP 
DCM 
 
Arterial Blood 
Pressure 
Invasive Taken from the 
radial or the 
femoral artery using 
a standard pressure 
monitoring kit 
(Baxter Healthcare 
C.A., U.S.A.; Sidcup, 
U.K.)] 
GE 
CARESCAPE 
B850 (GE 
Healthcare, 
Chicago, I.L., 
U.S.A.) 
 
ICM+TM Mean ABP 
CPP 
Mx_a 
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Chapter 4 
 
Clinical Implications of Intracranial Pressure 
in Brain Injury 
 
 
 
 
 
 
 
 
The following publications formed the basis of this chapter: 
 
❖ Calviello LA, Zeiler FA, Donnelly J, Smielewski P, Czigler A, Lavinio A, Hutchinson 
PJ, and Czosnyka M. Cerebrovascular Consequences of Elevated Intracranial 
Pressure after Traumatic Brain Injury. Neurocritical Care. In Review. 
 
❖ Calviello LA, Forcht Dagi T, Czosnyka Z, and Czosnyka M. Measurement Accuracy 
for Intracranial Pressure Monitoring. Neurosurgery. In Review. 
 
❖ Calviello LA, Donnelly J, Cardim D, Robba C, Zeiler FA, Smielewski P, Czosnyka M. 
Compensatory-reserve-weighted Intracranial Pressure and its association with 
outcome after Traumatic Brain Injury. Neurocritical Care. 2018 Apr 1;28(2):212-20. 
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4.1  Cerebrovascular Consequences of Elevated
   ICP after TBI 
 
4.1.1  Introduction 
TBI commonly results from external blunt force applied to the cranium during 
such adverse events as falls, motor vehicle accidents, assaults, and sporting injuries(3). 
Cerebral autoregulation is a complex intrinsic protective mechanism for the brain that 
is strongly dependent on the maintenance of clinically-appropriate levels of ABP, ICP, 
and CPP (the difference between ABP and ICP)(1). Complications of TBI often manifest 
in the first two days after admission(40) in the form of worsening cerebral autoregulation. 
However, this does not exclude other reasons for dysautoregulation such as endothelial 
dysfunction, metabolic failure, hyperemia, etc. 
 Perhaps the greatest risk factor for poor patient outcome is sustained, high 
values of ICP, which dangerously strain cranial volumetric capacity and can produce 
irreversible damage(11). According to the Monro-Kellie doctrine, ICP is comprised of four 
separate components: arterial blood inflow and venous blood outflow (both of which 
contribute to cerebral blood volume, CBV), cerebrospinal fluid (CSF), and a fixed brain 
volume(12); in a healthy system, when one component increases, the others should 
decrease to accommodate for this change in order to maintain a constant value. In TBI 
patients, ICP is often abnormally elevated, requiring aggressive clinical intervention to 
maintain perfusion and prevent brain herniation. These interventions include the use 
of sedative agents and vasopressors, head positioning, CSF drainage, osmotherapy, 
surgical evacuation or decompression, and targeted temperature management(11).  
Intracranial compliance is characteristically reduced in patients with intracranial 
hypertension, meaning that patients with elevated ICP are at risk of further significant 
spikes in ICP even in response to minor volume changes of intracranial blood and CSF 
or brain swelling.  High CPP inversely correlates with ICP, predisposing the injured 
brain to hypoxia by increasing the compartmental volume load until it triggers the 
ultimately deadly trifecta of “mechanical compression, displacement, and herniation of 
brain tissue”(13). Invasive ICP monitors are essential to the diagnosis and treatment of 
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high ICP; however, initial values of ICP (determined on admission to NCCU) are poor 
predictors of outcome, particularly in those with mass lesions(14). There is a bilateral, 
causal relationship between brain damage and high ICP; intracranial hypertension 
(sustained values of ICP >20 mm Hg) unfolding over a period of days can progressively 
alter the brain’s ability to adapt its cerebral structural and volumetric reserves(15) to 
maintain a reasonable degree of function. In survivors, the long-term effects of 
persistent neuroinflammation and chronic structural degeneration  can dramatically 
increase the risks of depression, susceptibility to cognitive loss and dementia, or 
accelerated rates of brain atrophy(3).  
In neurocritical care centers, outcome following TBI cannot be predicted on the 
basis of ICP alone. ICP interacts with a variety of other parameters (both “traditional” 
and derived) to influence the  tactics of individual management(9,81–87). In conjunction 
with invasive ICP, ABP, and cerebral tissue oxygenation monitoring (yielding PbtO2, 
brain tissue oxygen partial pressure), non-invasive methods such as TCD can strengthen 
clinical efforts to predict outcome. With this bedside tool, cerebral blood flow velocity 
(CBFV) from the middle cerebral artery, the waystation for cerebral circulation, can be 
measured and analyzed as a surrogate descriptor of global cerebral blood flow(81). 
Although CBFV in TBI cannot be correlated with CBF because of the variable cross-
sectional area of the investigated vessels, multiple indices of CBF based on TCD have 
been proposed.  TCD monitoring also returns the pulsatility index (PI), that has been 
suggested to alert clinicans to high ICP(88,89). Important clinical indices such as the 
invasively-quantified PRx (based on the analysis of slow vasogenic waves in ABP and 
ICP) and the non-invasive cerebral autoregulation index based on TCD (Mx – the linear 
correlation coefficient between CBFV and CPP) can also be displayed at the bedside; 
both indices are interpreted in the same fashion, with negative values of each suggesting 
preserved cerebral autoregulation and increasingly positive values indicating the 
opposite effect(1).   
This study examines the consequences of increasing ICP on cerebral 
autoregulation and their implications for TBI patients. It aims to provide clear 
description of the differences in both physiological and cerebral hemodynamic activities 
in a large population of TBI patients and their correlation with favorable or unfavorable 
outcome.  
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4.1.2  Methods 
Patients 
Patient data were retrospectively acquired from a database of patients subjected 
to continuous recording of ICP and ABP signals. These recordings were taken over the 
patients’ entire stay on the neurocritical care unit (NCCU) at Addenbrooke’s Hospital, 
Cambridge, U.K. from 1992-2013 (anywhere between 1 day to 4 weeks in duration, n= 
1,023). In an indicated further number of patients, brain tissue oxygenation was 
monitored. Some of these patients had TCD recordings (n=325) and TCD-related 
parameters were calculated. Six-month outcome data has been documented during the 
period between 1992-2015. Each cohort (intermittent TCD and long-term ICP/ABP/ 
PbtO2) was further separated into groups of patients with either normal ICP (<15 mm 
Hg) or elevated ICP (>23 mm Hg). All patients received continuous monitoring with 
ICM+TM software (Cambridge Enterprise Ltd., Cambridge, U.K., 
http://www.neurosurg.cam.ac.uk/icmplus) recorded together with continuous invasive 
ICP and ABP to provide a visualization of the pathophysiological effects of TBI. All 
patients were sedated with a mixture of propofol, fentanyl, and midazolam and were 
mechanically ventilated. 75% of patients presented with an admission GCS <9 and were 
treated with a graded management protocol aiming CPP above 60-70 mm Hg and ICP 
<20 mm Hg(36).  
 
Monitoring 
All patients underwent invasive ABP, ICP, and PbtO2 monitoring. A subset of 325 
patients also received non-invasive monitoring of TCD-based CBFV. Raw data signals 
from select monitoring devices were captured and digitally archived using WREC 
software (Warsaw University of Technology) or ICM+TM software (Cambridge 
Enterprise, Ltd. -contemporary to WREC software). ABP was continuously monitored 
invasively from the radial artery via pressure monitoring kits (Baxter Healthcare, C.A., 
U.S.A.; Sidcup, U.K.). ICP was also monitored continuously with invasive 
intraparenchymal probes equipped with strain gauge sensors (Codman & Shurtleff, 
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M.A., U.S.A. or Camino Laboratories, C.A., U.S.A.) inserted predominantly in the right 
frontal lobe. Mean cerebral blood flow velocity (CBFVm) was recorded from the middle 
cerebral artery (MCA) with a 2 MHz TCD probe (Multi Dop X4, DWL Elektronische 
Systeme, Sipplingen, Germany), on the side of the ICP microtransducer placement, or 
the opposite side if the TCD signal window was better. Data were processed through a 
16-bit, 100kHz analog-to-digital converter (DT9803 USB Data Acquisition (DAQ) 
Module, Measurement Computing Corporation, Norton, M.A., U.S.A.).  
 
Ethics 
All described monitoring modalities are routinely employed as standard care 
practice on NCCU, complete with an anonymized database of physiological parameters. 
Identifiable patient information such as age, injury severity, and clinical status at 
hospital discharge were recorded during monitoring periods; clinical records were not 
revisited for additional analytical purposes. At the time of data extraction from the 
hospital records, each archived monitoring session was fully anonymized so that 
obtaining formal patient or proxy consent for access was not required.  
Since all data was extracted from the hospital records and fully anonymized, no 
data on patient identifiers were available, and need for formal patient or proxy consent 
was waived. Within our institution, patient data may be collected with waiver of formal 
consent, as long as it remains fully anonymized, with no method of tracing this back to 
an individual patient. Patient physiologic, demographic, and outcome data was 
collected by the clinicians involved with patient care, and subsequently recorded in an 
anonymous format.  This anonymous data is then provided for future research purposes.  
Such data curation remains within compliance for research integrity as outlined in the 
UK Department of Health - Governance Arrangements for Research Ethics Committees 
(GAfREC), September 2011 guidelines, section 6.0.(90)  
 
Data Processing 
Raw data signals were supported and processed by ICM+TM software (Cambridge 
Enterprise, Cambridge, U.K., http://www.neurosurg.cam.ac.uk/icmplus). Signal 
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artifacts were manually removed by internal signal cropping tools within ICM+TM. CPP 
was calculated as the difference between the raw ABP and ICP signals.  
In the primary analysis phase, time-averaged mean values for ABP, CBFV, CPP, 
and ICP were calculated for each patient over 10-second time windows, updated every 
10 seconds to eliminate overlap. Mean CBFV was calculated from the raw CBFV signals. 
Next, in the intermittent TCD cohort, multi-parametric measures of autoregulation 
such as: Mx (mean flow index, the correlation between CBFV and CPP)(36), CrCP (critical 
closing pressure, the plotted comparison between ABP and CBFV where CBFV = 0)(91), 
DCM (diastolic closing margin, the difference between diastolic ABP and CrCP)(85), 
sPI(28) (spectral pulsatility index), F1/CBFVm (with F1 the fundamental frequency of 
CBFV), and ARI (autoregulation index, a graded reference index of cerebral 
autoregulation) were also calculated(36). In the long-term ICP/ABP/PbtO2 cohort, PRx 
(pressure reactivity index, the correlation between ABP and ICP)(92), HR (heart rate), 
AMP (the fundamental frequency of ICP, 20-second time windows updated every 10 
seconds), SLOW (slow waves of ICP, yielded through low-pass spectral filtration of raw 
ICP signals), PbtO2 (brain tissue oxygenation), PAx (pulse amplitude index, the 
correlation between AMP and mean ABP), and RAC (an autoregulation index 
determined by the correlation between AMP and CPP) were calculated in addition to 
the primary parameters(93). In all patients, age, admission GCS (Glasgow Coma Scale, 
assessing consciousness from scores of 3-15, with 15 representing the highest level of 
consciousness), and GOS (Glasgow Outcome Scale, ranging from 1-5, with 1 representing 
death and 5 a good outcome) were included as additional demographic data to identify 
long-term outcome trends.  
Final data processing involved the comparison of the above hemodynamic 
parameters between the two ICP groups (normal vs. elevated) within each cohort 
(intermittent TCD vs. long-term ICP/ABP/PbtO2). All data post-processing were 
exported from each patient to separate comma-separated variable (CSV) files for further 
statistical analysis. 
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Statistics 
 All statistical analyses were conducted using STATISTCA data analysis software. 
Post-processing data, exported as CSV files, were compiled into two large CSV 
documents (intermittent TCD and long-term ICP/ABP/PBtO2 cohorts) containing all of 
the above recorded signals for each patient. Data for each cohort was then filtered by 
ICP level (normal ICP <15 mm Hg, and elevated ICP >23 mm Hg). The value of 23 is a 
critical level of ICP from the point of view of differentiation between survival and 
mortality(36), whereas 15 mm Hg is a consensus -accepted threshold of value for normal 
ICP. Statistical significance for invasively-monitored variables and non-invasively 
derived variables (based on TCD) was determined both within and between each subset 
of patients via the Mann-Whitney U-test with an alpha of 0.05 assigned to entries with 
p-values below this threshold. Given that this analysis is an exploration into multi-
modal defined cerebrovascular parameters during normal ICP and intracranial 
hypertension (i.e. ICP >23 mmHg), we elected to not correct for multiple comparisons, 
in keeping with other physiologic exploratory studies. 
 In the TCD cohort, the relationships between CBFVdiastolic/CBFVm, Mx, CrCP, 
DCM, sPI, and ARI were compared between the normal and elevated ICP patient 
subgroups.  In the long-term cohorts, the effects of “normal” versus “elevated” ICP were 
similarly compared to outcome with respect to the following variables: age, admission 
GCS, GOS, PRx, CPP, ABP, HR, AMP, SLOW, PbtO2, PAx, and RAC. 
 
4.1.3  Results 
Examples of selected recorded vascular variables are provided in Figures 4.1-3. They 
include the short-term elevation of ICP provoked by cerebrovascular relaxation, causing 
a temporary increase in ICP – a plateau wave (Figure 4.1). The second example features 
refractory intracranial hypertension associated with malignant brain edema (Figure 
4.2). The third presents a temporary rise in ICP driven by an increase in CBFV; this may 
be attributable to an increase in either PaCO2 or brain metabolism (Figure 4.3). 
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Figure 4.1. Plateau Wave of ICP. This is an example of when CBFV decreases due to 
failing autoregulation. Brain oxygen saturation yielded from near-infrared spectroscopy 
(TOI) decreases, indicating a similar response in cerebral blood flow. This elevation in 
ICP occurred over 15 minutes and was managed by nursing intervention 
(vasoconstriction via Ambu-bag short-term hyperventilation). 
 
 
 
Figure 4.2. Refractory Intracranial Hypertension. After a few days of stable ICP 
(around or below 20 mm Hg) and CPP, dynamics of the signal increased. Finally, ICP 
increased to 90 mm Hg over a period of several hours, CPP decreased to below 40 mm 
Hg, and brain tissue oxygenation fell to below 10 mm Hg. 
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Figure 4.3. Effects of ICP on Cerebral Blood Flow. Deep ICP waves related to the 
increase in cerebral blood flow and therefore cerebral blood volume. This effect can be 
observed quite frequently after TBI. Note that the change in CBFV is not caused by 
intracranial hypertension, but that intracranial hypertension is secondary to the rise in 
cerebral blood volume. 
 
 Table 4.1 summarizes the mean values and standard deviations of each parameter 
compared against either normal or elevated levels of ICP; summary statistics data for 
each patient cohort are also featured in this table. Significance levels are reported at the 
bottom of the table. The results of the presented analyses indicated that irrespective of 
the patient cohort, elevated levels of ICP significantly affect cerebrovascular function, 
and subsequently, patient outcome after TBI.  
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Table 4.1.  Comparison of cerebral hemodynamics with both normal and elevated levels 
of intracranial pressure in both the intermittent and long-term ICP/ABP/ PbtO2 cohorts 
[mean values unless otherwise reported]. ABP – arterial blood pressure, Age – age 
measured in years, AMP – amplitude of the intracranial pressure wave, ARI – 
autoregulation index, bpm – beats per minute, CBFVdiastolic/CBFVm – the quotient of 
 
 
 
Normal ICP 
(<15 mm Hg) 
 
 
Elevated ICP 
(>23 mm Hg) 
 
p-value◊ 
Age [Years] 39.0 (±17.2) 
n = 419 
34.0 (±15.5) 
n = 115 
p=0.0065 
** 
Median GCS 7.0 n = 396 6.0 
n = 104 
p=0.089 
Median GOS 4.0 
n = 401 
1.0 
n = 116 
p<0.00001 
**** 
ICP [mm Hg] 10.504 (±3.21) 
n = 401 
31.1(±9.22) 
n =116 
p<0.0001 
*** 
CPP [mm Hg] 80.52 (±10.2) 
n = 401 
66.9 (±13.9) 
n = 116 
p=0 
**** 
ABP [mm Hg] 91.3 (±10.1) 
n = 401 
97.6 (±12.2) 
n = 116 
p<0.001 
** 
HR [bpm] 80.6 (±16.1) 
n = 413 
83.7 (±16.0) 
n = 105 
p=0.16 
 
PbtO2 [mm Hg] 30.14 (±19.8) 
n = 99 
24.9 (±45.0) 
n = 10 
p=0.15 
PRx 0.07 (±0.15) 
n = 334 
0.2 (±0.24) 
n = 66 
p<0.001 
*** 
PAx -0.12 (±0.17) 
n = 69 
0.41 (±0.17) 
n = 6 
p<0.0001 
*** 
RAC -0.252 (±0.24) 
n = 223 
-0.118 (±0.26) 
n = 38 
p=0.0076 
** 
AMP [mm Hg] 1.44 (±0.86) 
n = 394 
2.63 (±1.6) 
n = 110 
p=0 
**** 
SLOW [mm Hg] 1.28 (±2.52) 
n = 63 
1.13 (±1.28) 
n = 85 
p=0.63 
CBFVdiastolic/CBFVm  0.61 (±0.067) 
n = 127 
0.57 (±0.089) 
n = 66 
p=0.0056 
** 
Mx -0.015 (±0.29) 
n = 127 
0.13 (±0.31) 
n = 66 
p=0.0019 
** 
ARI 4.36 (±1.51) 
n = 101 
3.44 (±1.36) 
n = 52 
p<0.0001 
*** 
CrCP [mm Hg] 36.8 (±8.32) 
n = 109 
53.7 (±9.8) 
n = 56 
p=0 
**** 
DCM [mm Hg] 28.0 (±6.5) 
n = 109 
19.5 (±7.4) 
n = 56 
p<0.0001 
*** 
sPI 0.3 (±0.08) 
n =127 
0.36 (±0.096) 
n = 66 
p=0.0014 
** 
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diastolic cerebral blood flow velocity and mean cerebral blood flow, CPP – cerebral 
perfusion pressure, CrCP – critical closing pressure, DCM – diastolic closing margin, GCS 
- Glasgow Coma Scale, GOS – Glasgow Outcome Score, HR – heart rate, ICP – intracranial 
pressure, mm Hg – millimeters of mercury, Mx – mean flow velocity index, PAx – pulse 
amplitude index, PbtO2 – brain tissue oxygenation partial pressure, PRx – pressure 
reactivity index, RAC – the correlation coefficient between the pulse amplitude of 
intracranial pressure  and cerebral perfusion pressure, SLOW – slow waves of intracranial 
pressure, and sPI – spectral pulsatility index. * – significant, ** – very significant, *** – 
very highly significant, and **** –  extremely significant. 
◊Statistical significance) was determined via the Mann-Whitney U-test with an alpha of 
0.05 assigned to entries with p-values below this threshold. 
 
4.1.4  Discussion 
The main finding of this study is that elevated ICP significantly affects healthy 
cerebrovascular dynamic function. Both directly invasively-quantified parameters (i.e. 
mean values of CPP, PbtO2, etc.) and non-invasive, TCD-based derived parameters (i.e. 
CBFV, Mx, etc.) reflect physiological variability, with respect to patient subgroup.  
 In patients with intact autoregulatory capacity, ABP and ICP are inversely 
related. However, in those patients with failing autoregulatory capacity, this 
pressure/volume relationship becomes pressure-passive. ABP was determined to be 
higher in patients with elevated ICP, the result of either natural fluctuations in cerebral 
blood volume (CBV) attributable to vasodilation or to the administration of 
vasopressors to stabilize TBI patients(94) (additionally, more severely-injured patients 
had lower admission GCS scores and overall higher ICP(95). By treating 
dysautoregulation by altering either ABP or ICP to constrain CBV, the likelihood of 
pressure-passivity decreases(94). The pressure reactivity index (PRx), the linear 
correlation coefficient between mean ABP and mean ICP, was also determined to be 
higher in those with elevated ICP(95). As ABP becomes pressure-passive to rising ICP, 
the value of PRx increases from negative values to either approach or exceed 0. Patients 
with high ICP and high PRx are more likely to have poor long-term outcomes after 
TBI(1,21,90,95,96)  
CPP is classically recognized as the cerebrovascular pressure gradient(91), the 
calculated difference between ABP and ICP; values of CPP ranging from 55-105 mm Hg 
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are considered to be within the limits of normal cerebral autoregulation. Increasing ICP, 
and thus ICP wave amplitude (AMP), as a result of TBI is inversely related to the brain’s 
ability to maintain an appropriate level of CPP; continuous decrements of CPP can 
predispose patients towards ischemia(14). Our findings are consistent with this general 
knowledge of CPP. Furthermore, when plotting CBFV against CPP, yielding the non-
invasive, TCD-based parameter Mx, patients with intact autoregulation have values of 
Mx that are either negative or close to 0; conversely, it is expected that a 
dysautoregulating patient with high ICP and therefore low CPP, would have a higher 
Mx(9), a trend echoed by our analyses. Non-linear regression analysis of sPI (spectral 
pulsatility index) versus CPP also reveals worsening autoregulation, as the value of sPI 
increases with falling CPP(89). This parameter is also associated with the prediction of 
CPP reaching its lower bound, likely resultant of high ICP in susceptible patients(89). 
 Mean CBFV in the MCA is significantly affected by ICP. The flow velocity 
waveform is dampened in patients with intracranial hypertension, particularly in the 
diastolic portion of the raw wave signals extracted from TCD recordings(85). This effect 
can be attributed to the interaction between low CPP resultant of high ICP and the 
acceleration of global cerebral blood flow towards pressure-passivity, characteristic of 
dysautoregulation, which can be monitored by identifying the critical closing pressure 
(CrCP) for each patient, the value of ABP at which cerebral blood flow ceases. CrCP is 
defined as the sum of ICP and vascular wall tension, and calculated by correlating 
pulsatile CBFV and ABP and extrapolating the ABP value at which CBFV equals zero. 
CrCP can demonstrate CPP below its “safe” lower bound and can predict pressure-
passive responses to cerebral blood flow(28,84,85,92). Our results agree, as patients with 
elevated ICP would by definition have a higher threshold for CrCP(84);  when the brain 
is no longer able to compensate for declining CPP via vasodilation over repeated cardiac 
cycles, this absence of diastolic flow precludes “imminent” hypoxia and brain death(85). 
The diastolic closing margin (DCM), the difference between diastolic ABP and CrCP, 
describes the local point at which diastolic cerebral blood flow ceases, coupled with 
pressure-passivity and likely microvascular collapse when approaching 0 or negative 
values(85). Patients in the elevated ICP subgroups for both TCD monitoring and long-
term ICP/ABP/ PbtO2 exhibited lower DCM, which is consistent with the observed 
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trends of high ICP coupled with both dysautoregulation and poor outcome, in the wider 
body of literature.  
 Dysautoregulation can also be described by interactions between high ICP and 
the derived ARI, which quantifies dynamic changes in cerebral autoregulation after 
step-changes in CPP (by manipulating ABP via thigh-cuff release), and is a graded 
reference index that assesses appropriate cerebral blood flow moderation to ABP 
variability. When plotting CBFV against the elapsed time from the thigh-cuff release, a 
series of 10 best-fit template models emerges through transfer function analysis, with 
increasing steepness of these models reflecting better cerebral autoregulation (ARI=9), 
and more gradually-sloped models reflecting the latter (ARI=0)(93). ARI is compatible 
with outcome prediction scoring methods such as GOS, displaying higher values with 
GOS categories of 3-5 (severe disability, moderate disability, and good recovery, 
respectively), and lower values for GOS scores of 1 (dead) or 2 (vegetative state).  
 The continuous, ICP-based indices of autoregulation PAx (pulse amplitude 
index, the correlation between AMP and mean ABP) and RAC (the correlation between 
AMP and CPP) can also identify the effects of ICP on cerebral hemodynamics. Both 
indices are closely related to PRx(86), and are similarly scored, with the exception of RAC 
of 0 indicating worsening autoregulation as ICP increases. Patients with elevated ICP 
had significantly higher PAx (due to increased AMP and ABP) and RAC (due to low CPP) 
than those with normal levels of ICP. As RAC in particular is sensitive to ICP and CPP, 
plotting it against CPP produces a parabolic relationship between the parameters, 
suggestive of RAC’s potential use in the determination of individual values of optimal 
cerebral perfusion pressure(87). 
 
Limitations 
The predictive value of each of the above trends is directly related to the 
calculation methods required to yield each parameter, and how reliably each parameter 
represents true physiology. This being said, there is an established difficulty with the 
identification of a “universal, ‘normal’ value of ICP”(91), as ICP is strongly dependent on 
age, body position, and pathology; our study is limited by our arbitrary categorization 
of “normal” versus “elevated” ICP thresholds on the basis of grand mean values of ICP, 
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and the potential ramifications of this effect on our statistical reporting when assigning 
our patients into subgroups. These thresholds may explain the counter-intuitive 
relationships between ICP, age, and median GOS identified in our results (younger 
patients with lower ICP generally have a higher GOS score(9), as the number of patients 
assigned to each ICP group for comparison was uneven). Additionally, the amount of 
patient data available for multi-parametric autoregulation analysis varied according to 
different selection criteria necessary for the calculation of each parameter(9,36).   
It is of note that TCD monitoring is only a surrogate descriptor of cerebral 
autoregulation, and is fundamentally limited by both inter- and intra-operator 
variability; MCA flow velocity recordings may differ on the basis of probe position and 
return inconsistent measurements, or natural differences in patient skull thickness can 
affect the observed strength of the TCD signal. Although invasive measurement 
techniques are considered “gold standards”, they are flawed; ICP and ABP pressure 
transducers may not sample from the most reliable positions, potentially skewing values 
that then form the bases of derived parameters, such as CPP, which are increasingly 
becoming relied upon for clinical management(82). To minimize these effects and reduce 
the risk of infection, non-invasive ICP (nICP) monitoring derived from CBFV and ABP 
waveforms introduces temporally-sensitive reference data that bolsters reliability when 
predicting outcome(1,90); however, nICP protocols are not yet widely implemented in 
neurocritical care.  
 
4.1.5  Conclusions 
Elevated ICP after TBI directly contributes to decrements in cerebral blood flow. 
Significant alterations in cerebral hemodynamics are the result of the combined effects 
of high ICP, described by positive values of PRx and Mx, which signifies failing cerebral 
autoregulation and leads to more than two-fold increase in mortality.  
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4.2  Measurement Accuracy for Intracranial  
  Pressure Monitoring 
 
4.2.1  Introduction 
A variety of ICP sensors have been utilized to measure ICP and guide treatment. 
Lundberg is widely credited with establishing the clinical paradigm for continuous ICP 
monitoring in the 1960s(97). External ventricular drains (EVDs) are placed within the 
ventricle, measuring ICP pressure directly, and can be used to drain excess CSF and 
lower ICP. They are often characterized as the “gold standard” of ICP measurement. 
Other types of fluid-coupled systems, such as the Richmond bolt™, also measure 
pressure in the CSF but cannot effectively reduce it. ICP measurement devices have also 
been designed around fiberoptic, piezoelectric strain gauge, and pneumatic 
microsensor technologies. Depending on the specific design, they can be inserted into 
the parenchyma, ventricle, or the subarachnoid, subdural, or epidural spaces. While 
they cannot drain CSF, they are easier to implant correctly and carry lower risks of 
infection and complications than EVDs. ICP measurement is utilized routinely when 
there is concern about pressure elevation and there are no contraindications(98–101).  
Accuracy can be elusive when measuring ICP. The problem derives both from 
the physiology of ICP and the limitations of existing instrumentation(102). Two FDA-
approved devices of the same type by the same manufacturer can yield different 
measurements when put in two different regions of the brain. Almost every ICP 
measurement device may drift; some types may be recalibrated, but not all.  This paper 
reviews the concepts and factors that bear on the accuracy of ICP measurements 
including the reliability of the existing ICP measuring technologies. 
 
4.2.2   Intracranial Pressure Sensor Technology 
ICP can be monitored continuously by means of devices implanted in the ventricle, the 
parenchyma, the subarachnoid space, the epidural space, the skull (but open to the 
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subarachnoid space), the cervical cistern, or the lumbar subarachnoid space. Devices in 
the ventricle, the cervical cistern, and the lumbar subarachnoid space can be designed 
to drain CSF and measure ICP. Those implanted elsewhere are capable only of ICP 
measurement.  
Pressure measurement requires either a manometer to which the fluid-filled 
catheter is connected, or some kind of pressure transducer. A manometer is the classical 
instrument for pressure measurement. It displays a column of fluid, generally CSF but 
alternatively mercury, whose height corresponds to the pressure. This simple 
instrument gives rise to direct pressure readings taking the form “centimeters of H20” 
or “mm of Hg”, with both conventions accepted. A pressure transducer, in contrast, is a 
device with an elastic or moveable component which deforms or moves when subjected 
to pressure, and generates a signal. The signal is typically electrical and correlates with 
the pressure. CSF pressure is traditionally expressed in “centimeters of H20” or “mm of 
Hg” just as it would be on a manometer.  
The three most common types of pressure transducers are: piezoelectric, 
fiberoptic, and pneumatic. Piezoelectric sensors change their internal electrical 
resistance and produce electric signals when subjected to mechanical forces such as 
ICP(103). Fiberoptic sensors incorporate a calibrated mirror which changes position in 
response to pressure(104). Reflected light is transmitted fiber-optically to a photoelectric 
device that generates electrical signals(104). Pneumatic sensors typically consist of a small 
air-pouch balloon which changes volume with pressure. These changes are translated 
into ICP measurements(103,104). As already noted, pressure transducers can take many 
forms and can be implanted in various locations. One simple and particularly successful 
system is connected to a hollow bolt threaded into the calvaria and open to the 
subarachnoid space. This straightforward ICP monitor describes the original or 
modified Richmond subarachnoid screw(105,106) or the commonly-used Licox™ bolt 
(Integra Life Sciences, Plainsboro Township, N.J., U.S.A.).  Transducer-based devices are 
quicker to place and less technically demanding than catheter-based devices. Although 
both device families are relatively safe, either can be complicated by blockage, infection, 
and hemorrhage(107).  
Catheter systems can be calibrated or zeroed in-vivo. Pressure transducers, in 
contrast, must be calibrated before implantation with one exception: the Gaeltec™ 
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epidural system, which was designed to allow in-vivo calibration(108) (Gaeltec, 
Dunvegan, Isle of Skye, Scotland). Monitors that can be recalibrated (or zeroed) in-situ 
to overcome drift and to optimize measurement accuracy are often characterized as 
“gold standards” in ICP measurement(104,109,110). 
4.2.3   Rationale for Continuous ICP Monitoring 
ICP is monitored to help prevent secondary injury after a neurological event. 
Historically, the study of ICP has been pursued most intensively in TBI. Head-injured 
patients often exhibit abnormal ICP dynamics; elevated ICP interferes with cerebral 
blood flow, cerebral perfusion and cerebral compliance (Figure 4.4, below)(111–113). Very 
high levels of ICP can result in cerebral ischemia, herniation of the temporal lobe, or 
trans-tentorial brainstem herniation(111).  
The American Brain Trauma Foundation suggests ICP monitoring for all cases of 
TBI with GCS between 3-8 and abnormal CT scans(49), and for older patients with GCS 
3-8, with either uni- or bilateral motor posturing or with systolic blood pressure below 
90 mm Hg despite a normal scan(109). Some investigators have observed that invasive 
ICP monitoring correlates with improved patient outcomes, independently of 
intervention(104,114–119).  
However, the risks associated with ventriculostomy, which are shared by cervical 
and lumbar drains, include: infection, CSF leak, interference from air bubbles, clots and 
debris, secondary injury and hemorrhage from improper insertion, and other 
complications of prolonged monitoring such as (for ventricular catheters) slit 
ventricles(109,120–124). Intraparenchymal ICP sensors, typically implanted through a burr 
hole to a depth of about 2 centimeters, carry a lower risk of complications and  correlate 
closely with intra-ventricular pressure(104,121). 
Overall, intraparenchymal placement of contemporary ICP sensors is regarded 
as safe, with low risk of hemorrhage (<0.04%)(122). The disadvantages of 
intraparenchymal monitoring are linked to the fact that they measure vectors of force 
within the parenchyma rather than actual CSF pressures. These measurements are 
subject to distortion by several factors, including the direction of the vectors of force 
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exerted on the sensor. As already noted, they can neither drain excess CSF, nor be 
recalibrated following insertion(104,121). In the event that both an EVD and an 
intraparenchymal sensor are implanted at the same time in the same patient, the EVD 
must be closed for measurements to be comparable (Figure 4.5).  
The reliability of intraparenchymal catheters is dependent on pressure sampling 
and distribution, even if the instruments operate as intended. Pressure throughout the 
central nervous system (CNS) follows Pascal’s law: it is equally distributed throughout 
the CNS except in the case of rare stoppages or “hard blocks” in the circulation of CSF, 
although pressure differences are often small(125). Thus, in non-communicating 
hydrocephalus, the pressure gradient between the ventricles and subarachnoid space 
has been reported to be on the order of 1-2 mm Hg or less(125). Even though the 
correlation between two microsensors reporting simultaneously may vary over time and 
in terms of absolute value (Figure 4.6), intraparenchymal ICP measurements ought to 
be reliable. 
 
4.2.4   Thresholds for Clinical Intervention 
The threshold for intervention remains under study. Interventions including ventricular 
drainage, sedation, osmotic diuresis, hypothermia and decompressive craniectomy are 
generally recommended for ICP above 15-25 mm Hg(112). These guidelines are based 
primarily on historical outcome studies focused on survival. Large-scale studies 
emphasizing functional outcomes are currently underway(126–131) and may reach different 
conclusions. Outcome-based guidelines for monitoring in childhood and for other 
conditions are also under consideration(132–138). 
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Figure 4.4. The Pressure-Volume Curve and Brain Compliance. The general shape 
of the pressure-volume curve (upper panel) and related brain compliance (lower panel). 
When extra volume is loaded, ICP first increases linearly, until it reaches the “lower 
breakpoint”. In this zone of good compensatory reserve, brain compliance is 
independent of ICP (note: numerical values on this graph are given for orientation; 
individual limits may be variable). With a further volume load, the shape of the 
pressure-volume curve becomes exponential, and compliance decreases inversely to 
further ICP elevations to a state of poor compensatory reserve. Further, when ICP 
reaches a very high level (“critical” ICP), the arterial bed starts to become compressed, 
with usually observed decreases in cerebral blood flow – there is a threat of brain 
ischemia in this state. The pressure-volume curve deflects to the right and brain 
compliance increases. The shapes of curves and levels of all demarcation points are 
individual; they may be affected by many factors such as cerebral perfusion pressure, 
PaCO2, level of anesthesia, medication, etc. This graph is a compilation of many 
previous works, starting from Löfgren and Zwetnow(139), through Marmarou et al.(140), 
and many more contemporary authors(111). 
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Figure 4.5. Monitoring with an External Ventricular Drain. A recording featuring arterial blood pressure (ABP) and 
intraparenchymal pressure (IPP- bottom panel, grey line) together with EVD pressure (ICP- bottom panel, black line) using an 
external transducer in a patient after poor grade subarachnoid hemorrhage. The left panel demonstrates the results with the 
drain opened, whereas the right panel demonstrates results with the drain closed. With an open EVD, the two pressure readings 
failed to correlate. EVD pressure is held constant at a value representing the calibrated level of the drain above the heart. With 
a closed EVD (right panel), the two measured pressure values correlate over time.  
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Figure 4.6. ICP Sensor Discrepancies. A contradictory presentation of ICP recorded in one patient after TBI. ICP was recorded 
using two intraparenchymal microsensors (ICP- left hemisphere, ICP2- right hemisphere). In the left panel, the two pressures 
are very well-correlated in time, even though around 6 mm Hg of constant difference between the two readings is observed. In 
the right panel, in contrast, the difference is seen to have increased to 20 mm Hg three days later. This patient suffered from 
diffuse brain injury, without midline shift. The reason for the difference in readings was elusive. The true value of the ICP cannot 
be determined from these sensors. 
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As illustrated in Figure 4.6, ICP is not uniformly distributed within the cranial cavity. 
The ICP sensor can only report the value that is locally available(121).. In the brain 
parenchyma, these values are in fact not ICP (the pressure of the CSF fluid) but values 
of the tensor of forces in the parenchyma. Discrepancies between recorded 
intraparenchymal ICP values appear to be unavoidable with the current monitoring 
techniques. Treatment is quickly administered especially where protocols to this effect 
have been initiated. While pressure spikes might command more interest than low ICP, 
falsely low and normal values may be the result of ICP sensor dysfunction and must be 
evaluated in accordance with the specifics of the clinical context(124,141).  
 
4.2.5  Comparison of ICP Sensor Performance with  
  Laboratory Bench Testing 
Prior to regulatory approval, most ICP sensors undergo routine laboratory “bench 
testing” to confirm their performance relative to manufacturing specifications for zero 
drift standards and overall measurement accuracy. The Cambridge experimental bench 
test procedure mimics CSF and physiological compliance(142).. A bottle is filled with 
deionized water, leaving 20 mL of air to be removed during dynamic catheter testing. 
The bottle is then submerged horizontally in a water bath at a constant temperature of 
35°C. Static pressure on the bottle (representing pressure detected by ICP catheters) and 
reference static pressure (representing true ventricular pressure) are compared by 
changing the height of a water column in a 1.5 m graded vertical tube. Static pressure is 
released in intervals by allowing the water to flow out of an opened stopcock; 
conversely, pressure is increased by infusing fluid into the tubing(143,144) (Figure 4.7, 
below).  
Maximal zero drift measurements for a variety of ICP sensors were collected from 
the existing body of literature. They are presented in Table 4.2 (below).  Tables 4.3 and 
4.4 (below) display literature-based comparisons of ICP sensors to each other and to 
CSF reference pressure, respectively. 
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Figure 4.7. Bench Test Procedure. A sophisticated, computer-controlled rig was used 
to assess the compliance of ICP sensors and responsiveness to increased pressure loads. 
A detailed description can be found in Czosnyka et al.(142). 
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Table 4.2. Comparison of Zero Drift Among Different ICP Sensors. Zero drift refers to a 
drift in device calibration that can be remedied by resetting the zero point. ICP sensors 
that cannot be recalibrated in-situ (fiberoptic or piezoelectric strain gauge sensors) and 
even those that can be (pneumatic sensors) often present inaccurate assessments of ICP 
to clinicians that can misinform treatment proceedings. Each sensor is susceptible to 
zero drift, with comparative observations presented here. mm Hg – millimeters of 
mercury.  
 
Reference Sensor  Sensor Type Maximal 
Drift (mm 
Hg/day) 
Comments 
Allin et al. 
(2008)(143)  
Sophysa 
Pressio 
Piezoelectric 
Strain Gauge 
<0.05  Over a 7-day 
period 
Allin et al. 
(2008)(143) 
Codman 
MicroSensor 
Piezoelectric 
Strain Gauge 
<0.05 Over a 7-day 
period 
Al-Tamimi et 
al. (2009)(145)  
Codman 
MicroSensor 
Piezoelectric 
Strain Gauge 
2.0 Median value; 108 
in-situ hours 
(median); drift 
was found to 
increase over time 
(Spearman’s 
correlation 
coefficient = 0.342; 
p= 0.001); drift ≥ 
5.0 mm Hg found 
in 20% of sensors 
Citerio et al. 
(2004)(146)  
Raumedic 
Neurovent-P 
Piezoelectric 
Strain Gauge 
0-2.0 Overall drift past 5 
days; precise 
measurements for 
long-term, 
continuous 
recording 
Citerio et al. 
(2008)(147)  
Raumedic 
Neurovent-P 
Piezoelectric 
Strain Gauge 
±3.0 Clinical 
application of 
Citerio et al. 
(2004)51; 12-17% 
failure of sensor to 
accurately 
measure ICP 
(n=99) 
Czosnyka et 
al. (1996)(144)  
Camino 110-4B Fiberoptic  <0.8 24-hour period 
Czosnyka et 
al. (1996)(144) 
Codman 
MicroSensor 
Piezoelectric 
Strain Gauge 
<0.8 24-hour period 
Czosnyka et 
al. (1996)(148) 
InnerSpace 
Medical ICP 
Spectral 
Frequency 
<0.8 24-hour period; 
zero drift <0.4 mm 
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Monitoring 
Catheter Kit 
(OPD-SX) 
Hg measured at a 
static pressure of 0 
mm Hg 
Czosnyka et 
al. (1997)(142)  
Camino 110-4B Fiberoptic <0.7 24-hour period 
Czosnyka et 
al. (1997)(142) 
Spiegelberg Pneumatic <0.7 24-hour period; 
hourly 
adjustments to 
zero produced 
<0.3 mm Hg drift 
Gelabert-
González et 
al. (2006)(149)  
Camino 110-4B Fiberoptic 7.3 ±5.1 Mean value; 
clinical assessment 
of 1000 sensors:  
79 sensors (12.6%) 
showed no zero 
drift 
on removal; mean 
monitoring 
time of 58.4 ±8.6 
hours 
Gray et al. 
(1996)(150)  
Codman 
MicroSensor 
Piezoelectric 
Strain Gauge 
0-1.0 24-hour period; 
sensors inserted in 
both parenchymal 
(mean zero drift: 
0.312 mm Hg) and 
subdural (mean 
zero drift: 0.475 
mm Hg) locations 
Koskinen et 
al. (2005)(151)  
Codman 
MicroSensor 
Piezoelectric 
Strain Gauge 
0.9±0.2 Zero drift not 
correlated with 
duration of 
monitoring 
(analysis of data 
recorded over 7.2 
± 0.4 days; p= 0.9, 
Pearson R=0.002) 
Lang et al. 
(2003)(152)  
Spiegelberg Pneumatic ≥±2.0  Average 
monitoring time of 
10 days; sensors 
inserted in both 
intraparenchymal 
and subdural 
locations 
Lilja et al. 
(2014)(153)  
Raumedic 
Neurovent-P 
Piezoelectric 
Strain Gauge 
±2.0 Assessment of 
hydrocephalus 
patients (n=21); 
median duration 
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of sensor 
implantation was 
288 days; poor 
compatibility with 
ICP curve 
visualization 
software 
Martínez-
Mañas et al. 
(2000)(154) 
Camino 110-4B Fiberoptic 0±2.0 in the 
first 24 
hours, then 
<±1.0 per 
day 
56 probes tested to 
confirm 
manufacturer 
specifications; 
60.71% complied 
with zero drift 
standards, 39.28% 
drifted to positive 
or negative values; 
no observed  
correlation 
between  
monitoring 
duration and zero 
drift (p=0.27) 
 
Morgalla et 
al. (1999)(155)  
Camino 110-4B Fiberoptic 1.0-2.0 Microsensor 
accuracy was 
reported: 24-hour 
period (0.80 mm 
Hg drift), 
measurements 
binned at 5 mm 
Hg pressure 
intervals between 
0-80 mm Hg; 10-
day drift measured 
at the same 
intervals (8.0 mm 
Hg) 
Morgalla et 
al. (1999)(155) 
Codman 
MicroSensor 
Piezoelectric 
Strain Gauge 
4.0≥  Microsensor 
accuracy was 
reported: 
discrepancies 
observed at 
pressures ≥60 mm 
Hg; 24-hour 
period (0.95 mm 
Hg drift), 
measurements 
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binned at 5 mm 
Hg pressure 
intervals between 
0-80 mm Hg; 10-
day drift measured 
at the same 
intervals (2.0 mm 
Hg) 
Morgalla et 
al. (1999)(155) 
Epidyn Epidural >8.0 Microsensor 
accuracy was 
reported: 
underestimated 
ICP, especially at 
higher pressures; 
24-hour period 
(1.20 mm Hg 
drift), 
measurements 
binned at 5 mm 
Hg pressure 
intervals between 
0-80 mm Hg; 10-
day drift measured 
at the same 
intervals (15.0 mm 
Hg) 
Morgalla et 
al. (1999)(155) 
Gaeltec ICT/B Epidural 4.0≥ Microsensor 
accuracy was 
reported: 24-hour 
period (1.5 mm Hg 
drift), 
measurements 
binned at 5 mm 
Hg pressure 
intervals between 
0-80 mm Hg; 10-
day drift measured 
at the same 
intervals (10 mm 
Hg) 
Morgalla et 
al. (1999)(155) 
HanniSet External 
Ventricular 
Drain 
1.0-3.0 Microsensor 
accuracy was 
reported: 24-hour 
period (0.2 mm Hg 
drift), 
measurements 
binned at 5 mm 
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Hg pressure 
intervals between 
0-80 mm Hg; 10-
day drift measured 
at the same 
intervals (1.0 mm 
Hg) 
Morgalla et 
al. (1999)(155) 
Medex External 
Ventricular 
Drain 
2.0-4.0 Microsensor 
accuracy was 
reported: 24-hour 
period (1.8 mm Hg 
drift), 
measurements 
binned at 5 mm 
Hg pressure 
intervals between 
0-80 mm Hg; 10-
day drift measured 
at the same 
intervals (3.5 mm 
Hg) 
Morgalla et 
al. (1999)(155) 
Spiegelberg  Pnematic <4.0 at 
pressures 
>50mm Hg; 
≤6.0 at 
pressures 
>60 mm Hg 
Microsensor 
accuracy was 
reported: 24-hour 
period (2.1 mm Hg 
drift), 
measurements 
binned at 5 mm 
Hg pressure 
intervals between 
0-80 mm Hg; 10-
day drift measured 
at the same 
intervals (7.0 mm 
Hg) 
Morgalla et 
al. (2002)(156) 
Camino 110-4B Fiberoptic 2.9 Median values 
for mean absolute 
pressure changes; 
10-day drift: 4.0 
mm Hg 
(transducers 
tested at 0-50 mm 
Hg) 
Morgalla et 
al. (2002)(156) 
Gaeltec ICT/B Epidural 5.2 Median values 
for mean absolute 
pressure changes; 
10-day drift: 9.0 
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mm Hg 
(transducers 
tested at 0-50 mm 
Hg)  
Morgalla et 
al. (2002)(156) 
HanniSet External 
Ventricular 
Drain 
0 Median values 
for mean absolute 
pressure changes; 
10-day drift: 0 mm 
Hg (transducers 
tested at 0-50 mm 
Hg) 
Morgalla et 
al. (2002)(156) 
Spiegelberg Pneumatic  2.4 Median values 
for mean absolute 
pressure changes; 
10-day drift: 2.0 
mm Hg 
(transducers 
tested at 0-50 mm 
Hg) 
Norager et al. 
(2018)(124) 
Raumedic 
Neurovent-P 
Piezoelectric 
Strain Gauge 
2.5 Median baseline 
drift in 19 sensors 
(median 
implantation time 
of 241 days) 
Piper et al. 
(2001)(157)  
Camino 110-4B Fiberoptic -0.67 Mean zero drift (3-
day median 
implantation 
time); median 
drift reported at -1 
mm Hg; more 
than 
50% of the 
catheters had an 
observed drift >±3 
mm Hg 
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Table 4.3. Agreement Between Intraparenchymal ICP Sensors. This table highlights the 
main differences in measurement capacity found between popular intraparenchymal 
ICP sensors in laboratory* and clinical** studies of TBI patients; these results may 
influence the decision to introduce one sensor over another in clinical practice.  ICP – 
intracranial pressure, mm Hg – millimeters of mercury.   
 
Reference Sensor 1 Sensor 2 Agreement  Comments 
*Allin et al. 
(2008)(143)  
 
Codman 
MicroSensor 
Sophysa 
Pressio 
Excellent 
agreement 
(reported 
Pearson R= 
0.999) 
Codman devices 
require 
additional 
bridge 
amplifiers to 
connect to 
computerized 
data streaming  
**Banister et 
al. (2000)(158)  
 
Camino 110-
4B 
Codman 
MicroSensor 
ICP measured 
within 10 mm Hg 
in 11 patients; >10 
mm Hg disparity 
in 6 patients 
Small sample 
size (n=17); 
Codman was 
“misleading” in 
18% of patients; 
preference for 
Camino sensors 
to register 
clinical events 
*Czosnyka et 
al. (1996)(144)  
 
Camino 110-
4B 
Codman 
MicroSensor 
No significant 
differences in 
zero drift at a 
static pressure of 
20 mm Hg; 
comparable for 
pulsatile 
pressure 
measurement; 
Camino 
temperature 
drift (0.27 mm 
Hg/◦C) 
significantly 
higher than 
Codman; <0.3 
mm Hg static 
error (Camino) 
vs. <2 mm Hg 
static error 
Codman is 
preferred for 
clinical use; also 
bench tested 
InnerSpace 
Medical’s ICP 
Monitoring 
Catheter Kit 
(OPX-SD), 
which had the 
lowest 24-hour 
zero drift 
compared with 
both Codman 
and Camino 
sensors, but 
otherwise did 
not perform as 
well 
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(Codman); very 
good frequency 
detection for 
both (bandwidth 
>30 Hz) 
*Czosnyka et 
al. (1997)(142)  
 
Camino 110-
4B 
Spiegelberg Camino 
temperature 
drift recorded at 
0.27 mm Hg/◦C; 
excellent 
agreement 
between 
transducers at 
pressures 0-100 
mm Hg over 20 
minutes 
(reported 
Pearson R=0.99); 
static error <1 
mm Hg up to 
pressures of 40 
mm Hg that 
increased to 5 
mm Hg at 100 
mm Hg 
(Spiegelberg) vs. 
static error <0.7 
mm Hg 
(Camino) 
Spiegelberg 
devices are less 
expensive, but 
are “limited by 
low frequency 
response and 
non-linear 
distortion as 
amplitude 
underestimation 
increases [with] 
mean pressure”  
**Eide 
(2006)(159)  
 
Camino 110-
4B 
Codman 
MicroSensor 
Differences >5 
mm Hg observed 
in 13% of ICP 
recordings 
Extremely small 
sample size 
(n=3); 
discrepancies 
attributed to 
differing 
baseline 
pressures 
**Eide & 
Bakken 
(2011)(160)  
 
Codman 
MicroSensor 
Raumedic 
Neurovent-P 
Differences in 
baseline pressure 
≥2 mm Hg in 
96% of Codman 
sensors and 53% 
of Raumedic 
sensors observed 
as a result of 
electrostatic 
Discrepancies in 
baseline 
pressures (either 
sudden or 
gradual shifts) 
≥10 mm Hg can 
significantly 
affect ICP 
management 
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discharges (0.5-
5kV) 
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Table 4.4.  Agreement Between Intraparenchymal Sensors and CSF Pressure 
Measurement in Clinical Studies. Sensors that most accurately reflect reference 
pressures within the CSF demonstrate a clear advantage in ICP monitoring. It is worth 
noting that although each sensor sacrifices measurement accuracy to inherent 
differences between atmospheric and cranial compartment pressures, technical issues 
related to either surgical insertion or sensor composition can influence discrepancies 
between “real” and measured pressures. CSF – cerebrospinal fluid, ICP – intracranial 
pressure, and mm Hg – millimeters of mercury. 
 
Reference Sensor Differences from 
CSF Pressure 
Comments 
Brean et al.  
(2006)(161)  
Codman 
MicroSensor 
Mean difference 
between Codman 
and ventricular 
reference pressure 
reported at -0.71 ± 
6.8 mm Hg 
Data obtained from 
a case study; 
measurements from 
single wave 
parameters 
Bruder et 
al. 
(1995)(162)  
Camino 110-4B Camino 
underestimated 
ventricular pressure 
by about 
9 mm Hg 
 
95% confidence 
interval 
of bias: -9.8 to 27.8 
mm Hg; small 
sample size (n=10), 
male patients only 
Chambers 
et al. 
(1993)(163)  
Camino 110-4B Reads an average of 
1.15 mm Hg higher 
than ventricular 
pressure  
 
Chambers 
et al. 
(2001)(164)  
Spiegelberg Mean ICP 
differences >±1.5 
mm Hg between 
Spiegelberg and 
ventricular pressure 
Reported results 
obtained from 10 
patients; small 
overall sample size 
(n=11) 
Childs & 
Shen  
(2015)(165)  
Raumedic 
Neurovent-P 
Mean difference 
between 
intraparenchymal 
and ventricular 
pressure measured 
at −0.832 mm Hg  
Tissue pressure is 
reported to be 
marginally lower 
than ventricular 
pressure (p=0.379); 
temperature also 
did not vary 
significantly 
between local 
pressure sites 
(p=0.92); small 
sample size (n=17) 
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Crutchfield 
et al. 
(1990)(166)  
Camino Model 420 Camino estimated 
ventricular pressure 
within ±3 mm Hg 
over a 0-30-mm Hg 
pressure range; 
robust correlation 
of 0.977 
Study conducted in 
dogs 
Eide et al. 
 (2012)(167)  
 
 Codman 
MicroSensor,  
Edward’s fluid 
sensor connected to 
an external 
ventricular drain 
(Truwave PX-600 F 
Pressure 
Monitoring Set, 
Edwards Life 
sciences LLC, 
Irvine, C.A., U.S.A.), 
and Spiegelberg 
 
Significant 
differences in mean 
ICP reported >5 
mm Hg between 
ventricular pressure 
and each sensor 
type 
 
Comparison of solid 
strain gauge sensors 
with either fluid or 
air-pouch sensors; 
“simultaneous 
monitoring of ICP 
using two solid 
sensors may show 
marked differences 
in static ICP but 
close to identity in 
dynamic ICP 
waveforms”; solid 
ICP sensors exhibit 
less disparity from 
“true” ICP and are 
preferred for clinical 
use; small sample 
size (n=17) 
 
Gopinath 
et al. 
(1995)(168)  
Codman 
MicroSensor 
Mean difference 
between Codman 
and ventricular 
pressure measured 
at 0.5 ± 2.6 mm Hg 
Small sample size 
(n=25) 
Koskinen 
et al. 
(2005)(151)  
Codman 
MicroSensor 
Strong agreement 
between the 
Codman and 
ventricular pressure 
(p<0.0001, Pearson 
R= 0.79) 
 
Mean ICP in the 
ventricles measured 
at 18.3 ±0.3 mm Hg 
vs. 19.0 ±0.2 mm Hg 
measured by 
Codman (n=128) 
Lang et al. 
(2003)(152)  
Spiegelberg Absolute difference 
between 
Spiegelberg  
and intraventricular 
pressure >±3 mm 
Hg in 99.6% of 
paired readings and 
>±2 
Average Bland 
Altman bias of 0.5, 
with 10% lower 
Spiegelberg 
readings with ICP 
>25 mm Hg (n=87) 
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mm Hg in 91.3% of 
paired readings 
Lenfeldt et 
al. 
(2007)(169)  
Codman 
MicroSensor 
Measured 
differences between 
Codman and 
lumbar pressure 
observed at -0.75 
±2.10 mm Hg 
Agreement between 
intracranial and 
lumbar pressure 
assessed patients 
with normal 
pressure 
hydrocephalus 
(n=10) 
Schickner 
& Young 
(1992)(170)  
Camino 110-4B Mean ICP 
difference between 
the Camino and the 
ventricular catheter 
of 9.2 ±7.8 mm Hg 
ICP recorded for up 
to 118 hours; small 
sample size (n=10) 
 
 
4.2.6   Discussion 
Two ICP microsensors implanted in the same brain do not necessarily show the same 
pressure readings. On the basis of the known literature and of our own measurements, 
one can estimate the average 95% confidence limit of agreement to be around 6 mm Hg 
– this should be taken as the inherent accuracy of ICP measuring microsensors after 
implantation. While in-vitro bench-test studies demonstrate much better accuracy, 
accuracy decreases in-vivo.  
To illustrate this point, we performed the following experiment. An animal brain 
was submerged in a sealed jar and two microsensors were placed at the same depth 
beneath the top of the water column; one microsensor was inside the brain tissue and 
the other was in the surrounding water. When the jar was pressurized, the transducer 
in the water exhibited a pressure that was 20 mm Hg higher than that in the brain. This 
constant difference was maintained over several hours (Fig 4.8). In the living brain, 
there are still cerebral blood microcirculation pressure differences, but at a much lower 
rate (microsensor tips are in a semi-liquid extravascular environment). 
  
Chapter 4 – Clinical Implications of Intracranial Pressure in Brain Injury  84 
 
 
 
Figure 4.8. The “dead brain” in a jar (pressurized externally). The microsensor in the brain tissue shows a pressure measured at nearly 
20 mm Hg higher than that of the water. This difference remained unchanged over a long period.
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Comparison of Intraparenchymal Fiberoptic vs. Piezoelectric Strain Gauge Sensors 
 
Intraparenchymal ICP probes, particularly the fiberoptic Camino 110-4B sensor, 
and strain gauge probes, particularly the Codman MicroSensor, are very popular among 
neurocritical care centers for TBI management. In a laboratory bench test(144), both the 
Camino and Codman sensors exhibited zero drift <0.8 mm Hg over 24 hours at a static 
pressure of 20 mm Hg. In comparison, the Camino sensors were found to have 
significantly higher temperature drift than the Codman sensors(142). In a later paired 
comparison of clinical ICP recordings from the Camino and Codman sensors, however, 
the Codman was observed to be deviating by as much as 10 mm Hg in 18% of patients(158). 
Another clinical assessment of the two sensors suggested >5 mm Hg differences in 13% 
of paired ICP recordings(159).  
Paired measurements from Codman MicroSensor and the Sophysa Pressio sensor 
have been reported to be in excellent agreement in a laboratory bench test setting with 
a 7-day zero drift <0.05 mm Hg and static accuracy >0.5 mm Hg. over the tested range 
of 0-100 mm Hg(143). Clinical testing has yet to be completed.  
A paired comparison of the Codman MicroSensor and the Raumedic Neurovent-
P sensor revealed significant differences between baseline pressures (≥2 mm Hg in 96% 
of the Codman sensors and in 53% of the Raumedic sensors) due to either sudden or 
gradual shifts in baseline pressure. These measurement discrepancies were attributed 
to electrostatic discharges (0.5-5.0kV)(160)  
 
Comparison of Intraparenchymal versus Pneumatic Sensors 
Pneumatic sensors can be recalibrated to atmospheric pressure following 
implantation, unlike other intraparenchymal systems. Czosnyka et al.(142) compared the 
zero drift accuracy of the fiberoptic Camino 110-4B model to the Spiegelberg ICP 
Monitoring System sensor. Both sensors reported zero drift <0.7 mm Hg in a 24-hour 
period. The Spiegelberg’s automatic hourly adjustments contributed 0.3 mm Hg (42.9%) 
to the overall measurement drift. Morgalla et al.(155) compared the Speigelberg device to 
competitors and concluded that it exhibited less zero drift over a 10-day period(155,156). In 
contrast, the Spiegelberg device showed greater error than the Camino and Codman 
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sensors at pressures >60 mm Hg, and tended to underestimate pressures in bench 
testing as dynamic pressure loads increased(142). 
 
Overall Accuracy of ICP Sensors with Respect to CSF Reference Pressure 
The efficacy of an ICP sensor for clinical use is dependent on its competence to 
accurately reflect ventricular CSF pressure.  In one report, ICP readings from the 
fiberoptic Camino 110-4B sensor seemed to exceed true ventricular pressure by 1.15 mm 
Hg(163). Another indicated the mean differences to be as high as 9.2±7.8 mm Hg(170).  
The literature tends to be more supportive of the accuracy of piezoelectric strain 
gauge sensors. Koskinen et al.(151) observed strong agreement between mean ventricular 
ICP and the Codman probe (18.3±0.3 mm Hg vs. 19.0±0.2 mm Hg, respectively) in a 
population of 128 neuro-critically ill patients. The Codman MicroSensor was also found 
to approximate lumbar CSF pressure in hydrocephalus patients, with measured 
differences of -0.75±2.10 mm Hg(169). The Spiegelberg pneumatic sensor exhibited an 
absolute difference of 3 mm Hg between the transducer and intraventricular pressure. 
Spiegelberg was also reported to produce ICP values 10% lower than the reference 
pressure, especially when ICP >25 mm Hg(152). 
Current evaluations of ICP measurement accuracy for intraparenchymal sensors 
provide an average error of ±6.0 mm Hg, due to the fact that intraparenchymal pressure 
is not defined as a global value and can exhibit local pressure differences. Although zero 
drift remains a significant issue, ICP pulse waveforms are satisfactorily recorded by 
contemporary sensors, with good frequency properties (i.e. recorded pulse waveforms 
are not distorted).  
 
4.2.7   Limitations and Future Design Considerations  
This portion of this chapter is primarily a narrative review, although factual tables were 
provided. There is a vast heterogeneity in the methods, error presentations, and 
measurement protocols (both in-vitro and in-vivo) which made any attempt to perform 
a formal metanalysis impossible. 
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To improve resistance to infection following sensor insertion, future devices 
should function without cable connections to main monitors. Although the first 
implantable sensors are available (Raumedic, Miethke), accuracy and sampling 
frequency are unsatisfactory; these selective telemetric systems are additionally 
challenged to maintain a reliable power supply and to stream undistorted signal 
transmission to external recording units(171). Although telemetric sensors cannot provide 
detailed ICP pulse waveform information, they can be useful in the determination of the 
pressure reactivity index (PRx) and optimal cerebral perfusion pressure (CPPopt) in acute 
care settings(172). 
 
4.2.8   Conclusions 
Precise ICP monitoring is a key tenet of neurocritical care. Intraparenchymal 
piezoelectric strain gauge sensors are commonly implanted to monitor ICP. However, 
measured intraparenchymal pressure is not always equal to real ICP (the pressure 
measured in the CSF) – the average discrepancy may be ± 6 mm Hg.  Accounting for 
zero drift is vital. Laboratory bench testing reveals the shortcomings of current ICP 
sensors, although the results from bench tests may not always compare to in-vivo 
observations. It is important to continually revisit the performance of ICP monitors to 
optimize sensor and monitoring recommendations as ICP monitoring technology 
evolves(149,152,153,156,173). Despite awareness of ICP measurement inaccuracies, mean ICP 
values reported by these sensors are still routinely incorporated into and relied upon in 
current neurocritical care practices. The following section of this chapter seeks to 
account for ICP sensor drift by exploring the role of the compensatory reserve in the 
creation of a new, potentially more accurate ICP metric.  
 
 
 
4.3  Compensatory Reserve-Weighted 
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                 Intracranial Pressure and its Association 
with Outcome after Traumatic Brain Injury 
 
4.3.1  Introduction 
ICP is an essential monitoring modality that can provide feedback needed for 
appropriate and timely management of patients following TBI. High ICP has been 
associated with fatal outcome as a result of TBI(174). From this point of view, it is 
reasonable to monitor and to avoid high ICP during the intensive care period. Although 
the monitoring of ICP per se cannot improve outcome(175), a combination of monitoring 
with efficient management can assist in the prevention of mortality(176). 
Efficient management of raised ICP requires an understanding of intracranial 
pressure–volume relationships. An increase in ICP is associated with a change in volume 
of any of the four essential intracerebral compartments: arterial and venous blood, CSF, 
and the volume of brain tissue including any space-occupying lesions (i.e., hematomas, 
tumors, abscesses)(177). It is important to distinguish between different causes of raised 
ICP, as clinical strategies to fight intracranial hypertension depend upon which 
component is elevated. For example, changes in transmural pressure and thus cerebral 
arterial blood volume may elevate ICP to very high levels in a matter of tens of seconds 
(these events are known as plateau waves), secondary to massive, intrinsic arterial 
dilatation(178). These extreme fluctuations in ICP that affect the pressure-volume balance 
are influenced by a patient’s autoregulatory status; if cerebral autoregulation is 
disturbed, high ICP cannot be mitigated by adjustments in ABP or excess CSF 
drainage(94). Rapid, short-term hyperventilation usually reduces ICP in such cases. The 
cerebrospinal fluid circulatory component may elevate ICP in acute hydrocephalus(179), 
in which external ventricular drainage is helpful. Venous outflow obstruction may also 
elevate ICP, and can be combated with proper head positioning or investigation of 
possible venous thrombosis. Finally, if ICP is elevated due to brain edema or a space-
occupying lesion, osmotherapy or surgical intervention (including decompressive 
craniectomy) may be recruited, as the arterial bed would collapse at very high ICP and 
prohibit blood flow at a designated critical closing pressure (CrCP)(85). This 
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phenomenon, first described by Burton in 1951(180) as the sum of ICP and vascular wall 
tension (WT), may also explain the vascular mechanics of failing autoregulation when 
patients exhibit intracranial hypertension(85). 
Harnessing the additional information contained in the ICP signal could be an 
operable way to determine whether elevated ICP requires aggressive management or a 
more conservative approach. While ICP above 20–25 mm Hg increases the risk of 
mortality more than twofold, a more exact threshold in a large patient cohort has been 
demonstrated at 23 mm Hg(21). It has also been stressed that this threshold may be 
variable between patients (and perhaps even within a patient), in the same way that has 
been proposed for CPP(61). In a retrospective survey, Lazaridis(181) combined ICP with a 
measure of cerebrovascular pressure reactivity, and observed that the threshold for ICP 
associated with the loss of cerebral pressure reactivity can vary from 18 to 35 mm Hg.  
Additionally, this study demonstrated that these variable ICP thresholds can be further 
individually-tailored to patients when based on PRx, a strong predictor of outcome(1) 
rather than on the fixed Brain Trauma Foundation guidelines of 20 mm Hg and 25 mm 
Hg(182). If clinicians strictly adhere to these values only when revisiting ICP management 
protocols, some patients may not receive life-saving treatment if their ICP is not 
“objectively” worrisome.  
The cerebrospinal pressure–volume compensatory reserve can be illustrated by 
an exponential pressure–volume curve. However, at both extremes of the pressure–
volume curve, the relationship may not be exponential. With a low intracranial volume, 
increases in volume are linearly associated with an increase in ICP. With further 
increases in intracranial volume, a classical exponential relationship occurs between 
increases in volume and pressure, in which the value of one component rises rapidly as 
a result of incremental increases in the other. Finally, at extreme levels of intracranial 
volume, further increases in volume are weakly transmitted to ICP, and the curve 
deflects to the right. This occurs at CPP values well below the lower limit of 
autoregulation, where the deflection to the right is due to the hypothetical collapse of 
cerebral arterial vessels (Fig. 4.9) as cerebral blood flow becomes pressure-passive(85). 
This phenomenon has been described by Lofgren et al.(139) through direct observations 
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of pressure during the experimental inflation of a subdural balloon and has also been 
demonstrated as an increase in the pressure–volume index at very high levels of ICP(183). 
 
 
 
  
Figure 4.9. Relationship Between RAP and ICP. Schematic diagrams showing the 
foundation of the model behind the general relationship between the RAP (R—
correlation, A—amplitude, and P—pressure) index and mean intracranial pressure 
(ICP) (139,140,184,185). Left: The extended shape of the pressure–volume (P/V) curve showing 
three zones: good compensatory reserve when the P/V relationship is linear, poor 
compensatory reserve when the P/V curve is exponential, and the zone of disturbed CBF 
due to arterial bed collapse. Along the y-axis, there are two ICP thresholds: the first 
between the linear and the exponential zones, delineating good versus affected 
compensatory reserve. Almost all patients after TBI (exception—those after 
craniotomy) have poor compensatory reserve. The second threshold is: ‘critical ICP,’ 
above which the curve deflects to right and the system gains some extra compensatory 
reserve due to the collapse of cerebral microvasculature. This is associated with the 
discontinuity of CBF. Right: The associated relationship between the pulse amplitude of 
ICP (AMP) and mean ICP. In the zone of good compensatory reserve, AMP does not 
depend upon mean ICP. In the exponential zone (poor compensatory reserve), AMP 
increases with increasing mean ICP. For ICP above the ‘critical threshold,’ AMP 
decreases when ICP increases further. The RAP index is zero within the zone of good 
compensatory reserve, +1 with poor compensatory reserve, and negative above the 
‘critical ICP’ level. 
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The shape of the pressure–volume curve described, according to the classical 
interpretation of Marmarou(140), has implications for the relationship between the 
changes in mean ICP and the changes in the amplitude of ICP pulsations (AMP). When 
plotting these pulsations against the incoming cerebral blood volume load (modeled by 
the height of the AMP signal), an exponential pressure-volume curve appears when 
mean ICP rapidly increases as a function of small volumetric step-increases(185). 
However, these changes in volume may be affected by fluctuations in arterial CO2 (a 
potent vasodilator), ABP, and underlying arterial pulse pressure(185). 
In the linear zone, where pressure–volume compensation is good, AMP is not 
correlated with mean ICP. In the exponential zone, AMP is positively correlated with 
increasing mean ICP. Above a critical level of ICP, at the point of rightward deflection 
of the pressure–volume curve, AMP starts to decrease with rising ICP, resulting in a 
negative correlation (Fig. 4.9, right panel). Thus, the moving correlation coefficient 
between AMP and ICP (10-second averages) calculated over a 5-min period has been 
termed RAP (R—correlation, A—amplitude, and P—pressure) and described(184) as an 
index of compensatory reserve. It is 0 in the linear zone (good compensatory reserve), 
+1 in the exponential zone (poor compensatory reserve), and negative at very high ICP 
levels—indicative of crossing the threshold for “critical ICP”. 
Incorporating both the potential detrimental effects of position on the pressure–
volume curve and the mean ICP, a “compensatory-reserve-weighted ICP” metric can be 
created as the product of mean ICP and (1−RAP)(186):  
• If the compensatory reserve is good (RAP=0) at low ICP, ICP*(1−RAP) remains 
low. 
• If the compensatory reserve is exhausted (RAP=1) at a medium ICP (which is 
often the case after TBI, due to brain swelling), ICP*(1−RAP) stays low. 
• Conversely, if ICP crosses the “critical threshold”, RAP becomes negative and 
ICP*(1−RAP) increases abruptly—see samples in Fig.4.10a, b. 
 
Chapter 4 – Clinical Implications of Intracranial Pressure in Brain Injury  92 
 
 
Figure 4.10. Monitoring “WeightedICP”, Mean ICP, AMP, and RAP: Example of the 
monitoring of weightedICP, mean ICP, the pulse amplitude of ICP (AMP), the index of 
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compensatory reserve (RAP), and the statistical relationship between RAP and mean 
ICP in the whole cohort of analyzed cases. A) During a plateau wave of ICP, the 
correlation between AMP and ICP shows a dip at the beginning of the plateau wave—
RAP decreases to negative values and weightedICP increases, suggesting that the rise of 
ICP is associated with cerebrovascular deterioration. B) Example of nearly 20 hours of 
monitoring of a patient with a closed-head injury who gradually developed intracranial 
hypertension up to 35 mm Hg (starting from a baseline of 12 mm Hg). CPP remained 
above 60 mm Hg for the whole monitoring period. Gradually-increasing ICP was 
followed by an increase in pulse amplitude (AMP) and values of RAP close to +1. 
WeightedICP was below 5 mm Hg in this period. When ICP increased above 25 mm Hg, 
AMP stabilized and then started to decrease with further increases in ICP. RAP 
decreased down to zero and even negative values, indicative of reaching a ‘critical’ value 
for ICP. WeightedICP started to increase at this point. C) Empirical regression of RAP 
versus mean ICP in a cohort of patients. It indicates that RAP is low with low ICP levels, 
increases for ICP 20–30 mm Hg, and decreases for ICP above 30 mm Hg. Results of 
averaging in a large cohort of patients make RAP never ideally equal to 0, +1, or a 
negative value. However, the general classification is similar (Fig. 4.9). Below 20 mm 
Hg: good compensatory reserve, between 20-30 mm Hg: poor compensatory reserve, 
and above 40 mm Hg: intracranial hypertension is interfering with cerebral blood flow. 
The vertical bars show 95% confidence intervals for mean values, with the red line 
connecting mean values in each category along the x-axis. 
 
Our current aim is to investigate the metric which translates the absolute mean ICP 
value to a variable which expresses both the absolute level of intracranial hypertension 
and the state of the cerebrospinal compensatory reserve. 
 
4.3.2  Methods 
Clinical Material 
Computer-assisted ICP monitoring has been used in patients receiving critical care after 
TBI since 1992(187). Over a nearly 25-year period, we accumulated computer recordings 
from 1023 patients. Patients were admitted to the Addenbrooke’s Hospital 
Neurosurgical Neuro-Rehabilitation Annex between 1992 and 1995, and from 1995 
onward, the Neurocritical Care Unit (NCCU). All patients suffered from TBI, with initial 
GCS less than 9 (75%) or above 8 who deteriorated later and required intensive care 
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(25%). The average patient age was 37 years (range: 15–85 years old), and the 
male/female ratio was 3:5. 
Over this period, patients were treated in accordance with various rules ranging 
from no formal protocol (1992–1994), classical CPP-oriented therapy with a fixed 
threshold of 70 mm Hg (1994–1996), to a mixed CPP–ICP protocol(184) (from 1997) with 
a gradually-decreasing threshold of CPP (65, 60 mm Hg). Later, additional monitoring 
modalities (autoregulation, brain oxygenation, microdialysis, etc.) were introduced into 
patient assessment (188). 
Patients were sedated, intubated, and mechanically ventilated. Interventions 
were aimed at keeping ICP <20 mm Hg using a step-wise approach of positioning, 
sedation, ventriculostomy drainage, hypothermia, and finally barbiturate-induced burst 
suppression of electroencephalography and decompressive craniectomy as rescue 
therapies. ICP monitoring was conducted over this period as an element of standard 
clinical care. The use of computer-recorded data was approved by the NCCU Users’ 
Committee and conducted before 1997 as a part of an anonymous clinical audit. After 
1997, national ethical approval was obtained (30 REC 97/291). 
Monitoring and Computations 
ICP was monitored with an intraparenchymal sensor inserted into the frontal cortex 
(Codman ICP Micro-Sensor, Codman & Shurtleff, Raynham, M.A., U.S.A.) via a burr 
hole. Data were sampled at 100 Hz with proprietary data acquisition software, which 
was also used to calculate the RAP index in real time with ICM(140) (pre-2003) and 
ICM+TM onward(189). (http://www.neurosurg.cam.ac.uk/icmplus, Cambridge Enterprise, 
Cambridge, U.K.). All of these signals were then stored digitally for retrospective 
analysis. 
The pulse amplitude of ICP (AMP) was calculated using spectral analysis, which 
is defined by the detection of fundamental frequencies and the conversion of power 
associated with a peak at a particular frequency equal to that of heart rate, to the value 
of AMP updated every 10 seconds. Mean ICP was also averaged within 10-second 
windows. RAP was calculated as the Pearson correlation coefficient of 30 consecutive 
values of AMP and ICP, also averaged within 10-second windows. Values were averaged 
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every 60 seconds. For statistical purposes, patients were characterized by grand averages 
of mean ICP, AMP, RAP, and “weightedICP” expressed as ICP*(1−RAP). It should be 
emphasized that RAP and weightedICP calculations are not software-specific. Not only 
ICM+TM can be used, but also simple macro written for Excel, script for MATLAB, or any 
homemade code. 
 
Statistical Analysis 
Statistical analysis was performed using Statgraphics software. Empirical regression was 
used to show the non-linear relationships between ICP and RAP, and ICP, weightedICP, 
and mortality rate. Analysis of variance was used to visualize the differences between 
variables such as ICP, ICP*(1−RAP), and different outcome categories, with a Kruskal–
Wallis statistics number (K) assigned to compare which parameter most strongly 
differentiated outcome groups. ROC analysis with (AUC) was performed to compare 
the abilities of weightedICP or ICP to predict mortality. 
 
4.3.3  Results 
The distributions of age, sex, GCS, outcome, and mean values of blood pressure, ICP, 
CPP, and the RAP index are listed in Table 4.5. None of these variables were different 
between males and females, with the exception of CPP (females: 75 ±12 mm Hg; males: 
78 ± 9 mm Hg; p<0.001)
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Table 4.5. Distribution of outcome plus mean value/standard deviations of monitored 
parameters (R—correlation, A—amplitude, and P—pressure). 
 
 
Outcome Mean SD 
Good 22%   
Moderate Disability 25%   
Severe Disability 28%   
Vegetative State 2%   
Dead 23%   
Female/Male Ratio 2:7   
Age 37 16 
Glasgow Coma Score (median;〈25%,75% quartiles) 6; 〈4;9〉 – 
Arterial Blood Pressure (mm Hg) 93.3 9.46 
Intracranial Pressure (mm Hg) 16.3 8.98 
Cerebral Perfusion Pressure (mm Hg) 77.3 10.56 
Compensatory Reserve Index RAP (a.u.) 0.53 0.22 
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Examples of individual recordings during plateau waves of ICP and in patients 
who died from refractory intracranial hypertension are given in Fig. 4.10A, and 4.10B. In 
both cases, RAP became negative at increased ICP levels. In the case of refractory 
intracranial hypertension, it was at the level of 84 mm Hg; with respect to plateau waves, 
it was at 47 mm Hg. We can expect that these “critical ICP” levels (84 and 47 mm Hg as 
in the examples in Fig. 4.10 A, 4.10B) change from patient to patient, and may also 
remain different in various scenarios of ICP elevation (like plateau waves–spikes in ICP 
of vasogenic origin, and refractory intracranial hypertension, which in most instances is 
caused by rapidly-evolving brain edema). 
The distribution of the RAP coefficient along the variable of ICP presented an 
inverse U-shaped curve (Fig. 4.10C). Mean ICP is related to mortality after TBI; the 
distribution of ICP in different outcome groups suggests that in patients who died, ICP 
is significantly higher (p<0.05) than in patients who survived, without a difference 
between outcome categories among survivors. The multiple range test, Fig.4.11, shows 
that ICP values for the outcomes of disability (good, moderate, and severe) and 
vegetative state are homogenous, and ICP for patients who died is greater at p<0.05. 
Compensatory reserve, as described with the RAP index, is best in patients with good 
outcome and moderate disability, and worsens in patients with severe disability and 
non-survivors. Vegetative-state patients are underrepresented with only 18 cases in our 
database (Fig.4.11B). The multiple-range test shows that good and moderate disability 
form one homogenous group, severely disabled patients another, and patients who died 
yet another group, with the lowest RAP value (p<0.05). 
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Figure 4.11. Distribution of Mean ICP, RAP, and weightedICP Between Five 
Outcome Categories. Vertical bars show 95% confidence intervals for mean values. 
Points indicate mean values in each category. WeightedICP (p<0.0001) differentiates 
between survival and death better than absolute ICP (p<0.0005) and RAP (p=0.002). 
However, RAP significantly differentiates between severe disability and favorable 
outcome groups (p=0.004), which is not the case for ICP and weightedICP.
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“WeightedICP” only visually shows a more gradual rise of its value through 
worsening outcome categories than does absolute ICP (Fig.4.11c). A multiple-range test 
showed homogenous groups identical to those for ICP distribution (p<0.05). 
Relationships with outcome remained significant when weightedICP and mean ICP 
were corrected for known factors affecting outcome, such as age and GCS on admission. 
Both weightedICP and mean ICP were also able to differentiate between 
favorable and unfavorable outcome (weightedICP: 6.1 ±4.1 vs. 9.1 ±8.4 mm Hg; p<0.0001 
and mean ICP: 14.5 ± 5.3 vs 17.8 ± 10.6 mm Hg; p<0.0001; ANOVA, N=1023). Analysis of 
variance (Kruskal–Wallis statistics value K) showed higher values of test statistics for 
weightedICP (K=93) than ICP (K=64) in outcome categorization. 
Additionally, ROC analysis indicated greater AUC for weightedICP (0.71) than 
mean ICP (0.67) for the prediction of mortality. However, these two parameters were 
not significantly different (De Long test; p=0.12). The best threshold (maximizing jointly 
sensitivity and specificity) for the mean ICP ROC curve is 19.5 mm Hg, and for 
weightedICP, 8 mm Hg. Finally, mortality rate depicted as a function of both mean ICP 
and weightedICP showed ascending distribution (Fig. 4.12). Mortality versus mean ICP 
showed abrupt increases for ICP between 20-30 mm Hg. For weightedICP, mortality 
increased more gradually for values between 10-30 mm Hg. 
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Figure 4.12. Distribution of mortality rate versus mean intracranial pressure 
(ICP) and “weighted ICP”. Vertical bars show 95% confidence intervals for mean 
values. The line connects mean values in each category along the x-axis. 
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4.3.4  Discussion 
ICP discriminates between life and death in many clinical emergency situations. 
However, thresholds for increased and normal ICP may vary from patient to patient(85). 
An alternative measure of ICP is proposed, which magnifies the state in which raised 
pressure obstructs cerebral blood flow—presuming that such a situation is detrimental 
for critically ill patients and is evaluated at the bedside. Hassler et al.(190) observed with 
TCD that intracranial circulatory arrest begins at the capillary bed, where blood flow 
stagnates in the distal-to-proximal direction if ICP reaches a terminally-high value. The 
resulting brain death can also be confirmed with TCD, and is characterized by absent 
or reversed diastolic flow, or small early systolic spikes in the flow velocity waveform(191). 
Continuous monitoring of this “weightedICP” index has the potential to distinguish 
between situations where increased ICP is still tolerable, or is threatening a deficit of 
cerebral blood flow able to inflict irreversible brain damage. However, taking into 
account the retrospective character of this study, this effect should be investigated in a 
prospective manner. WeightedICP has previously been investigated (186) as “trueICP” in 
a limited group of patients. 
The clinical value of ICP monitoring is still controversial(175). The existing body 
of the literature states that since ICP can modulate cerebral blood flow through its direct 
impact on CPP, it should be monitored minutely to avoid ischemic insults as a 
component of an efficient management protocol. Short periods of critical rises in ICP 
(like plateau waves) can drag CPP below the lower limit of autoregulation and cause 
ischemia. If elevated ICP lasts longer, it starts to associate strongly with mortality(192). A 
recent randomized trial was unable to show the clinical benefit of ICP monitoring on 
outcome following TBI, with patients separated into decompressive craniectomy or 
ongoing care groups if ICP exceeded 25 mm Hg. After 6 months, patients receiving 
decompressive craniectomies were found to have lower instances of mortality and 
disability than those receiving bedside ICP interventions(193). However, some caveats 
need to be appreciated—the trial was underpowered, and the monitoring of ICP was 
not continuous; end-hour instant ICP values were taken for control of the treatment 
protocol. 
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There is an open debate over which value of ICP is a best as an input variable for 
any management protocol: mean ICP, a “dose of ICP”(194), complexity of ICP(195), or 
anything else. “WeightedICP” was proposed as a shorthand form of “compensatory-
reserve-weighted ICP”. RAP is an index of compensatory reserve that switches from 
positive to negative values at high ICP, hypothetically denoting the final deterioration 
of cerebral blood flow continuity, caused by extremely advanced intracranial 
hypertension(11). The exact meaning of a “critical threshold” for ICP is still uncertain. 
One theory states that at the “critical threshold”, diastolic blood pressure becomes equal 
to critical closing pressure (driven up by increasing ICP), and cerebral arterioles start to 
collapse during each cardiac cycle. This causes cerebral blood flow to be intermittently 
discontinued and aggravates ischemia as the lower limit of autoregulation is 
approached(85). It also prevents proper transmission of intra-arterial pulsations to the 
cerebrospinal space due to a decrease in pulsating arterial blood volume, which disrupts 
the coupling between mean ICP and its pulse amplitude, thus driving RAP towards 
negative values. Such a situation is clinically rare and requires simultaneous monitoring 
of ABP, ICP, and TCD blood flow velocity; as TCD is primarily viewed as a research tool 
and is only applied intermittently, there is not much evidence to support the above 
hypothesis. 
It is demonstrated that weightedICP shows greater values (>10 mm Hg) only if 
ICP increases above the individualized critical level (see Fig. 4.10). Its value correlates 
with worsening clinical outcome. WeightedICP is simple to calculate and is expressed 
as a time trend on the screen of bedside monitoring systems. It may be of assistance in 
making clinical decisions about the individual safety threshold for ICP in addition to 
the previously-described autoregulation-weighted ICP(181). It may be true that 
weightedICP is a better indicator of ICP-related vascular obstruction, but this should be 
demonstrated by prospective study. 
 
4.3.5  Limitations 
This is a retrospective study utilizing clinical material that has been gathered for over 
25 years. Different treatment protocols have been used during this period(188), and thus 
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different approaches to ICP management may have affected final outcome statistics. 
This study does not account for variable intensity of treatment. Outcome distribution 
is not representative for all TBI cases requiring NCCU treatment. Overall, it can be 
estimated that around 50% of cases over the years spanning from 1992 to 2015 were 
monitored using bedside computer systems (ICM and ICM+TM software). Also, in this 
statistical analysis, we did not take into account the potential difference between 
patients with closed-head injury and craniotomy. 
The RAP index can be affected by local differences in compensatory reserve, as 
demonstrated by Eide and Sorteberg(196) using two different ICP sensors and revealing 
marked differences in RAP. Furthermore, Hall and O’Kane(197) emphasized its 
susceptibility to baseline error effects, which also could influence weightedICP. 
Approximately, 20% of patients underwent decompressive craniectomy in our cohort. 
Craniectomy on average reduces both ICP and RAP, therefore reducing weightedICP. 
However, the duration of monitoring after craniectomy is relatively short; therefore, if 
RAP and weightedICP are reduced, it does not “contaminate” overall results heavily.  
Furthermore, our anonymized database does not contain information 
identifying which patients had infratentorial lesions. Hence, the possibility of 
calculating the “wrong ICP” and the “wrong RAP” using intraparenchymal frontal cortex 
sensors cannot be evaluated. In general, all ICP sensors, irrespective of design and 
manufacturer, are subject to systematic and random measurement inaccuracies that can 
adversely affect patient care. The ICP values that are streamed from bedside monitors 
may not be reflective of the patient’s true condition, and can misinform essential 
outcome-predictive calculations such as weightedICP and PRx. 
WeightedICP is also a “vasculo-centric” index characterizing the consequences 
of raised ICP and is exclusive of the additional neuronal mechanisms of TBI when 
exposed to high ICP, primarily the acute diffuse membrane perturbations that result in 
chronic neural loss over time(198). This suggests that increases in ICP may have 
deleterious effects even in the absence of critical vascular obstruction (198).  
Finally, the comparison of Fig. 4.10A–C may appear misleading. One should bear 
in mind that while in Fig.4.10 A and B we show two individual examples of when RAP 
becomes negative at two individual “critical ICP” levels, that the curve in Fig.4.10 C is an 
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effect of the averaging of 1023 individual cases. Given that “critical ICP” levels are 
different among patients, these averaged RAP values never cross the level of zero. 
4.3.6  Conclusions 
Compensatory-reserve-weighted ICP (“weightedICP”) normally stays below 8 mm Hg. 
It increases above this threshold when ICP contributes to the final deterioration of 
patients after TBI. 
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5.1.  The Relationship Between Brain Pulsatility 
and CPP 
 
5.1.1.  Introduction 
Multi-modal, high-resolution intracranial monitoring for critically-ill neurological 
patients is becoming standard in most high-volume neurocritical care units. Recent 
endorsement of multi-modal monitoring has come from a multitude of professional 
societies associated with the critical care management of these patients(199). Worldwide 
interest in noninvasive measurement of various cranial hemodynamic indices has 
driven the application of TCD in a variety of scenarios, with the goal of correlating MCA 
flow velocity and pulsatility index (PI) to common invasive measures such as ICP and 
CPP, as documented within a recent systematic review(200).  
The brain is extraordinarily fragile following TBI. Patients are at risk of increasing 
ICP, and of sudden changes in ABP or CPP that may require immediate clinical 
intervention. Low CPP is associated with potential instances of delayed cerebral 
ischemia; conversely, high CPP is associated with edema(28). The pulsatility index, PI, 
has been found to be a complex descriptor of several “mutually interdependent” 
parameters within the brain(28). In TBI, adequate cerebral circulation is essential for the 
maintenance of autoregulation. Elevated PI can signal rising ICP, decreasing ABP, low 
PaCO2, and can additionally inform of both decreasing CPP and of increasing 
cerebrovascular resistance.  
These correlations are particularly relevant to the study of plateau waves, 
phenomena characterized by unexpected elevations in ICP above 50 mm Hg 
accompanied by marked depletions of CPP for a duration of at least 5 minutes that 
either resolve on their own or through treatment with vasopressors. The resolution of 
plateau waves has been associated with relatively intact autoregulatory mechanisms, as 
the fluctuations in ICP are attributed to the redistribution of brain volume when CPP 
changes (178). In addition to plateau waves, alterations of mean arterial pressure (MAP) 
can upset the balance of CPP in critically-ill neurological patients, due to the 
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fundamental nature of ABP within the CPP derivation. Clinical analysis of unstable, 
decreasing MAP can assist in the ongoing investigation of the relationships between 
various cerebral hemodynamic parameters. 
To delineate the relationships between CPP, ICP, MAP, and TCD parameters, 
continuous data series through large ranges of CPP and ICP values are ideal. Difficulties 
with long-term, high-quality TCD signal acquisition have led to limited studies in 
humans correlating TCD measures to CPP, ICP, and MAP(201) , with some animal studies 
documenting the relationship(202) and others utilizing mathematical modeling(203) where 
PI had been found to increase in tandem with the amplitude of the FV waveform(202). 
The components of the FV waveform can be further analyzed to provide more 
information about the underlying cerebral hemodynamic mechanisms of TBI(203). 
Ideally, being able to correlate TCD-based PI with ICP pulse amplitude (AMP), MAP, 
and CPP could bolster the concept of reliable non-invasive measurement of these 
hemodynamic parameters. A previous study outlined the possibility of an inverse non-
linear correlation between PI and CPP, utilizing “spectral” PI (sPI, defined as the first 
harmonic of the flow velocity (FV) pulse waveform divided by mean FV) in 51 patients 
with plateau waves and continuous TCD monitoring(202). The following relationship 
between PI and CPP (Equation 5.1) was proposed within the supplementary portion of 
that same manuscript(28): 
 
 
𝑃𝐼 =  
𝐴1
𝐶𝑃𝑃𝑚
 ×  √(𝐶𝑉𝑅 × 𝐶𝑎)2𝐻𝑅2 × (2𝜋)2 + 1 
            
          [5.1] 
 
In this equation, A1 represents the fundamental harmonic of ABP, CPPm the calculated 
mean of recorded CPP values, CVR the cerebrovascular resistance, Ca the cerebral 
arterial compliance, and HR the heart rate. 
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It was hypothesized that the validation of relationships between CPP and indices 
of cerebrovascular pulsatility (defined using either sPI or AMP) would be strengthened 
by demonstrating similar relationships in clinical situations where the drivers of CPP 
change were different (either through the mitigation of high ICP in plateau waves, or as 
a direct result of unstable ABP). This study aimed to describe and compare the 
relationships between spectral PI (sPI) and various invasively-derived cerebral 
hemodynamic measures across two groups of TBI patients demonstrating either plateau 
waves or unstable MAP while recording FV with TCD. These patients were of interest 
given the continuous data recorded through a wide range of CPP values, allowing better 
insight into the relationship between TCD and invasively-monitored parameters. The 
following relationships are described for each cohort: ICP versus AMP, ICP versus sPI, 
AMP versus sPI, CPP versus AMP, and CPP versus sPI. 
 
5.1.2.  Methods 
Patients 
From a database of 1,023 head-injured patients with continuous ICM+TM 
(Intensive Care Monitoring) monitoring and TCD recordings of ABP and ICP, a 
retrospective review of recorded data was performed for patients exhibiting ICP 
plateau waves during the period from 1992 to 1998. This study primarily observed 
physiological effects in subsets of TBI patients, with plateau waves of special interest 
because they are relatively uncommon. Each recording lasted for a maximum of 15–30 
minutes. These patients have previously been described within other published 
studies(202,204,205) and were selected to evaluate the relationship between CPP versus 
sPI and CPP versus AMP over a large range of CPP that was observed secondary to 
large fluctuations in ICP, as seen during plateau waves. 5,643 minute-by-minute data 
points for each variable were analyzed across all patients. 
A second cohort of severe TBI patients with unstable MAP was retrospectively 
analyzed to determine the relationships between CPP versus sPI and CPP versus AMP 
during wide fluctuations in CPP secondary to unstable MAP. The definition of 
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“unstable MAP” describes mean ABP changing by a minimum of 15 mm Hg in either a 
monotonic or a fluctuating manner during recording. All patients in both cohorts 
suffered moderate–severe TBI and were admitted to the Neurosciences Critical Care 
Unit (NCCU) at Addenbrooke’s Hospital, Cambridge. Patients were managed 
according to an ICP-oriented protocol which aimed to keep ICP below 20 mm Hg. 
Institutional ICP protocols were employed during the patients’ NCCU stay, to provide 
homogeneity of care between patients. Of note, these patients were not treated via 
CPP-directed therapies, as this was not the standard of care within the NCCU at that 
time. Thus, fluctuations in CPP seen during plateau wave recordings are natural CPP 
responses, with no influence of vasoactive substances during recording. Patients 
within the unstable MAP cohort may have received vasopressors in an attempt to 
stabilize blood pressure; however, this was not titrated to CPP goals. 
 
Monitoring 
All patients underwent both invasive and noninvasive monitoring throughout 
admission. Raw data signals from select monitoring devices were recorded and 
electronically stored using WREC software (Warsaw University of Technology). 
ABP was continuously monitored both invasively (from the radial artery using 
a pressure monitoring kit [Baxter Healthcare C.A., U.S.A.; Sidcup, U.K.]) and 
noninvasively. ICP was monitored using an intraparenchymal probe with strain gauge 
sensors (Codman & Shurtleff, M.A., U.S.A., or Camino Laboratories, C.A., U.S.A.). 
Mean and peak blood flow velocities (FVm and FVx, respectively) were monitored 
from the MCA with a 2 MHz probe. 
Raw data recordings within the plateau wave cohort patients included only 20–
40 minutes of continuous data, focusing on the immediate periods before, during, and 
after ICP plateau waves. Within the unstable MAP cohort, raw data recording occurred 
throughout the entire period of unstable blood pressures. 
The monitoring of the above brain modalities was conducted as a part of 
standard NCCU patient care using an anonymized database of physiological 
monitoring variables in neurocritical care. Data on age, injury severity, and clinical 
status at hospital discharge were recorded at the time of monitoring on this database, 
Chapter 5 – Understanding and Modeling of Pulsatile Cerebral Hemodynamics   110 
 
and no attempt was made to re-access clinical records for additional information. 
Since all data were extracted from the hospital records and fully anonymized, no data 
on long-term outcomes or patient identifiers were available, and formal patient or 
proxy consent was not sought. 
 
Data Processing 
Processing of raw data signals utilized ICM+TM software (Cambridge Enterprise, 
Cambridge, UK; http://www.neurosurg.cam.ac.uk/icmplus). Signal artifact removal 
was first conducted with signal cropping tools within ICM+TM. CPP was determined 
from the difference between raw ABP and ICP signals. 
Primary analysis involved the calculation of time-averaged mean values for ABP 
(MAP), ICP, cerebral blood FV, and CPP. These means were calculated during 10-
seconds time windows and were updated every 10 seconds to eliminate overlap. Mean 
FV was calculated using the data from FV. In addition, we determined the amplitude 
of the fundamental frequency of FV (F1) and the amplitude of the fundamental 
frequency of ICP (AMP). Both fundamental amplitude calculations were done by 
applying a 20-second time window, updated every 10 seconds. 
Final data processing involved the calculations of sPI over the course of each 
individual recording utilizing the equation: Mean F1/Mean FV. Mean F1 and FV were 
calculated utilizing a 10-second time window, updated every 10 seconds. All data post-
processing was exported from each patient to separate comma-separated variable 
(CSV) files for further statistical analysis. 
 
Statistics 
 All statistical analyses were conducted utilizing the XLSTAT (Addinsoft, New 
York, USA; https://www.xlstat.com/en/) add-on package to Microsoft Excel 
(Microsoft Office 15, Version 16.0.7369.1323) and IBM SPSS Statistics 23 software. Post-
processing data of individual patients, as CSV documents, were compiled into one CSV 
document containing all patients and signals described previously. Statistical 
significance for measured and derived variables, both within and between the two 
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patient cohorts, was determined utilizing a two-tailed t-test, with an alpha set at 0.05. 
Various statistical techniques were employed to describe the following relationships 
in both patient cohorts: ICP versus AMP, ICP versus sPI, AMP versus sPI, CPP versus 
AMP, and CPP versus sPI. Relationships between ICP, AMP, and sPI were analyzed 
utilizing linear regression techniques. Goodness of fit was reported utilizing the 
Pearson correlation coefficient (r) and the determination coefficient (R2). All R2 values 
were reported. Statistical significance was assigned only if the p value was less than 
0.05.  
Analysis of the relationship between CPP, AMP, and sPI was conducted 
utilizing both linear and non-linear techniques, with goodness of fit reported via R2. 
Non-linear regression involved the fitting of existing functions within the statistical 
programs, in addition to manual function fitting utilizing the non-linear inverse 
function: y=a+(b/x). 
 
5.1.3. Results 
Patient Demographics 
11 patients were eligible for inclusion within the plateau wave cohort of this study, 
with a total of 18 plateau waves recorded. 9 patients comprised the unstable MAP 
cohort, with 13 separate recordings of unstable blood pressure. Figure 5.1 displays an 
example of the ICP, CPP, and MAP recordings from individual patients during plateau 
waves (Figure 5.1A) and unstable blood pressure (Figure 5.1B). All available demographic 
details are listed in Table 5.1. 
Table 5.2 summarizes the mean ICP, ABP, CPP, HR, FV, and sPI for both the 
plateau wave and unstable MAP cohorts. Data for the plateau wave cohort were split 
into measurements before the plateau wave (i.e., “baseline”) and during the plateau 
wave, with comparison done via two-tailed t-test. Data for the unstable MAP cohort 
were split into the recorded variables during the “Lowest 10%” and “Highest 10%” of 
recorded arterial blood pressures, with comparison done via two-tailed t-test. 
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Figure 5.1. ICP, CPP, and MAP Recordings in both Plateau Wave and Unstable 
MAP Patients. In plateau waves, ABP, CPP, and FV decrease as ICP steeply increases 
during the plateau event. With unstable MAP, CPP increases along with MAP, while 
FV slightly increases and ICP is relatively constant.  
 
ABP – arterial blood pressure, CPP – cerebral perfusion, FV – flow velocity, ICP – 
intracranial pressure, MAP – mean arterial pressure, and mm Hg – millimeters of 
mercury.   
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Table 5.1. Plateau Wave and Unstable MAP Patient Demographics. GOS utilized within this study is an inverted GOS, with 5=death 
and 1=good outcome. GCS – Glasgow Coma Scale, GOS– Glasgow Outcome Scale, #- number, MAP – mean arterial pressure, and PVS – 
persistent vegetative state.  
 
Patient 
Cohort 
Number of 
Patients 
Mean Age 
(Years) 
Male:Female 
Ratio 
Median 
Admission GCS 
GOS at Discharge 
Plateau 
Waves 
11 27.2 (range: 
17–76) 
8:3 5 (range: 3–10) GOS # of 
patients 
Dead 2 
PVS 0 
Severe 
disability 
5 
Chapter 5 – Understanding and Modeling of Pulsatile Cerebral Hemodynamics   114 
 
Patient 
Cohort 
Number of 
Patients 
Mean Age 
(Years) 
Male:Female 
Ratio 
Median 
Admission GCS 
GOS at Discharge 
Moderate 
disability 
4 
Good 0 
Unstable 
MAP 
9 25.1 (range: 
17–60) 
5:4 5 (range: 3–7) GOS # of 
patients 
Dead 2 
PVS 1 
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Patient 
Cohort 
Number of 
Patients 
Mean Age 
(Years) 
Male:Female 
Ratio 
Median 
Admission GCS 
GOS at Discharge 
Severe 
disability 
5 
Moderate 
disability 
1 
Good 0 
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Table 5.2. Measured and Derived Signals in the Plateau Waves and Unstable MAP Cohorts. MAP – mean arterial pressure, CPP – cerebral 
perfusion pressure, ICP – intra-cranial pressure, AMP – fundamental amplitude of ICP, PI – pulsatility index, mm Hg – millimeters of 
Mercury, SD – standard deviation, and A1 – fundamental amplitude of arterial blood pressure. 
 
  Plateau Wave Recordings Unstable MAP Recordings 
Baseline Plateau Lowest 10% of MAP Highest 10% of MAP 
Mean SD Mean SD p value Mean SD Mean SD p value◊ 
MAP  
(mm Hg) 
96.93 10.12 95.06 8.39 0.52 71.96 15.96 103.65 20.05 0.0002 
A1  
(mm Hg) 
16.41 2.32 15.96 2.25 0.53 15.61 3.76 19.10 5.30 0.07 
ICP  
(mm Hg) 
25.60 5.92 50.12 8.66 <0.0001 21.8 10.58 20.65 10.64 0.78 
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  Plateau Wave Recordings Unstable MAP Recordings 
Baseline Plateau Lowest 10% of MAP Highest 10% of MAP 
Mean SD Mean SD p value Mean SD Mean SD p value◊ 
AMP 
(mm Hg) 
2.23 0.73 6.41 1.64 <0.0001 2.51 2.16 1.71 1.15 0.25 
CPP 
(mm Hg) 
71.34 12.73 44.94 10.29 <0.0001 50.16 14.91 83.00 19.77 <0.0001 
sPI (a.u.) 0.29 0.16 0.48 0.23 0.004 0.51 0.27 0.28 0.12 0.01 
 
◊Statistical significance was determined via two-tailed t-test with an alpha of 0.05 assigned to entries with p-values below this 
threshold. 
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Relationships Between CPP, AMP, and sPI During Plateau Waves and Unstable MAP 
Linear regression techniques failed to yield satisfactory relationships between 
CPP and AMP, or CPP and sPI. Their correlation coefficients were poor, and variance 
measures had large mean squared errors. As the scatterplots for each of these 
comparisons produced a non-linear pattern, non-linear regression analyses (with 
functions within XLSTAT and IBM SPSS Statistics 23 software) were utilized to 
determine the relationships displayed between these variables during ICP plateau 
waves, using an inverse function that was previously theorized to characterize this 
relationship. Non-linear regression analysis for CPP versus sPI in each individual 
plateau wave patient is shown in Appendix A of this thesis. Non-linear regression 
analysis for CPP versus sPI in each unstable MAP patient is shown in Appendix B. 
The results of the non-linear regression across the compiled plateau wave patient 
data for CPP versus sPI are shown in Figure 5.2A. Similarly, the non-linear regression 
for CPP versus AMP is shown for Figure.5.2B. The corresponding results for the 
compiled unstable MAP patient data are shown in Figure 5.3A and Figure 5.3B 
respectively. 
 
 
Figure 5.2. Non-linear Regression Analysis of CPP versus sPI (F1/FV) and CPP 
versus AMP in the Plateau Waves Cohort. A) Non-linear regression of CPP versus 
sPI. B) Non-linear regression of CPP versus AMP. 
 
AMP – ICP pulse amplitude, CPP – cerebral perfusion pressure, F1 – amplitude of the 
fundamental frequency of FV, FV – mean blood flow velocity in the mean cerebral artery 
(MCA), mm Hg – millimeters of mercury, and sPI – spectral pulsatility index. 
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Figure 5.3. Non-Linear Regression Analysis of CPP versus sPI (F1/FV) and CPP 
versus AMP in the Unstable MAP Cohort. A) Non-linear regression of CPP versus sPI. 
B) Non-linear regression of CPP versus AMP. 
 
AMP – ICP pulse amplitude, CPP – cerebral perfusion pressure, F1 – amplitude of the 
fundamental frequency of FV, FV – mean blood flow velocity in the mean cerebral artery 
(MCA), mm Hg – millimeters of mercury, and sPI – spectral pulsatility index. 
 
 
AMP versus CPP 
Non-linear regression analysis of the relationship between CPP and AMP in 
plateau wave patients produced an inverse relationship between CPP and AMP 
(R2=0.610). Non-linear regression analysis of the relationship between CPP and AMP in 
unstable MAP patients produced an inverse relationship between the two parameters 
(R2=0.36). 
 
sPI versus CPP 
Similarly, non-linear regression analysis of the relationship between CPP and sPI 
in the plateau wave cohort produced an inverse relationship (R2=0.820), best described 
by the following function: 
sPI =a+(b/CPP)                                                [5.2] 
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with CPP measured in mm Hg, and the statistical analysis concluding: a=−0.03 and 
b=26.4. When the individual plateau wave patients were analyzed via non-linear 
regression, the mean and standard deviation for the values of “a” and “b” were: a=0.005 
±0.061, b=23.61 ±6.33. 
 
Non-linear regression analysis of CPP versus sPI in the unstable MAP cohort also 
demonstrated an inverse relationship between CPP and sPI (R2=0.61), as shown in Figure 
5.3A. As seen within the plateau cohort’s non-linear regression of CPP versus sPI, the 
model of best fit showed the same function (with CPP measured in mm Hg, a=−0.061 
and b=25.3). When the individual unstable MAP patients were analyzed via non-linear 
regression, the mean and standard deviation for the values of “a” and “b” were: a=−0.144 
±0.391, b=27.43 ± 21.72. Interestingly, both relationships closely resemble and support 
the inverse non-linear relationship between CPP and PI previously proposed by de Riva 
et al.(28). 
The “a” and “b” values calculated for each patient cohort were compared in a two-
tailed independent-samples t-test to evaluate significant differences between the 
plateau wave versus unstable MAP cohorts. Levene’s test for equality of variances was 
assumed and dictated a nonsignificant difference between both the “a” and the “b” 
values obtained from the two groups (t[27]=−1.507, p=0.143 and t[27]= 0.670, p=0.509, 
respectively). The effects of this hypothesis were further examined to determine 
whether each group’s sets of “a” values were statistically different from the test value of 
0 via two-tailed one-sample t-tests. There was a nonsignificant difference between 0 and 
the “a” values in unstable MAP patients as well as in plateau wave patients (t[12]=−1.330, 
p=0.208 and t[15]=0.300, p=0.768, respectively). 
 
Relationships Between ICP, AMP, and sPI During Plateau Waves and Unstable MAP 
Unlike the relationships between CPP versus sPI and AMP (where non-linear 
relationships were found), linear regression techniques yielded robust relationships of 
ICP with calculated variables in the plateau waves cohort. 
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The relationship between ICP and AMP across the compiled patient data for the 
plateau wave cohort is shown in Figure 5.4A A statistically significant linear relationship 
was described between ICP and AMP (r= 0.871, R2=0.758). Similarly, a statistically 
significant linear relationship was described between ICP and sPI (r= 0.728, R2=0.530), 
as displayed in Figure 5.4B. The relationship between AMP and sPI is displayed in Figure 
5.4C. Linear regression techniques yielded a significant relationship between AMP and 
sPI(r=0.700, R2=0.490).  
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Figure 5.4. Linear Regression Analysis of ICP versus AMP, ICP versus sPI, and AMP 
versus sPI in the Plateau Waves Cohort. A) Linear regression of ICP versus AMP. B) 
Linear regression of ICP versus sPI. C) Linear regression of AMP versus sPI. 
 
AMP– ICP pulse amplitude, ICP– intracranial pressure, mm Hg– millimeters of mercury, 
sPI– spectral pulsatility index, and R2 – the coefficient of determination.  
 
While linear regression also demonstrated significant relationships between ICP 
and AMP across the unstable MAP cohort, these relationships were less robust (Figure 
5.5A). A statistically significant linear relationship was described between ICP and AMP 
(R2=0.470). A very weak linear relationship was described between ICP and sPI 
(R2=0.059), as displayed in Figure 5.5B. Finally, the relationship between AMP and sPI 
was linear (R2=0.310) (Figure 5.5C).
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Figure 5.5. Linear Regression Analysis of ICP versus AMP, ICP versus sPI, and AMP 
versus sPI in the Unstable MAP Cohort. A) Linear regression of ICP versus AMP; B) 
Linear regression of ICP versus sPI; C) Linear regression of AMP versus sPI. 
 
AMP – ICP pulse amplitude, ICP – intracranial pressure, mm Hg – millimeters of mercury, 
sPI– spectral pulsatility index, and R2 – the coefficient of determination. 
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5.1.4.  Discussion 
In the past, observations of brain pulsatility in the context of lowering CPP(206) and 
increasing ICP(185) were reported, although much mixed methodology was used in 
those works. In this study, a unified method compared the same relationship in 
clinical conditions where CPP is affected either by increasing ICP or by the oscillations 
of unstable MAP. 
The application of linear and non-linear regression analysis, has displayed both 
confirmatory and new results regarding the relationships between TCD-based PI and 
invasively-measured cerebral hemodynamic indices, ICP and CPP. This is older data 
harvested from the “Cambridge database” of high-resolution recorded signals from the 
1990s, as neuro-intensive care TBI patients at that time were not treated according to 
a rigorous CPP-/ICP-oriented protocol; therefore, incidences of lowered CPP were 
recorded more easily. This is a relevant major aspect of these data recordings given 
that it is uncommon to have high-resolution datasets in the absence of CPP-directed 
therapy post-TBI.          
 Here, it has been demonstrated that large fluctuations in CPP, either via 
changes in ICP or MAP, hold true the inverse non-linear relationship between CPP 
versus sPI, and this relationship can be best described through the function: PI=a 
+(b/CPP); with a~0 (i.e., plateau waves, a=−0.03; unstable MAP, a=−0.06) and b almost 
identical between both cohorts (i.e., plateau waves, b=26.4; unstable MAP, b=25.3). 
Furthermore, non-linear regression analysis of each individual patient in both cohorts 
shows that the value for “a” is also close to 0. This was displayed strongly within the 
plateau waves cohort (mean “a”=0.005; SD= 0.061). The unstable MAP cohort 
displayed this same relationship, but less substantially (mean “a=−0.144; SD= 0.391). 
The statement that “a” was no different from 0 was further solidified via t-test analysis 
demonstrating no statistically significant difference between “a” and 0 in both cohorts. 
Therefore, if “a” is essentially equal to 0, then the relationship between CPP versus sPI 
can be approximated by the relation: PI=b/CPP, with b~25. This closely models the 
relation proposed by de Riva et al.(28) and provides the first evidence in support of this 
mathematical relationship between CPP and PI in human models. 
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Secondly, positive linear correlations were demonstrated between ICP versus 
AMP, ICP versus sPI, and AMP versus sPI in both the plateau waves and unstable MAP 
cohorts. Linear regression analysis of ICP versus AMP displayed the most robust linear 
relationship. Although the relationship between ICP versus non-spectral methods of 
PI calculation had been already described (i.e. that ICP can be well-approximated by 
TCD-based PI models)(11,207–209), limited literature exists utilizing spectral methods for 
PI determination. Furthermore, the relationship between ICP versus AMP and AMP 
versus sPI is seldom described, leaving this study as a clear example of their linear 
relationships. 
Third, it is also remarkable that the relationship between CPP and AMP also 
followed an inverse non-linear relationship through non-linear regression techniques. 
Again, this was also confirmed for both the plateau waves and unstable MAP cohorts. 
In contrast, ICP seems to have a stronger link to intra-cranial/extra-vascular 
parameters (i.e., AMP, with an R2=0.758) compared to intra-vascular measurements 
(i.e., sPI, with an R2=0.530). Conversely, CPP displays a stronger relationship to intra-
vascular parameters (i.e., sPI, with an R2=0.820) versus extra-vascular intra-cranial 
measures (i.e., AMP, with an R2=0.610). 
Finally, the fact that sPI is a smooth inverse function of CPP makes it very 
difficult to prove that the CPP level below which sPI starts to increase could denote 
the lower limit of autoregulation (where the brain is on the verge of becoming unable 
to maintain a constant level of blood flow). Chan et al.(206) observed in patients with 
disturbed autoregulation that at a CPP value of about 40 mm Hg, adequate blood flow 
perfusion becomes more dependent on MAP than on CPP itself. However, later 
experimental challenges(210) demonstrated that increases in PI secondary to instances 
of decreasing CPP do not automatically signify a patient reaching the lower limit of 
autoregulation(210).  
Clinical Implications 
The most recent edition of the Brain Trauma Foundation Guidelines 
recommends that CPP be directed towards the target range of 60–70 mm Hg. 
Constraining CPP between these values is thought to prevent either the hyper- or hypo-
perfusion that could, respectively, increase patient risk of poor outcome. When 
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considering trends across individual patient data, all sPI versus CPP curves suggest that 
values of sPI around 0.4 correspond to CPP values around 60 mm Hg. In this manner, 
sPI can easily be interpreted by clinicians as an indicator of the accepted “safe” lower 
bound of CPP(182). Furthermore, the above analysis demonstrated the correlation 
between TCD-based sPI and CPP. This reinforces previous literature stating that TCD 
potentially provides the ability for non-invasive estimation of CPP in the absence of 
invasive ICP monitoring, which could expand the usage of both TCD as a technique and 
CPP as a metric outside of neurocritical care environments(82). Finally, this study 
suggests that the relationship between CPP- and TCD-based sPI is maintained during 
extremes of physiology (i.e., plateau waves and unstable MAP), and can be theoretically 
applied to TBI monitoring. Thus, if clinician apply this methodology of non-invasive 
CPP estimation, this data suggests that the relationship between sPI and CPP should 
hold true, regardless of the individual clinical situation and extremes of physiology seen 
at the time of measurement. 
Limitations 
Several limitations must be acknowledged. First, the analyses are based on 
observational data, rather than a prospective recording of response to a change in CPP. 
Consequently, many confounders may have affected critical variables, and the data 
access (and the relatively small volume of data compatible with ICM+TM during this 
period) does not allow full accountability for them. Second, results are derived from 
only 11 sets of patient data containing 18 distinct plateau waves and 9 datasets containing 
13 instances of variable MAP. Consequently, extrapolation of this data to all patients 
with TBI is not possible, and confirmation of the described relationships will need to 
occur through comparative analysis of larger datasets. 
Third, non-linear regression techniques for the relationships between CPP versus 
AMP and CPP versus sPI described the best fit with an inverse non-linear function. 
However, with a total of only 20 patients, larger datasets are needed to better delineate 
and further prove this inverse relationship. Given that this patient population was so 
small, the next step is to validate these findings within a large TBI cohort to show that 
the proposed relationship holds. The relation yielded via non-linear regression cannot 
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be extrapolated and must serve only as a point of interest in the relationship between 
CPP versus AMP and CPP versus sPI, providing preliminary supporting evidence for the 
theorized non-linear relation previously described by Czosnyka et al.(202). Fourth, within 
the unstable MAP cohort, it is difficult clinically to isolate pure MAP from pure ICP 
contributions to changes in CPP. These patients exhibit significant fluctuations in 
various physiologic measures, as shown in Table 5.2. Finally, patients with severe TBI 
and plateau waves are an extreme cohort of critically ill patients, with injuries that may 
yield abnormal physiologic brain properties. Therefore, the distinct relationships 
described in this small study cannot necessarily be applied to all TBI patients. 
 
5.1.5.  Conclusions 
In severe TBI patients with plateau waves or unstable MAP, the relationships between 
CPP and pulsatility of brain signals are inversely proportional, irrespective of the 
mechanism that lowers CPP. ICP versus AMP, ICP versus sPI, and AMP versus sPI 
display positive linear correlations. 
 
5.2.  Estimation of Pulsatile Cerebral Arterial  
  Blood Volume Based on Transcranial   
  Doppler Signals  
 
 
5.2.1.  Introduction 
The volume of arterial blood circulating throughout the brain at any one time can be 
adversely affected by traumatic brain injury (TBI) (211). Pulsatile cerebral arterial blood 
volume (CaBV) can now be modeled with different input signals. Although this 
modeling reflects the inherent nature of blood flow throughout the brain, there is no 
Chapter 5 – Understanding and Modeling of Pulsatile Cerebral Hemodynamics   128 
 
consensus on which specific combination of model elements yields a best-fit equation 
that could be globally applied in neurocritical care. This specific study sought to revisit 
the extant modeling methods(1,92,212–216) with the following aims: a) to comprehend which 
method is most suitable for describing patient hemodynamics, and b) to build a 
function able to monitor changes in cerebral compartmental compliances when 
considered alongside invasive monitoring and data-driven trend charts.   
 
Fundamentals of Mathematical Modeling 
Mathematical models of cerebral circulation must be able to account for pulsatile 
changes in the vasculature as a result of the cardiac cycle. TCD can both capture and 
continuously monitor cerebral hemodynamic changes in real time; FV through the MCA 
can be expressed as a variable that can be further analyzed with ICM+TM software to 
provide additional descriptors of hemodynamic activity. 
With this application, Kim et al.(212) studied the changes in compartmental 
compliances (pressure/volume ratios expressed as either: Ca – the compliance of the 
cerebral arterial bed or Ci – the compliance of the cerebrospinal space) during plateau 
waves of ICP. During this event, the Ca and Ci compartments of the brain vary inversely 
as a result of dynamic shifts in the vasomotor tone of the cerebral vessels(212). These 
authors(212) emphasized the mean arterial inflow curve when computing a 
comprehensive descriptor of cerebral arterial blood volume and their model below(212) 
returns the TCD-derived parameter CaBV. This parameter can be mathematically 
transformed through Fourier analysis to yield the fundamental harmonics of pulsatile 
components of CaBV, allowing a further-detailed expression of cerebral hemodynamics: 
 
𝐶𝑎𝐵𝑉(𝑛) =  𝑆𝑎 × ∑ [𝐶𝐵𝐹𝑉𝑎(𝑖) − 𝑚𝑒𝑎𝑛(𝐶𝐵𝐹𝑉𝑎)]∆𝑡 (𝑖)
𝑚𝑛
𝑖=𝑚1
 
                                                                                                                                            [5.3.] 
where: 𝑆𝑎  represents the cross-sectional area of the MCA, 𝑚1 the first sample of the 
interval, n the number of samples, CBFVa the cerebral arterial blood flow velocity, and 
∆𝑡 is the time interval between two consecutive samples(212).  
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The foundations of this present study are rooted in the outcomes from laboratory 
modeling research conducted by Uryga et al.(216). While manipulating arterial blood 
carbon dioxide concentration in healthy volunteers, the abilities of continuous flow 
forward (CFF) and pulsatile flow forward (PFF) models of CaBV change were compared 
as holistic descriptors of various cerebral hemodynamic indices. “Flow forward” refers 
to the direction of cerebral blood transport from large arteries into resistive arterioles. 
The CFF modeling approach relies on the balance between the simultaneously-opposing 
forces of pulsatile cerebral blood inflow and cerebral blood outflow, which influence 
changes in CaBV. Citing Avezaat and van Eijndhoven(217), Uryga et al. (216) created a time-
integrated function of the difference between both inflow and outflow over a single 
cardiac cycle (Equation 5.4., below).  
 
                 
0
( ) ( ( ) )
t
a CFF a
t
aC BV t CBF s meanCBF ds = −                                   [5.4.] 
 
However, when employing TCD, this simplistic function requires averaging over 
several cardiac cycles to provide a surrogate measure of the blood inflow and outflow 
that occur in tandem(184,216). To counter the effects of the variability of both blood 
outflow and systemic vascular impedances as a result of pulsatile changes in the ABP 
waveform, a second modeling approach was necessitated, becoming PFF. CaBV 
expressed by PFF would be a time-integrated function of the difference between the 
cerebral blood flow (CBF) signal and the ABP signal divided by CVR. The CVR can be 
estimated by TCD (i.e. the ratio between mean ABP and CBF, normalized by the 
unknown cross-sectional area of the MCA, which is presumed constant, see Equation 
5.5, below). Uryga et al.(216) reported that each model’s virtual signal is able to capture 
the pulsatile nature of its constituents and is respectively identified by their different 
waveform shapes and amplitudes. 
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0
( )
( ) ( )
t
a a
t
PFF
ABP s
C BV t CBF s ds
CVR
 
 = − 
 
                                  [5.5.] 
 
where: s – the arbitrary time variable of integration, CBFa – cerebral blood flow velocity, 
ABP –arterial blood pressure, and CVR – cerebrovascular resistance(216).  
 
This study modifies the PFF modeling approach in particular to include both ABP 
and cerebral perfusion pressure (CPP), and to consider both CFF and PFF as potentially 
useful tools in the determination of clinical outcome. The previous method of CaBV 
modeling assumed constant outflow of the blood from the modeled compartment 
(compliance of cerebral arteries and vascular resistance). The proposed modification 
(PFF) presumes that outflow may be pulsatile, and investigates changes in formulas for 
the calculation of the amplitude of CaBV estimators. As there is no objective gold 
standard for the non-invasive calculation of CaBV, the novel CaBV estimator models are 
further compared against the spectral pulsatility index (sPI)(88) to assess their respective 
capabilities to approximate the cerebral blood volume component of ICP in extreme 
pathologies. To current knowledge, this paper is the first of its kind attempting to apply 
these modeling perspectives to a population of neuro-critically ill patients. 
 
5.2.2.  Methods 
Patients 
52 adult patients were selected from a database of 432 moderately to severely 
head-injured patients with TCD, ICP, and ABP monitoring, stored between 1992 and 
2012 that demonstrated a variety of clinically-extreme scenarios. Of these 52 patient 
datasets: 16 presented plateau waves of ICP which are difficult to capture during routine 
TCD monitoring sessions(88), 19 underwent a period of mild, controlled hypocapnia (30-
60 minutes’ duration), and 17 received vasopressors to stabilize mean ABP that 
fluctuated at least 15 mm Hg during the recording. All patients were admitted to the 
Neurosciences Critical Care Unit (NCCU) at Addenbrooke’s Hospital, Cambridge, 
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United Kingdom. All patients were sedated and mechanically ventilated; barring the 
hypocapnic challenge to assess CO2 reactivity, all patients were treated in accordance 
with an ICP/CPP-oriented protocol that constrained ICP below 20-25 mm Hg and 
maintained CPP between 60-70 mm Hg(218,219). Table 5.3 describes these patients in 
detail. 
These particular patient groups were chosen in the interest of observing the 
direction(s) of CaBV changes in response to biophysical “challenges”(218–226) which are 
thought to mimic physiological responses to hemodynamic disturbances that are 
provoked, pathological, or pharmacological. Therefore, CaBV can be manipulated by 
ICP(218,220,221) CO2(219,222–224), and ABP(225–227), making these parameters important clinical 
discriminants. Dramatic fluctuations in CaBV can be best studied in patients exhibiting 
complex clinical profiles, such as plateau waves of ICP, hypocapnia, and unstable ABP; 
these specific patient cohorts were chosen to test the veritable limits of the 
mathematical modeling of cerebral hemodynamics, and to provide secondary insight 
into outcome prediction.  
Retrospective data was anonymized and is stored as such in the NCCU Users 
Group database. TCD recordings were incorporated into standard patient monitoring 
practices on the NCCU and utilized an anonymized database of physiological 
monitoring variables in neurocritical care. Demographic data, injury severity, and 
clinical status at hospital discharge were collected prospectively during the monitoring 
of these patients; these clinical records were not consulted further to provide additional 
information for this study. All data retrieved from the database was extracted from these 
pre-existing patient records, and fully anonymized. Data pertaining to long-term 
outcome or patient-identifiers was not available, and formal patient or proxy consent to 
access these items was not sought, with the exception of the vasopressors cohort, which 
consented for positron emission tomography (PET) under two different blood pressure 
levels. 
 
ICP Plateau Waves 
The observable phenomenon of an ICP plateau wave has been explained as a 
function of increasing CaBV at the expense of cerebral vasomotor tone and flow 
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regulatory mechanisms(222). As cerebral vessels react with maximal dilation and obstruct 
draining veins, both the velocity and the volume of blood flowing within their walls 
increases. However, the brain cannot accommodate these alterations as they occur, so 
ICP rapidly increases. The increased amplitude of the raw ICP waveforms can be 
attributed to the influx of pulsatile cerebral blood coursing through the cerebral vessels, 
as opposed to an increase in mean ICP(220,228). Both the CFF and PFF models can express 
the heightened magnitude of pulsatile changes in CaBV as a result of ICP plateau waves. 
It was hypothesized that this cohort in particular would be best-described by the PFF 
model using CPP as input, as plateau waves increase ICP, and therefore will affect CPP.  
 
Hypocapnia   
Data from patients submitted to short-term episodes of hypocapnia (mean 
PaCO2, the partial pressure of carbon dioxide in arterial blood, was maintained at 
4.38±0.34 kPa and deviated on average by 0.72±0.26 kPa during hypocapnia) were also 
included to test the limits of CaBV modeling in the opposite direction. The 
vasoconstrictive effects of hypocapnia can be observed in the characteristic reduction 
of ICP attributed to a “backshift of the working point on [the] pressure-volume curve”, 
in which CaBV circulation is negatively affected by the increasing resistance to arterial 
inflow(225). Cerebral autoregulation is thus compromised(229); prolonged exposure to 
hypocapnia exacerbates the risk of both disability and mortality, as decreasing ICP at 
the expense of CPP overreaching its targeted value can lead to ischemia or irreversible 
damage to brain tissue(224). 
 
Vasopressors 
Infusions of vasopressors such as norepinephrine or phenylephrine have been 
found to increase cerebral perfusion and oxygenation in both human and swine 
models(25). Following TBI, they are administered to increase ABP and CPP to prevent 
secondary ischemia (Meng 2012; Sperna 2017). The selected cohort of patients 
maintained a mean ABP of 87.31±7.16 mm Hg that was increased to 111.41±6.45 mm Hg 
following infusion of either phenylephrine (0.5 mcg/kg/min) or norepinephrine (0.05 
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mcg/kg/min). It was hypothesized that both PFF models, either with ABP or CPP used 
as input, would be strongly correlated with this cohort.  
 
Monitoring 
All patients received both invasive and non-invasive monitoring while under 
clinical observation. Raw data signals from select monitoring devices were captured and 
archived electronically through WREC software (Warsaw University of Technology) or 
ICM+TM (licensed through Cambridge Enterprise, Cambridge, U.K.; 
http://www.neurosurg.cam.ac.uk/icmplus).  
ABP was continuously monitored invasively [from the radial artery using a 
pressure monitoring kit (Baxter Healthcare C.A., U.S.A.; Sidcup, U.K.)]. ICP was 
monitored using an intraparenchymal probe with strain gauge sensors (Codman & 
Shurtleff, M.A., U.S.A.). End-tidal CO2 (ETCO2) was measured in the patients 
experiencing periods of mild, controlled hypocapnia via capnograph (Marquette Solar 
8000 M, GE Medical Systems, U.K.). Cerebral blood flow velocity (FV) was recorded 
from both unilateral and bilateral monitoring of the middle cerebral artery (MCA) with 
a 2 MHz TCD probe (Multi Dop X4, DWL Elektronische Systeme, Sipplingen, Germany). 
Data were processed through a 16-bit, 100kHz analog-to-digital converter (DT9803 USB 
Data Acquisition (DAQ) Module, Measurement Computing Corporation, Norton, M.A., 
U.S.A.). 
Raw TCD data sampled from the three types of events (ICP plateau waves, 
hypocapnia, and vasopressors) included in the study encapsulated the baseline 
readings, the entirety of the challenge/event, and the post-event recordings. Signal 
artifact removal was achieved manually. CPP was determined from the difference 
between raw ABP and ICP signals. The average duration of these TCD recordings was 
over 108.59±57.56 minutes, with a minimum of 18 minutes and maximum of 177 minutes 
captured per patient. 18-90 minutes of continuous TCD data recordings were obtained 
from the plateau waves cohort, with 85-138 and 135-177 minutes each obtained from the 
hypocapnia and vasopressors cohorts, respectively.  
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Data Processing 
The previous section of this thesis(88,184) allowed the expression of a TCD-based 
“spectral pulsatility index” (sPI), defined above as sPI = F1/FVm) using the following 
model presented below in Equation 5.6. This model describes the relationships among 
several cerebral hemodynamic parameters that would be expected to yield variations in 
CPP(88). Here, estimators for Ca and CaBV were chosen, which produce the best 
agreement between the left and right sides of this equation.  
                     
                                      𝑠𝑃𝐼 =  
𝐴1
𝐶𝑃𝑃𝑚
 × √(𝐶𝑉𝑅 ×  𝐶𝑎)2  × 𝐻𝑅2 ×  (2𝜋)2 + 1                     [5.6.]
    
 
where: A1 represents the fundamental harmonic of the ABP pulse waveform determined 
using Fourier transformation, Ca the cerebral arterial compliance, CPPm the calculated 
mean of recorded CPP values, CVR the cerebrovascular resistance, and HR the heart 
rate calculated in Hz(184). All parameters were calculated as averages over a 10-second 
time window. 
 
 Within ICM+TM, virtual signals from the invasive monitoring (ABP and ICP) 
devices and from TCD blood flow velocity monitoring (FV) were sampled at a frequency 
of 50 Hz to form the backbones of the three CaBV change approximation models. A 
continuous flow forward model (CFF)(28,92,216,217) was applied as a time-integral of FV to 
form CaBVCFF (CaBV1; Equation 5.7) sampled at a frequency of 50 Hz (Equation 5.7), 
whereas the two pulsatile flow forward models (PFFABP and PFFCPP) were similarly 
derived using ABP and CPP as input, to form the respective CaBVPFFABP (CaBV2; Equation 
5.8) and CaBVPFFCPP (CaBV3; Equation 5.9).  
                
                                Δ𝐶𝑎𝐵𝑉𝐶𝐹𝐹(𝑡) = ∫  (𝐹𝑉 (𝑖) − 𝐹𝑉𝑚 ) 𝑑𝑖
𝑡
𝑡𝑜
                                        [5.7.] 
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                                   Δ𝐶𝑎𝐵𝑉𝑃𝐹𝐹𝐴𝐵𝑃(𝑡) =  ∫ (𝐹𝑉(𝑖) − (
𝐴𝐵𝑃(𝑖)
𝐴𝐵𝑃𝑚
𝐹𝑉𝑚
)
𝑡
𝑡𝑜
 𝑑𝑖                                               [5.8.] 
                                Δ𝐶𝑎𝐵𝑉𝑃𝐹𝐹𝐶𝑃𝑃(𝑡) =  ∫ (𝐹𝑉(𝑖) − (
𝐴𝐵𝑃(𝑖)−𝐼𝐶𝑃(𝑖)
𝐴𝐵𝑃𝑚−𝐼𝐶𝑃𝑚
𝐹𝑉𝑚
 )
𝑡
𝑡𝑜
) 𝑑𝑖                       [5.9.] 
 
where: t0 and t are the respective beginning and end of a single cardiac cycle, ∆𝑡 is the 
time interval between two consecutive samples, 𝐹𝑉(𝑖), 𝐴𝐵𝑃(𝑖), 𝑎𝑛𝑑 𝐼𝐶𝑃(𝑖) are the moving 
averages of FV, ABP, and ICP over a specified time window including previous cardiac 
cycles (a moving average filter of 600 seconds was applied), FVm is the mean value of 
FV, ABPm is the mean value of ABP, ICPm is the mean value of ICP, and s is the arbitrary 
variable of integration.  
 
  Primary analysis involved the determination of time-averaged mean values for 
ABP, CPP, FV, ICP, ΔCaBV1, ΔCaBV2, and ΔCaBV3. Each mean was calculated during 10-
second time windows and continuously updated every 10 seconds. For the CFF model, 
Fourier transformation was employed to determine the fundamental frequencies of 
each of the above parameters, to use as scaffolds for more extensive evaluation of 
spectral changes in ΔCaBV, yielding AmpCaBVCFF. For the PFF models, the fundamental 
amplitudes were calculated with Equation 5.10 (see Appendix C); AmpCaBVPFFCPP was 
obtained with this same formula but required AmpCPP as input rather than AmpABP 
(see Appendix C). Each of these calculations was similarly sampled and updated over a 
10-second time window.   
  The secondary phase of analysis computed time-averaged mean values of all of 
the above parameters, sampled and updated over a 10-second time window, with the 
introduction of time-averaged mean values of ΔCABV1, ΔCABV2, and ΔCABV3 resolved 
into the spectral domain to yield the respective CABV1S, CABV2S, and CABV3S. These 
spectral components were included in the final analysis to create nine separate models 
of CaBV approximation to be validated against the existing sPI model(88,184) describing 
changes in CPP as a result of extreme pathology that were directly observed by TCD.  
Final data processing efforts continued to determine the time-averaged mean 
values from previous analytic phases, each sampled and updated over a 10-second time 
window. Several new derived parameters were introduced here, including: sPI as the 
quotient of the means of F1 and FV, mean CABV1S, CABV2S, and CABV3S, and the time 
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constant of the cerebral arterial bed (tau, τ). Commonly interpreted as a simplified 
electronic circuit model consisting of a single resistor and capacitor, τ is evaluated as 
the relative time period required to fill the cerebral arterial bed(92,216). τ is the product of 
Ca and CVR and emphasizes the “mutual interdependence” of these parameters from 
an absolute value of ABP(210,230). Additionally, τ is not affected by the surface area of the 
middle cerebral artery (MCA), so challenges to the long-held assumption of its constant 
value do not pose a threat to this parameter’s applicability to patient data. 
Although the calculation of τ was not the primary feature of this report, its 
inclusion in the final analysis supports its utility for further description of changes in 
CaBV. τ varies inversely with fluctuations in ABP or CPP, which are crucial components 
of the interpretation of CFF and PFF models(210,230). The nine derived estimators of CaBV 
pulsatility each employ a similar circuit model to τ, with single resistors (Ra1-Ra3) and 
capacitors represented by manipulated combinations of aspects of either the 
continuous or pulsatile flow forward models and cerebral hemodynamic parameters 
(ABP, CPP, FV) sourced through ICM+TM. The resistors and capacitors “available” (listed 
as PI_CxRax) for the creation of each of these models are listed below, with the full 
formulaic characterizations to be found in Appendix D.  
All data post-processing was exported from each patient to separate comma-
separated variable (CSV) files for further statistical analysis. 
 
Statistics 
 All statistical analyses were conducted utilizing R (R Core Team [2017]; R: a 
language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. URL https://www.R-project.org/). Post-processing, 
individual CSV documents containing the data of each patient, were compiled into 
one CSV document per cohort containing the relevant patients and all of the signals 
described above.  Cerebral hemodynamic trends were separately analyzed for each of 
the three patient cohorts (as plateau waves, hypocapnia, and vasopressors) to 
appreciate the physiological differences between clinical profiles. A visual example of 
the trends exhibited by a patient from each group was exported from ICM+TM, and is 
provided in Figure 5.6 below.
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Figure 5.6. Examples of sPI, ABP, CPP, FV, and ICP dynamic trends exported 
directly from ICM+TM for a single patient in the A) plateau waves, B) mild 
hypocapnia, and C) arterial hypertension cohorts. 
 sPI- spectral pulsatility index, ABP- arterial blood pressure, CPP- cerebral perfusion 
pressure, FV- flow velocity, ICP- intracranial pressure, mm Hg- millimeters of mercury.  
 
Various statistical techniques were employed to describe the strength of the 
following relationships in all three patient cohorts: sPI vs. PI_C1Ra1, PI_C1Ra2, PI_C1Ra3, 
PI_C2Ra1, PI_C2Ra2, PI_C2Ra3, PI_C3Ra1, PI_C3Ra2, and PI_C3Ra3.  Goodness of fit 
between the metric of sPI and each of the nine CaBV estimator models was assessed via 
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linear regression in R; this was achieved with the Pearson correlation coefficient (r) and 
the determination coefficient (R2).  
The Bland Altman method was applied, also in R, to measure the agreement 
between sPI and each respective estimator model for the purpose of explaining changes 
in CaBV demonstrated by each pathology. Descriptive statistics for each of the three 
patient cohorts, along with the results of the linear regression and Bland Altman 
analyses, are reported in Tables 5.4-5.6.   
 
5.2.3. Results 
 
Relationships between sPI and CaBV Estimators  
Tables 5.4 (plateau waves), 5.5 (hypocapnia), and 5.6 (vasopressors) summarize 
the mean values and standard deviations of sPI and of the estimator models.; they 
additionally feature summary statistics data for all TCD recordings comprising each of 
the patient cohorts, and Bland Altman means and critical differences for sPI and each 
estimator model. To appreciate the agreement between the sPI and each estimator 
model, the Pearson correlation coefficients (r) were also listed per respective cohort.  
The results of the final analyses indicated that irrespective of the patient cohort, 
each of the nine CaBV estimator models was robustly correlated with sPI. However, the 
best-fit estimator model that was superior in approximating changes in CaBV 
throughout the entire recording varied as a result of the distinct clinical profiles of these 
patients. Tables 5.4-5.6 demonstrate these trends. 
 
Plateau Waves 
 This cohort demonstrated high agreement between the derived and the 
“traditional” parameters comprising the electronic circuit-inspired estimator models. 
The readings from each subgroup were closely approximated to sPI by all of the models 
(fully detailed in Appendix C) but were most strongly determined by PI_C1Ra3 with an 
average r-value of 0.915 for the entire recording (Figure 5.7). The strengths of each 
estimator as measured against sPI are reported in Table 5.4, below.  
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Table 5.3. Patient Demographics and Outcomes 
 
Patient Cohort Number of 
Patients 
Mean 
Age 
(years) 
Male:Female 
Ratio 
Median 
Admission 
GCS  
Glasgow Outcome 
Scale at Discharge 
Plateau Waves 16  
(5/16 lost to 
follow-up) 
 
27.18 
(range: 
17 to 
32) 
12:4 
 
5 (range: 1 
to 10) 
GOS  # of 
Patients 
Dead 0 
PVS 4 
Severe 
disability 
5 
Moderate 
disability 
0 
Good 2 
N.A.: 5 
 
 
 
Hypocapnia 19 
(4/19 lost to 
follow-up) 
 
39.1 
(range: 
17 to 
70) 
14:5 
 
6 (range: 3 
to 12) 
GOS  # of 
Patients 
Dead 1 
PVS 0 
Severe 
disability 
5 
Moderate 
disability 
8 
Good 1 
N.A.: 4 
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Vasopressors 17 
(5/17 lost to 
follow-up) 
32.79 
(range: 
18 to 
69) 
13:4 5 (range: 3 
to 9) 
GOS  # of 
Patients 
Dead 2 
PVS 0 
Severe 
disability 
2 
Moderate 
disability 
4 
Good 4 
N.A.: 5 
 
GCS = Glasgow Coma Scale, GOS = Glasgow Outcome Score, # = number, PVS – 
persistent vegetative state.   
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Table 5.4. sPI vs. Derived PI Models in the Plateau Waves Cohort 
 
                                                               sPI PI_C1Ra1 PI_C1Ra2 PI_C1Ra3 PI_C2Ra1 PI_C2Ra2 PI_C2Ra3 PI_C3Ra1 PI_C3Ra2 PI_C3Ra3 
           
 
Entire Recording 
          
Mean 0.340 0.639 0.369 0.448 0.459 0.326 0.343 0.428 0.325 0.329 
Standard Deviation 0.176 0.392 0.119 0.147 0.311 0.182 0.134 0.281 0.212 0.128 
Bland Altman Mean --- -0.299 -0.028 -0.084 -0.119 0.014 -0.002 -0.088 -0.015 0.012 
Bland Altman 
Critical Difference 
--- 0.548 0.337 0.17 0.506 0.538 0.306 0.501 0.610 0.333 
Pearson Correlation 
Coefficient  
--- 0.888 0.843 0.915 0.886 0.888 0.889 0.887 0.882 0.886 
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Figure 5.7. A Bland Altman plot representing the compatibility between sPI and 
PI_C1Ra3 to estimate changes in CaBV in the plateau waves patient cohort. The 
bold lines indicate the limits of agreement as measured with a confidence interval of 
95%, yielding a bias of -0.0836.  
 
Hypocapnia Cohort 
The hypocapnia patient cohort provided a similar example of high agreement 
between parameters determined both invasively and non-invasively. In conjunction 
with the results from the plateau waves cohort, sPI was closely approximated by all of 
the models, in particular by PI_C1Ra3 with an average r-value of 0.955 for the entire 
recording (see Table 5.5, below). PI_C1Ra3 was overwhelmingly found to be the superior 
estimator of the volumetric changes in cerebral arterial blood within the hypocapnia 
patient cohort. As above, complete descriptions of each of the models are contained in 
Appendix C. 
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Table 5.5. sPI vs. Derived PI Models in the Hypocapnia Cohort 
 
 
sPI PI_C1Ra1 PI_C1Ra2 PI_C1Ra3 PI_C2Ra1 PI_C2Ra2 PI_C2Ra3 PI_C3Ra1 PI_C3Ra2 PI_C3Ra3 
 
Entire Recording 
          
Mean 0.301 0.432 0.337 0.385 0.273 0.253 0.262 0.265 0.250 0.257 
Standard Deviation 0.102 0.150 0.109 0.124 0.094 0.104 0.086 0.087 0.103 0.082 
Bland Altman Mean --- -0.131 -0.036 -0.084 0.029 0.048 0.039 0.036 0.051 0.044 
Bland Altman Critical 
Difference 
--- 0.117 0.102 0.061 0.065 0.161 0.065 0.068 0.165 0.072 
Pearson Correlation 
Coefficient 
--- 0.918 0.588 0.955 0.830 0.600 0.821 0.830 0.613 0.815 
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Vasopressors Cohort 
 As observed in both the plateau waves and the hypocapnia patient cohorts, the 
vasopressors cohort also suggested high agreement with sPI. However, when compared 
to the previous cohorts, the variability between each of the models as predictors of sPI 
was significantly greater for each recording subgroup, although PI_C1Ra1 and PI_C1Ra3 
were repeatedly closely-matched (see Table 5.6, below).  When considering the average 
r-value, the vasopressors patient cohort challenged the notion of PI_C1Ra3 as being 
considered the “best-fit” for sPI. PI_C1Ra1 and PI_C1Ra3 were nearly identical 
approximators of sPI, with respective average r-values of 0.938 and 0.931. As above, the 
construction of each model is outlined in Appendix C. 
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Table 5.6. sPI vs. Derived PI Models in the Vasopressors Cohort 
 
 
sPI PI_C1Ra1 PI_C1Ra2 PI_C1Ra3 PI_C2Ra1 PI_C2Ra2 PI_C2Ra3 PI_C3Ra1 PI_C3Ra2 PI_C3Ra3 
 
           
Entire Recording 
          
Mean 0.299 0.484 0.374 0.434 0.324 0.306 0.312 0.314 0.305 0.305 
Standard Deviation 0.647 0.710 0.088 0.628 0.714 0.721 0.631 0.715 0.807 0.631 
Bland Altman Mean --- -0.044 -0.075 -0.134 -0.024 -0.006 -0.023 -0.014 -0.005 -0.005 
Bland Altman Critical 
Difference 
--- 0.072 1.264    0.987 1.099 1.910 1.025 1.104 2.040 1.029 
Pearson Correlation 
Coefficient 
--- 0.938 0.621 0.931 0.870 0.687 0.826 0.814 0.652 0.781 
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5.2.4.   Discussion 
The first aim of this study was to assess the feasibility of either a CFF or a PFF model to 
approximate CaBV in physiologically extreme conditions affecting neurocritical care 
patients. It was hypothesized that a PFF model with CPP as the input signal (PI_C3Ra3) 
would be the best-fit estimator model because its core parameter contains raw signals 
from both standard cerebral hemodynamic indices (ABP and ICP) that largely direct 
patient management. However, the results seem to disprove this hypothesis, suggesting 
that it is mainly PI_C1Ra3 (closely followed by PI_C1Ra1, but only for the vasopressors 
cohort – see Tables 5.4-5.6) that is the best fit for these groups of neurocritical patients. 
 Although inspired by the work of Uryga et al.(216) which concluded that PFF was 
superior to CFF when measured in healthy volunteers during hypo- and hypercapnia, 
these results taken from a population of TBI patients contradict this point. This could 
be related to the fact that the CFF method of CaBV estimation is more “stable” for 
measurement, as it discards the dependence on ABP for calculation that characterizes 
both PFF modeling scaffolds. ABP appears to be the most sensitive parameter, as any 
large fluctuations of ABP in patients would dramatically change the value of the 
numerators of any one of the three resistors applied to either PFF model (please see 
Appendix C). Though the TCD-based pulsatility index can describe hemodynamic 
asymmetry and alert clinicians to low CPP, it cannot reliably explain CVR or be 
considered a secure measure of risk against intracranial hypertension or 
dysautoregulation(184). When plotting sPI against CPP(88), the curve does not exhibit an 
abrupt breakpoint that would indicate the lower limit of autoregulation when targeting 
CPP in accordance with neuro-intensive care protocols(184). 
This section concentrated on building mathematical models of cerebral 
circulation able to account for pulsatile changes in the vasculature as a result of the 
cardiac cycle. TCD can capture continuous monitoring of cerebral hemodynamic 
changes in real time that can be further analyzed with ICM+TM software to provide 
additional descriptors of hemodynamic activity, such as the compliance of the cerebral 
arterial bed (Ca) and the cerebrovascular resistance (CVR). Although the diameter of 
the MCA has been observed as relatively constant in healthy volunteers(231,232) 
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(discounting cases of vasospasm), the volume of cerebral arterial blood flowing through 
it is subject to change, especially when exposed to extreme physiological conditions (i.e. 
plateau waves of ICP, hypocapnia, or unstable ABP requiring the use of vasopressors for 
stabilization)(88).  
Although the modeled approximation of CaBV without its venous component 
appears noncompliant with natural circulatory transit cycles, there is a long-standing 
assumption that venous flow pulsatility is much lower than its arterial counterpart. 
Regarding the possible influence of the venous component, Carrera et al.(220) reported 
that during one cardiac cycle, venous outflow carries a low enough pulsatility to be 
deemed “negligible” when calculating CaBV changes(184,212,217,220,230). Therefore, ΔCaBV 
can be represented as the time-integrated difference between the values of current and 
mean cerebral blood flow velocity(212,220). In fact, Avezaat & van Eijndhoven(217) had 
already noted the influence of pulsatile in- and outflow curves in determining the subtle, 
time-sensitive variations in ΔCaBV that occur over one cardiac cycle. The degree of 
quantifiable change in pulsatile CaBV would be an effect of the “temporal relationship” 
between cerebral arterial inflow and venous outflow processes; this is contingent on the 
impedances of the vascular bed, which can be both actively and passively mediated by 
either vasomotor tone or compression within the cerebral compartment(217). 
 
Clinical Implications 
Improvements in the estimation of CaBV provide various potentially crucial 
advancements for the monitoring of critically-ill patients. First, in patients suffering 
from intracranial hypertension, knowledge of which intracranial component is 
contributing most to ICP elevation is not always clear (i.e. CSF, blood volume, edema, 
etc.). Optimal models for CaBV estimation, such as those presented here, are required 
to properly outline the blood volume component of ICP. Such knowledge may allow the 
implementation of targeted therapies for particular intracranial components 
contributing to elevated ICP. Second, most clinicians currently manage intracranial 
hypertension by treating a single number, based on the Brain Trauma Foundation 
guidelines(182). It is unknown if targeting particular aspects of ICP, such as standard 
invasively-measured parameters or estimated CaBV, could provide greater impact on 
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patient functional outcome. However, adequate, optimized models of CaBV estimation 
are required prior to investigating therapies directed at continuously/semi-
continuously measured CaBV. 
Third, it is understood that persistent ICP elevations near, or at, the critical 
closing pressure (CrCP) are detrimental to sustained cerebral blood flow in the setting 
of brain injury. As accurate CrCP is predicated on CBV estimation, it becomes 
theoretically possible to estimate an individual patient’s CrCP in a continuous/semi-
continuous manner, allowing clinicians real-time knowledge of this critical threshold 
that can be incorporated into therapeutic interventions. Fourth, to date, the majority of 
continuously-measured indices of cerebrovascular reactivity are derived based on the 
notion that the correlation between slow-wave fluctuations in a surrogate measure of 
cerebral blood flow (such as TCD-based FV) or ΔCaBV (such as ICP) and a driving 
pressure (such as ABP or CPP), provide information regarding cerebral autoregulatory 
status. The most widely-employed index, pressure reactivity index (PRx)(92) is based on 
the correlation between slow-wave fluctuations of ICP (surrogate of CaBV) and mean 
ABP. In (TBI), PRx has demonstrated a strong association with global outcome(21) and 
has been validated as a measure of the lower limit of autoregulation in experimental 
models(18,93). However, there exists the potential to further optimize the ability to 
continuously assess cerebrovascular reactivity. With accurate CaBV estimation, instead 
of evaluating a surrogate measure of ΔCaBV, such as ICP, vasogenic slow-wave 
fluctuations in CaBV and their association with either ABP or CPP can be evaluated 
more directly. Such measures may prove superior to existing measures of 
cerebrovascular reactivity; prior to the evaluation of such measures, one requires 
optimal models for CBV estimation.   
Finally, as both medicine and the critical care management of brain injury 
patients shift towards a personalized approach, the ability to accurately and 
continuously assess various aspects of cerebral physiology is of the utmost importance. 
In TBI care, the emergence of literature on both individualized CPP(5,61,233) and ICP(181) is 
based on various aspects of physiologic signal measurement, processing, and analysis. 
It is unknown where continuously measured CaBV or CrCP will provide additional 
benefit in such care.  However, it isn’t until accurate estimation of CaBV is provided, 
that any benefit towards the goal of purely individualized care can be evaluated. 
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Limitations 
Although a single model could be identified as the most robust estimator of CaBV 
changes when compared against sPI, this study provided only a correlational assessment 
of model efficacy. Additionally, the proposed model requires numerical integration over 
sampled signals; this process is prone to errors due to noise. The immediate validity of 
this study is limited by the common, nearly fundamental assumption that the cross-
sectional area of the MCA is of a constant, yet unknown, value. If the MCA is indeed 
proven variant(234,235), then these calculations would require reconfiguration in order to 
accommodate for the additional fluctuations in its tone. These calculations would also 
be discounted if the negligible contribution of the venous outflow to ΔCaBV 
calculations is found to be just the opposite; the current models are comprised of time-
integrated differences between current and mean cerebral blood flow velocity that make 
no allowance for venous outflow during raw signal collection. Statistical analysis yields 
such robust agreement among the estimators largely due to their shared parameters 
with slight mathematical modifications. Further, the patient cohorts selected for this 
study made up a fraction of the patients within the Cambridge TBI database; these 
cohorts were specifically chosen because they represent physiological extremes that 
would test the limits of the models. Therefore, it was presumed that if the models 
demonstrated such significant effects in these patients, that they should also for the 
entire database. Finally, of overwhelming significance, is the inability of these TCD-
based parameters to provide direct measurements. Despite the power of TCD as a non-
invasive predictive tool, each derived parameter contingent on the TCD waveform can 
only be interpreted as a surrogate descriptor of cerebral hemodynamics. The true value 
of a TCD-based model (such as PI_C1Ra3) in the determination of pulstile CaBV changes 
can only be investigated via comparison with invasive measures, such as PET(224,236,237) 
or a reference method based on plethysmography (electrical impedance) to attempt to 
validate alternative techniques.  
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5.2.5.   Conclusions 
sPI is considered a theoretical explanation of the effects of extreme pathology on CPPs. 
Our results indicated that the CFF-based model of sPI using ICP as an input signal 
(PI_C1Ra3) performed well within all of the three patient cohorts that were examined; 
however, this cannot be generalized to the entire population receiving neurocritical 
care. Further investigation of CaBV approximation needs to be conducted in a larger, 
more heterogenous sample of TBI patients. 
 
 
 
 
 
 
 
 
 
 
Chapter 6 – Applications of Non-Invasive Neuromonitoring 151 
 
 
Chapter 6 
 
Applications of Non-Invasive Neuromonitoring 
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6.1.  Validation of Non-Invasive Cerebrovascular 
  Pressure Reactivity and Pulse Amplitude  
  Reactivity Indices in Traumatic Brain Injury 
 
6.1.1.  Introduction 
PRx is a common descriptor of cerebrovascular reactivity (CVR) following TBI.  
PRx quantifies the changes in vascular smooth muscle tone that occur as a result of 
variations in transmural pressure(1) and is calculated as the moving linear correlation 
coefficient between MAP and ICP. PRx has become essential to mortality prediction, 
with negative or zero values of PRx indicative of favorable outcome and positive values 
indicative of poor outcome(95). Traditionally relying on the input from invasive, 
continuous ABP and ICP monitors, PRx is considered to be an invasively-quantified 
surrogate marker of cerebral autoregulation (CA) that accounts for changes in 
intracerebral blood volume attributable to either vasodilation or vasoconstriction(239). 
The pulse-amplitude index (PAx) is another index of cerebrovascular reactivity, 
which theoretically can outperform PRx when the compliance of the cranial space is 
increased (i.e. after craniotomy, with CSF leakages, etc.). It correlates the changes in the 
pulse amplitude of ICP (AMP) with changes in mean ABP (as the moving correlation 
coefficient of 30 samples of 10-second averages of AMP and mean ABP). Both PRx and 
PAx can be only calculated when ICP is monitored. Since ICP monitoring usually 
provides a clear signal over a few days or even weeks after TBI, PRx and PAx may be 
used for long-term management of patients (i.e. for example optimal-CPP oriented 
therapy(23,240–242)  
Indices of cerebral autoregulation can be calculated directly with TCD 
monitoring. The mean flow index (Mx) or the systolic flow index (Sx) show stronger 
performance than PRx (the moving correlation coefficients of 30 samples of 10-second 
averages of mean or systolic CBFV and mean CPP)(86,243). However, TCD monitoring is 
intermittent (30 minutes to a few hours daily), whereas ICP monitoring is continuous. 
This is associated with the difficulty to maintain the continuous insonation of cerebral 
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vessels that is essential to the calculation of TCD indices; Sx and Mx are probably more 
accurate than PRx and PAx, but the latter indices can be used continuously.  
Changes in cerebral arterial blood volume can be calculated in two ways. 
Equation 6.1 presumes that pulsatile inflow through the basal arteries is equilibrated by 
non-pulsatile blood outflow through the dural sinuses, creating the continuous flow 
forward model (CFF). Equation 6.2 presumes that the inflow of arterial blood is 
equilibrated by pulsatile flow forward through the regulating arterioles (the pulsatile 
flow forward model, PFF)(216). 
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where: s – the arbitrary time variable of integration, CBFa– cerebral blood flow, ABP–
arterial blood pressure, and CVR – cerebrovascular resistance(216).  
 
 
 There is great clinical interest in the application of non-invasive metrics 
(particularly more accurate surrogate measures of PRx and PAx) during the subacute 
and long-term phases of TBI care, where invasive ICP monitoring is no longer present 
and is thus unable to influence patient management or contribute to traditional PRx 
and/or PAx evaluation. Although the established Mx and Sx are TCD metrics of 
cerebrovascular reactivity, they are in composition not true direct surrogates of PRx and 
PAx, even if there is a moderate correlation between them. The purpose of nPRx and 
nPAx is to provide, as closely as possible, non-invasive measures for PRx and PAx by 
modeling the constituent components of invasively-derived PRx and PAx using non-
invasive TCD-based models of pulsatile CaBV as a direct surrogate for ICP. Doing so 
provides nPRx and nPAx metrics which are more similar in method of derivation and 
physiologic composition than other TCD metrics (i.e. Mx and Sx). 
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 This retrospective study seeks to explore the utility of the nPRx and nPAx indices 
(calculated with both the CFF and the PFF models of CaBV) by correlating them with 
the established cerebrovascular reactivity markers PRx and PAx. As slow waves between 
ICP and CaBV are well-synchronized (due to ICP pulsatility and CaBV modifications 
being triggered simultaneously during the cardiac cycle), it was presumed that the CFF 
and PFF models could evaluate cerebrovascular reactivity in the absence of invasive ICP 
monitoring. A secondary aim of this work is correlate all of the aforementioned indices 
with patient outcome according to the Glasgow Outcome Score (GOS).  
 
6.1.2.  Methods 
Patients 
273 severely head-injured patients (218 males and 55 females with an average age 
of 33 years old [range: 3-77 years]) were admitted to the Neurosciences Critical Care 
Unit (NCCU) at Addenbrooke’s Hospital, Cambridge, United Kingdom between 1992 
and 2012. All patients were managed in accordance with an ICP/CPP-oriented protocol 
designed to maintain ICP below 20 mm Hg. The exact protocol changed several times 
over the monitoring period, but its essential components were stable(88). 
 
Monitoring 
All patients underwent both invasive (ABP and ICP) and daily non-invasive 
monitoring (TCD) while admitted to NCCU. Raw data signals from select monitoring 
devices were recorded and electronically stored using WREC software (Warsaw 
University of Technology) and ICM+TM software (Cambridge Enterprise, Cambridge, 
United Kingdom; http://www.neurosurg.cam.ac.uk/icmplus).   
ABP was continuously monitored both invasively [from the radial artery using a 
pressure monitoring kit (Baxter Healthcare C.A., U.S.A.; Sidcup, U.K.)] and non-
invasively. ICP was monitored using an intraparenchymal probe with strain gauge 
sensors (Codman & Shurtleff, M.A., U.S.A. or Camino Laboratories, C.A., U.S.A.). Blood 
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flow velocities were monitored from the middle cerebral artery (MCA) with a 2 MHz 
probe (Multi Dop X4, DWL Elektronische Systeme, Sipplingen, Germany). Raw TCD 
data recordings within the entire patient cohort (295 individual recordings) with an 
average continuous monitoring duration of 35 minutes. Of the patients receiving 
multiple TCD monitoring sessions, all recordings were utilized where signal quality was 
adequate. TCD measurements were intermittently performed anywhere between the 
first 24 hours of admission and before final removal of intraparenchymal ICP sensors. 
The exact period and availability of TCD monitoring varied on an individual basis. 
This study was conducted as a retrospective analysis of a prospectively 
maintained database cohort, in which high frequency clinical neuromonitoring data had 
been archived. Monitoring of brain modalities was conducted as a part of standard 
NCCU patient care using an anonymized database of physiological monitoring variables 
in neurocritical care. Data on age, injury severity, and clinical status at hospital 
discharge were recorded at the time of monitoring on this database, and no attempt was 
made to re-access clinical records for additional information (REC 97/291). Since all data 
was extracted from the hospital records and fully anonymized, no data on patient 
identifiers were available, and need for formal patient or proxy consent was waived. 
Within our institution, patient data may be collected with waiver of formal consent, as 
long as it remains fully anonymized, with no method of tracing it back to an individual 
patient. Patient physiologic, demographic, and outcome data was collected by the 
clinicians involved with patient care, and subsequently recorded in an anonymous 
format. This anonymous data is then provided for future research purposes.  Such data 
curation remains within compliance for research integrity as outlined in the UK 
Department of Health - Governance Arrangements for Research Ethics Committees 
(GAfREC), guidelines, section 6.0.  
 
Data Processing 
Processing of raw data signals utilized ICM+TM software (Cambridge Enterprise, 
Cambridge, United Kingdom; http://www.neurosurg.cam.ac.uk/icmplus). Signal 
artifact removal was first conducted with signal cropping tools within ICM+TM. CPP was 
determined from the difference between raw ABP and ICP signals.   
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 Primary analysis involved the calculation of time-averaged mean values for ABP, 
ICP, cerebral blood flow velocity (FV), CPP, CaBV_CFF (according to Equation 6.1, 
taking the FV signal instead of CBF), and CaBV_PFF (according to Equation 6.2, taking 
the FV signal instead of CBF). Substituting CBF in Equations 6.1 and 6.2 with blood flow 
velocities has a consequence; estimators of blood volume are presented as blood volume 
per 1 cm2 of cross-sectional area of the vessel. Also, the arbitrary choice of t0 within the 
calculation window of each interval containing 10 to 20 heartbeats, produces the effect 
that only the relative changes of cerebral arterial blood volume can be observed with 
the CaBV(t) signals. The amplitudes of the fundamental frequencies of CaBV_CFF and 
CaBV_PFF pulse waveforms (i.e. for a frequency equivalent to a heart rate) were also 
calculated as AMP_CFF and AMP_PFF, respectively. 
Mean values of the listed parameters were calculated during 10-second time 
windows, and were updated every 10 seconds to emphasize vasogenic slow wave 
fluctuations and to eliminate overlap. A coherence module was calculated between 
series of 10-second averages of ICP, CaBV_CFF, and CaBV_PFF in the frequency band 
ranging from 0.005Hz to 0.05 Hz. The same calculations were applied to time series of 
AMP, AMP_CFF, and AMP_PFF.  
 Final data processing involved the calculations from the primary analysis, with 
the addition of PRx (the correlation between ABP and ICP), nPRx_CFF (the correlation 
between CaBV_CFF and ABP), and nPRx_PFF (the correlation between CaBV_PFF and 
ABP). Non-invasive PAx was calculated by correlating ABP with either AMP_CFF or 
AMP_PFF (nPAx_CFF and nPAx_PFF, respectively). Each of these parameters was 
calculated utilizing a 300-second time window, updated every 10 seconds. 
 Post-processing, all 10-second by 10-second data were exported from each patient 
to separate comma-separated variable (CSV) files for further statistical analysis. 
 
Statistics 
 All statistical analyses were conducted utilizing R software (R Core Team [2017]; 
R: a language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria, URL https://www.R-project.org/). Grand means of and 
descriptive statistics for each parameter were calculated. Data were normally-
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distributed. Descriptive analyses were applied to the coherences between ICP slow 
waves and CaBV and between the AMP and AMP_CaBV series. 
Linear regression techniques were employed to describe the following 
relationships in the entire cohort: PRx vs. nPRx_CFF, PRx vs. nPRx_PFF, PAx vs 
mPAx_CFF, and PAx vs. nPAx_PFF. Goodness of fit was reported utilizing the Pearson 
correlation coefficient (R). Agreement between the parameters was assessed with the 
Bland Altman method. 
Each of the above indices were also correlated with dichotomized GOS data 
(favorable versus unfavorable outcome). Favorable outcome was classified by GOS 
scores of 4 (moderate disability) and 5 (mild to no disability). Unfavorable outcome was 
classified by GOS scores of 1 (dead) or 2 (vegetative state), or 3 (severe disability). The 
strength of the relationship between each index and outcome was reported via area 
under the receiver operating curve (AUC), with bold AUCs reaching p<0.05 (statistical 
significance identified by the Delong test;. p-values between groups were compared 
with t- and Mann-U tests. 
 
6.1.3.  Results 
Table 6.1 summarizes descriptive statistics for the entire cohort of TBI patients. Slow 
waves of ICP and CaBV in most cases appeared well-synchronized in time (Figure 6.1A, 
top panel). The same observation can be made for time series of AMP, AMP_CFF, and 
AMP_PFF (Figure 6.1B, bottom panel). The averages of the modules of coherence 
functions in low frequency limits (0.005Hz to 0.05 Hz) are presented in Table 6.2.  
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Table 6.1. Mean Cerebral Hemodynamic Parameters in TBI. ABP – arterial blood 
pressure, CaBV_CFF – cerebral arterial blood volume calculated with the continuous flow 
forward method, CaBV_PFF – cerebral arterial blood volume calculated with the pulsatile 
flow forward method, cm/s – centimeters per second, CPP – cerebral perfusion pressure, 
Favorable: Unfavorable Outcome – Glasgow Outcome Score [Favorable: GOS 4-5 
(moderate-mild, or no disability); Unfavorable: GOS 1-3 (dead, vegetative state, or severe 
disability)], FV – cerebral blood flow velocity, Admission GCS – Glasgow Coma Score on 
admission, mm Hg – millimeters of mercury, IQR – interquartile range, nPAx_CFF – non-
invasive PAx calculated with the continuous flow forward method, nPAx_PFF – non-
invasive PAx calculated with the pulsatile flow forward method, nPRx_CFF – non-invasive 
PRx calculated with the continuous flow forward method, nPRx_PFF – non-invasive PRx 
calculated with the pulsatile flow forward method, PAx – pulse amplitude index, and PRx 
– pressure reactivity index. 
 
Parameter Mean Range Standard Deviation 
Age [Years] 33.14 3.0-77.0 ± 15.96 
Favorable: Unfavorable 
Outcome 
 
132:122 
 
1-5 
 
--- 
Admission GCS (Median) 6.0 1-15 IQR 4 
ABP [mm Hg] 91.36 58.61-147.57 ± 12.08 
ICP [mm Hg] 18.12 -3.27-75.69 ± 9.92 
CPP [mm Hg] 73.61 20.63-109.55 ± 13.20 
FV [cm/s] 63.41 19.67-168.79 ± 25.64 
PRx 0.02 -0.65-0.96 ± 0.27 
PAx -0.10 -0.93-0.76 ± 0.20 
nPRx_CFF 0.16 -0.41-0.80 ± 0.20 
nPRx_PFF -0.21 -0.69-0.45 ± 0.19 
nPAx_CFF -0.07 -0.45-0.56 ± 0.14 
nPAx_PFF -0.06 -0.44-0.62 ± 0.13 
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Figure 6.1. ICP Waveforms and CaBV Modeling. Examples of good synchronization 
of mean ICP and CaBV time series in a frequency range of slow waves (Figure 6.1A). 
Figure 6.1B demonstrates good synchronization of AMP time series with AMP_CFF and 
AMP_PFF. 
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Table 6.2. Coherences between variables within the frequency range 0.005-0.05 Hz.  
 
Variables Module of Coherence 
<0.005-0.05 Hz> 
95% Confidence 
Intervals 
ICP vs. CaBVCFF 0.765 0.748-0.782 
ICP vs. CaBVPFF 0.758 0.741-0.776 
AMP vs. AMP_CFF 0.73 0.718-0.747 
AMP vs. AMP_PFF 0.678 0.665-0.692 
 
The correlations between PRx and nPRx and those between PAx and nPAx are 
only moderately strong (although the R-value is significantly non-zero at p<0.0001). 
Scatterplots and correlation coefficients for each model (calculated with either the CFF 
or PFF methods) are shown in Figure 6.2. Table 6.3 includes the results of Bland-Altman 
analysis for invasive and non-invasive reactivity indices. The majority of data points 
were clustered around the mean for each of the modeled pairs with few outliers. It must 
be noted that the outliers derived from the results shown in Fig. 6.2 are due to the 
varying blood pressures exhibited by patients in the TBI database. 
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Figure 6.2. Scatterplots of PRx vs. nPRx and PAx vs. nPAx calculated by the 
different CaBV models. Pearson correlation coefficients are given. The correlation 
between PAx and nPAx_CFF is significantly the strongest (p<0.003). Correlations 
between traditional parameters and derived parameters based on CFF models are 
stronger than those based on PFF models (p<0.01 for nPAx and p<0.076 for nPRx). 
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Table 6.3. Bland Altman Agreement Between PRx-nPRx and PAx-nPAx. 
 
 
 
Critical 
Difference 
 
Lower Limit 
 
Mean 
Difference 
 
Upper 
Limit 
     
PRx vs. 
nPRx_CFF 
0.51 -0.65 -0.13 0.38 
PRx vs. 
nPRx_PFF 
0.52 -0.28 0.24 0.76 
PAx vs. 
nPAx_CFF 
0.33 -0.36 -0.03 0.30 
PAx vs. 
nPAx_PFF 
0.40 -0.44 -0.03 0.37 
 
Finally, all reactivity indices (invasive and non-invasive) were compared in two 
outcome groups: favorable outcome (n=132) and unfavorable outcome (n=122). 19 
patients were not available for follow up. The strongest separation was detected for the 
nPAx_CFF index (Table 6.4). nPAx_CFF performed the best when compared to 
outcome, but was not significantly different from the other indices when evaluated with 
the Delong test.  
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Table 6.4. Differences between reactivity indices in patients with favorable and 
unfavorable outcomes at 6 months after TBI. The strength of the relationship between 
each index and outcome was additionally reported via area under the receiver operating 
curve (AUC), with bold AUCs reaching p<0.05. 
 
 
 
◊Statistical significance was determined via both t- and Mann-Whitney U-tests with an 
alpha of 0.05 assigned to entries with p-values below this threshold. 
Pressure 
Reactivity 
Index 
FAVORABLE 
Mean and 
95% CI 
UNFAVORABLE 
Mean and 95% 
CI 
p-value◊ 
t-test 
 
p-value◊ 
Mann-U 
 
AUC 
95% CI 
PRx -0.014 
[-0.046;0.018] 
0.189 
[0.165;0.21] 
0.022 0.078 0.564 
[0.493-0.635] 
nPRx_CFF 0.137 
[0.113;0.161] 
0.189 
[0.165;0.21] 
0.037 0.021 0.584 
[0.514-0.654] 
 
nPRx_PFF -0.242 
[-0.26;-0.22] 
-0.018 
[-0.21;-0.16] 
0.013 0.015 0.601 
[0.531-0.671] 
 
PAx -0.134 
[-0.159;-0.11] 
-0.055 
[-0.08;-0.028] 
0.018 0.002 0.615 
[0.546-0.684] 
 
nPAx_CFF -0.10 
[-0.12;-0.085] 
-0.037 
[-0.055;-0.019] 
0.0003 0.0003 0.632 
[0.564-0.701] 
 
nPAx_PFF -0.076 
[-0.09;-0.059] 
-0.052 
[-0.069;-0.035] 
0.164 0.093 0.561 
[0.490-0.632] 
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6.1.4.  Discussion 
In the evaluated population of TBI patients, nPRx and nPAx calculated with the CFF 
model were found to better approximate PRx and PAx. It is likely that the PFF model in 
general is more susceptible to variations in its key components (i.e. unstable ABP in 
patients would affect the numerators in Equation 6.2) that impact its stability as a 
calculation method; this effect is consistent with the findings of Eide et al.(244), which 
discovered weak correlations between ABP and ICP pulse pressure amplitudes and 
autoregulation indices such as PRx. On the basis of their results(244), as the PFF model is 
comprised of input from the ABP signal, it is fitting that the nature of the nPRx_PFF 
index is incompatible with PRx and PAx, which are all “noisy” surrogate markers of 
cerebral autoregulation to begin with. The CFF and PFF models partially account for 
total cerebral blood volume change, as they are calculated as the difference between 
systolic and mean cerebral blood flow integrated over a given period of time. Cerebral 
blood flow velocity as assessed by TCD is a surrogate measure of cerebral blood flow, as 
the TCD monitoring technique does not directly quantify cerebral circulation. Thus, 
current applications of these models can only approximate cerebral blood volume 
change. 
PRx ultimately responds to alterations in cerebral blood volume, and responds 
to both ICP and ABP fluctuations as vessel diameter changes There is the additional 
possibility that PRx may be inaccurately represented in TBI patients with either low or 
high levels of ICP, as the index does not describe cerebrospinal fluid compliance, which 
influences the direction of cerebral blood volume change, and thus measured ICP(240). 
As the nPRx and nPAx indices do not rely on information from invasive ICP sensors but 
rather ABP, they only moderately correlated with traditional PRx and PAx, which are 
both more commonly associated with ICP. It is important to note that the 
determination of nPRx and nPAx with the current TCD-based CFF and PFF models 
cannot definitively describe the relationships between the “true” input from cerebral 
blood flow and either the ABP or the ICP signals. 
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These non-invasive TCD models of PRx and PAx based on CaBV estimates 
provide information closer to invasively-derived ICP. Further refinement of the 
nPRx_CFF model in particular will enhance the ability to non-invasively approximate 
traditional PRx, which has been experimentally-validated as a measure of the lower limit 
of autoregulation(245). nPRx can be employed for long-term follow-up using continuous, 
non-invasive ABP (via finger-cuff). Cerebrovascular reactivity during the subacute 
phase of care can be correlated with long-term autoregulatory status, inclusive of 
clinical phenotype and chronic neuroimaging changes (i.e. magnetic resonance imaging 
(MRI)-based cortical atrophy or diffusion tensor imaging (DTI) white matter tract 
volume). nPRx can inform clinicians of patient autoregulatory status in the absence of 
neurosurgical placement of invasive monitors; it can be directly calculated from 
emergency rooms or in remote hospitals without neurosurgical services. Non-invasive 
determinations of optimal cerebral perfusion pressure (nCPPOPT) can also benefit from 
nPRx, as PRx is a key component in the visualization of CPP(242).  
When comparing both traditional and derived autoregulation indices with 
outcome, nPAx_CFF trended towards higher AUCs in association with dichotomized 6-
month outcomes. It must be acknowledged that TCD-based indices such as Mx and Sx, 
and both sets of nPRx and nPAx estimators can only be calculated if patients receive 
TCD monitoring, which is intermittently applied at best; at present, it is difficult to 
provide continuous measures of nPRx or nPAx in the absence of invasive monitoring. 
Traditional TCD devices such as the DWL Multi Dop X4 require careful placement of 
TCD probes that are both fragile and very easily disturbed by small movements. 
Although emerging TCD technology with robotic-assisted probes allows for longer, 
uninterrupted TCD monitoring, these newer devices are ultimately less popular and too 
expensive for the majority of centers to obtain for purely research purposes.  
 
Limitations 
The strength of this study is fundamentally limited by the reliance on 
intermittent TCD recordings that were relatively short in duration, and susceptible to 
motion artifacts. Additionally, statistical analyses were based on grand mean data, 
which reduces the natural variability within datasets and can potentially create artificial 
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effects. The correlation coefficient values are in a weak to moderate range for strength.  
As such, the definitiveness of conclusions from this current study are limited, and 
should not be extrapolated to other TBI populations at this time. It is also worth noting 
that Mx and Sx have been previously validated as having stronger outcome-predictive 
power than PRx(244), which was not addressed in this study. The rationale for nPRx and 
nPAx is somewhat artificial at the moment; these indices may become more clinically 
relevant when the next generation of continuous TCD monitoring devices becomes 
available. There are differences between TCD-based autoregulation and pressure 
reactivity(47); with better technology, it may be useful to explore them jointly. 
 
6.1.5.  Conclusions 
With TCD, it is possible to derive non-invasive estimators of PRx (nPRx) and PAx 
(nPAx) based on cerebral blood volume modeling (nPRx_CFF, nPRx_PFF, nPAx_CFF, 
and nPAx_PFF). Direct clinical application of these non-invasive cerebrovascular 
reactivity indices is limited by the current state of continuous TCD monitoring, but 
following further improvements on the autofocusing of TCD probes and waveform 
visualization, they may become clinically useful. 
 
 
6.2.  Feasibility of Non-Invasive Brain Multi- 
  Modal Neuromonitoring in Intensive Care 
  Patients 
 
6.2.1.  Introduction 
Secondary neurological complications may occur in patients admitted to general 
intensive care for a variety of conditions, such as cardiac arrest, metabolic 
encephalopathies, sepsis, and multi-organ failure(246–249). Coma is associated with 
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increased risk of life-threatening events (status epilepticus, stroke, intracranial 
hemorrhage, etc.). Often, clinicians can no longer obtain critical neurological 
information before brain injury may be already beyond treatment. Implanted probes 
that continuously monitor cerebral dynamic functions (i.e. intracranial pressure, brain 
tissue oxygenation, cerebral metabolism, etc.) have become well-established modalities 
used during neurocritical treatment protocols; however, they are seldom used outside 
of neurocritical care. Continuous neuromonitoring is not routinely in place for these 
patients, and as a result, comatose patients under intensive care do not receive 
neuromonitoring outside of intermittent clinical assessments, which roughly 
approximate neurological status at the time of intervention and are commonly 
influenced by sedative drugs. Neurophysiological tests such as electroencephalography 
(EEG), somatosensory evoked potentials (SSEP) and brain stem auditory evoked 
potentials are at best available intermittently; likewise, the information provided by 
other imaging techniques such as magnetic resonance imaging (MRI) or computed 
tomography (CT), which require transfer out of the intensive care unit.   
TCD is commonly utilized in neurocritical care for brain multi-modal 
monitoring; it examines the cerebral blood flow velocity (CBFV) of basal cerebral 
arteries via ultrasound probe(s) placed on the temporal window(32). TCD is a reliable 
method of assessing cerebral blood circulation by the bedside with minimal disruption 
to nursing interventions. The TCD-based CBFV signal, in particular, can be further 
derived to provide non-invasive assessment of cerebral blood flow autoregulation, 
estimates of intracranial pressure(250) and cerebral perfusion pressure, which are 
essential to outcome prediction. Previously, TCD has been applied outside of the 
neurocritical care environment to evaluate patient risk of secondary neurological 
complications(251) in non-neurosurgical settings. The combination of TCD and non-
invasive ABP monitoring has been utilized in orthopedic(252) surgery to assess position-
based changes that could adversely affect cardiac output, or transplant procedures(253) 
to identify instances of intracranial hypertension and/or post-operative neurological 
damage.  
This study aimed to assess the feasibility and preemptive clinical benefits of a 
TCD-based non-invasive multi-modal approach for neuromonitoring in critically-ill 
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patients. Additionally, it attempted to describe the outcome-predictive power of TCD-
related indices in a population of general intensive care patients. 
 
6.2.2.  Methods 
Patient Recruitment and Ethics 
 Intensive care staff at the Neurosciences Critical Care Unit (NCCU) and the John 
Farman Intensive Care Unit (JFICU) at Addenbrooke’s Hospital, Cambridge, U.K., 
identified eligible patients and referred them to the research team at the University of 
Cambridge Brain Physics Laboratory for inclusion in this study conducted between 
March 2017 and March 2019. The experimental protocol and informed consent were 
approved by the institutional review board at Addenbrooke’s Hospital, Cambridge 
University Hospitals Foundation Trust (Cerebral Autonomic Regulation in Multi-Modal 
Monitoring After Cardiac Arrest – A TTM2 Sub-Trial (TTM2-CAR), shortened to “Triple 
M”, IRAS: 165207). Patients who failed to awaken appropriately after resuscitation from 
cardiac arrest, or were in coma due to a number of medical conditions including 
meningitis, seizures, sepsis, metabolic encephalopathies, overdose, multi-organ failure, 
or transplant were eligible for inclusion. Patients were considered eligible for the study 
if they were at least 18 years of age and comatose following resuscitation from cardiac 
arrest or any of the above listed conditions. As patients were unable to provide informed 
consent themselves at the point of inclusion, they were included either by a process of 
deferred assent by next of kin or of inclusion by professional assent through treating 
physicians, who were not involved in the trial. Exclusion criteria comprised of patients 
under the age of 18, a pre-existing lack of mental capacity to consent, express wish to 
not participate in research, or inability to undergo transcutaneous TCD monitoring 
safely such as skin infections or known allergies. 
  
Clinical Data  
Data was gathered on admission diagnosis, duration of ventilation, length of stay 
in the ICU, length of stay in the hospital, and discharge status using Cerebral 
Performance Categories (CPC). A detailed neurological status was obtained on the day 
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of monitoring.  All patients had CT and EEG; individual cases were investigated with 
MRI, continuous EEG, and SSEP as indicated clinically.  
 
Data Collection 
ABP was continuously monitored invasively from the radial artery using a 
pressure monitoring kit [Baxter Healthcare C.A., U.S.A.; Sidcup, U.K.]). Mean and peak 
blood flow velocities were non-invasively monitored from the middle cerebral artery 
(MCA) with a unilateral 2 MHz TCD probe (Rimed Digi-LiteTM, Rimed Ltd., Israel). The 
probe was held in place during the entire recording session using a head frame provided 
by the TCD device manufacturer. The signals were all sampled at 300 Hz, digitally 
transferred from the patient monitor (Carescape B850, GE, U.S.A.) or digitized using an 
analogue to digital converter (DT9801, Data Translation, Marlboro, M.A., U.S.A.), and 
were recorded using a laptop computer with ICM+TM software (Cambridge Enterprise 
Ltd., Cambridge, U.K., http://www.icmplus.neurosurg.cam.ac.uk/).  
The above monitoring procedures are in compliance with standardized patient 
care management using an anonymized database of physiological variables (UK Health 
Departments Governance Arrangements for Research Ethics Committees (GAfREC)). 
Demographic data such as age, diagnosis and brain dysfunction on admission, and 
clinical status as hospital discharge were documented at the time of monitoring; clinical 
records were not further consulted for additional information for this part of the study, 
as all extracted data were fully anonymized.  
 
Data Processing and Analysis  
Signal artifacts were manually removed by internal signal cropping tools within 
ICM+TM. In the primary analysis phase, time-averaged mean values of both FV and ABP 
were calculated over 10-second time windows, and updated every 10 seconds to 
eliminate overlap. Heart rate (HR, Hz) was calculated as the fundamental amplitude of 
the ABP signal, and both F1 and A1, the fundamental frequencies of FV and ABP, 
respectively, were each calculated over 20-second time windows and updated every 10 
seconds. Baroreflex sensitivity (BRS, ms/mm Hg) was calculated using the ABP 
waveform according to the algorithm described by Nasr et al.(254). Heart rate variability 
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in both the low and high frequency ranges (HRV_LFHF, Hz) was calculated over 300-
second time windows and updated every 10 seconds, using specialized ICM+TM 
functions (255).  
Non-invasive ICP (nICP, mm Hg) was estimated using the method developed by 
Schmidt et al.(256), which describes nICP using a “black box” model with the FV and ABP 
waveforms as input variables that return the nICP waveform as output. Diastolic ABP 
(ABPd, mm Hg) and FV (FVd, cm/s) were each determined as the minimum values of 
their respective signals, and calculated over 2-second time windows with a 2-second 
update. Systolic FV (FVs, cm/s) was determined as the maximum value of the FV signal, 
and similarly calculated and updated over 2-second time windows. The autoregulation 
of cerebral blood flow was estimated by the Mx_a index as a running correlation 
coefficient between 30 consecutive 10-second time averages of the FV and ABP signals. 
Clinical evaluation of Mx_a has specified a critical threshold for dichotomized outcome 
at 0.62 (based on the area under the curve (257)). 
Critical closing pressure (CrCP, mm Hg) was calculated using mean values and 
spectral heart rate fundamental components of the ABP and FV signals (Equation 6.3): 
 
CrCP (mm Hg) = 𝑀𝑒𝑎𝑛 (𝐴𝐵𝑃) −
𝑀𝑒𝑎𝑛(𝐴1)
𝑀𝑒𝑎𝑛(𝐹1)
∗ 𝑀𝑒𝑎𝑛(𝐹𝑉) 
 
                     [6.3] 
 
The diastolic closing margin was calculated as the difference between diastolic 
ABP and CrCP (Equation 6.4, below). 
 
DCM (mm Hg) = 𝑀𝑒𝑎𝑛(𝐴𝐵𝑃𝑑) − 𝑀𝑒𝑎𝑛(𝐶𝑟𝐶𝑃) 
                   [6.4] 
            
 Non-invasive cerebral perfusion pressure (nCPP) was assessed using ABP and FV 
signals using a formula adopted from studies of TBI patients (Equation 6.5, below)(258): 
             
nCPP (mm Hg) = (
(𝑀𝑒𝑎𝑛 𝐴𝐵𝑃 𝑥 𝑀𝑒𝑎𝑛 𝐹𝑉𝑑)
𝑀𝑒𝑎𝑛 𝐹𝑉
)  + 14 
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                 [6.5] 
 
The cerebrovascular time constant was calculated as the product of cerebrovascular 
resistance (Ra= Mean (ABP)/Mean (FV)) and compliance, Ca (Equation 6.6, below):
     
 
𝐶𝑎 =  
(
𝐹1 − 𝐴1
𝑀𝑒𝑎𝑛 𝑅𝑎)
2𝜋 × 𝐻𝑅
 
           [6.6] 
 
Finally, two indices describing the shape of the TCD pulse waveform were calculated: 
Gosling pulsatility index, gPI (gPI = (FVs-FVd)/FVmean), and the waveform index, 
Waveform, which indicates how much the TCD waveform differs from the “ideal” 
triangular shape (Waveform = FVmean- ((2(FVd+FVs))/3). gPI has previously been 
posited as a non-invasive estimator of both ICP and CPP, with gPI thresholds for ICP 
based on the area under the curve varying from 0.62 (ICP >15 mm Hg) to 0.74 (ICP >35 
mm Hg) for ICP, and 0.68 (CPP <70 mm Hg) to 0.81 (CPP <50 mm Hg) for CPP(259). A 
summary of calculated secondary indices is given in Table 6.5.  
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Table 6.5.  Summary of Calculated Secondary Parameters. 
 
Parameter Description Interpretation 
BRS (ms/mm Hg) Baroreflex Sensitivity  Index demonstrating how strong changes 
in baroreflex can regulate systolic blood 
pressure; normal value: >10. 
HRV_LF/HF (Hz) Heart Rate Variability (Low Frequency to 
High Frequency Ratio) 
Index describing the ratio of sympathetic-
derived heart rate variability (low 
frequency) to parasympathetic variability 
(high frequency); normal value: >2. 
TAU (s) Cerebrovascular Time Constant Hypothetically, how fast arterial blood 
covers the distance between the 
conducting to regulating brain arteries, 
normal value: 0.1 seconds. 
Mx_a Cerebral Autoregulation Index describing the passivity of changes 
in FV when mean ABP changes. Disturbed 
autoregulation shows Mx_a >0.3. 
CrCP (mm Hg) Critical Closing Pressure  Index describing the minimal blood 
pressure value which keeps cerebral 
arteries open. 
DCM (mm Hg) Diastolic Closing Margin Index describing the distance between 
diastolic ABP and CrCP. When DCM 
reaches 0, there is no diastolic blood flow 
observed with TCD. 
gPI Gosling Pulsatility Index Index which shows the proportion of 
pulsatile to total blood transport. It is an 
inverse function of cerebral perfusion 
pressure, PaCO2, and blood pressure 
pulsatility (A1), normal value: 1.  
Waveform Waveform Shows how much the shape of the TCD 
pulse waveform differs from the ideal 
triangular pattern.  
nICP Non-Invasive Intracranial Pressure This is an estimator only, real term 
accuracy ±10 mm Hg.  
nCPP Non-Invasive Cerebral Perfusion Pressure This is an estimator (but independent of 
nICP, above), accuracy ±15 mm Hg. 
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Statistical Analysis 
 
All statistical analyses were conducted using Statgraphics Version 5 
(Manugistics, Irvine, C.A., U.S.A,) and R data analysis software ((R Core Team [2017]; R: 
a language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. URL https://www.R-project.org/).  Post-processing data, 
exported as CSV files, were compiled into one large CSV document containing all of the 
above recorded signals for each patient. Summary statistics for each parameter were 
calculated across the entire patient cohort (Table 6.6). Patient data was further 
dichotomized into subsets according to available outcome data (Table 6.7). Statistical 
significance for invasively-monitored variables (ABP) and non-invasively derived 
variables (based on TCD) was determined both within and between each subset of 
patients via the Mann-Whitney U-test with an alpha of 0.05 and assigned to entries with 
p-values below this value.  
 
6.2.3. Results 
40 patients (27 males: 13 females; age range: 20-69 years with an average age of 53.79 ± 
13.11 years) were identified and enrolled in the study. Data from 37 of these 40 patients 
were included in our analysis, as 3 patient datasets were later excluded due to poor TCD 
signal acquisition or the absence of invasive ABP monitoring. Patients were admitted 
for the following conditions: cardiac arrest (14), complications relating to sepsis (6), 
meningitis (5), organ transplant (5), drug/alcohol overdose (3), encephalopathy (2), 
sickle cell crisis (1), pancreatitis (1), colitis (1), pneumonia (1), and refractory status 
epilepticus (1). It is important to note that findings were not discriminated across the 
different disease categories. The data recording sessions within the entire patient cohort 
(68 individual recordings) lasted between 19.5 and 171.75 minutes, with an average 
continuous monitoring duration of 43.68 ± 16.14 minutes.  Figure 6.3 (below) illustrates 
a typical example of the monitored signals and calculated parameters. 
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Figure 6.3. An example of a TCD monitoring session for a 3M patient, with both 
standard and derived parameters. 
 
FV – TCD-based flow velocity, ABP – arterial blood pressure (measured invasively), HR – 
heart rate, DCM – diastolic closing margin, Mx_a – cerebral autoregulation, HRV_LFHF 
– heart rate variability (low frequency to high frequency ratio), TAUs – cerebrovascular 
time constant, BRS – baroreflex sensitivity, cm/s – centimeters per second, mm Hg – 
millimeters of mercury, Hz – Hertz, s – seconds, a.u. – arbitrary units, and ms/mm Hg – 
milliseconds per millimeter of mercury. 
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Table 6.6 summarizes the mean values and standard deviations, minimum, maximum, 
and median values of each parameter across the entire patient cohort.  Table 6.7 reports 
the effects of the measured parameters on patient outcome. Significance levels are 
highlighted in bold typeface. The results of the presented analyses indicated that 
irrespective of condition, this population of general intensive care patients had 
significantly disturbed cerebral autoregulation when comparing survivors to non-
survivors (TAUs: p=0.03; Mx_a: p<0.01; and Waveform: p=0.03). Apart from these three 
parameters that demonstrated a robust relationship with outcome, none of the other 
metrics reached statistical significance. We further evaluated the differences between 
those patients who survived according to “good” (CPC 1-2) or “bad” (CPC 3-4) outcome 
to identify whether there were significant changes in cerebral hemodynamics that 
predicated poorer recovery. This additional comparison did not present any 
relationships reaching statistical significance. 
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Table 6.6. Grand Mean Values of Cerebral Hemodynamic Parameters Across All 
Patients. Calculated parameters are explained in Table 6.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Mean 
Standard 
Deviation Minimum Maximum Median 
FV (cm/s) 48.40 22.23 16.26 107.90 38.88 
ABP (mm Hg) 84.23 15.48 57.25 118.1 78.00 
HR (Hz) 1.44 0.31 0.79 2.34 1.41 
BRS (ms/mm Hg) 11.06 9.56 1.11 53.5 9.97 
TAUs (s) 0.06 0.03 0.002 0.14 0.06 
HRV_LFHF (Hz) 1.24 1.10 0.18 5.60 0.91 
Mx_a 0.23 0.25 -0.34 0.71 0.22 
Waveform 1.49 2.73 -3.45 8.64 1.34 
CrCP (mm Hg) 28.37 14.98 -16.90 64.24 27.77 
DCM (mm Hg) 32.43 15.03 9.99 72.06 30.88 
gPI 1.36 0.40 0.68 2.36 1.30 
nICP (mm Hg) 15.74 5.38 5.14 28.78 14.58 
nCPP (mm Hg) 57.65 13.75 34.31 87.34 56.25 
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Table 6.7. Dichotomized Outcomes of Patients. Calculated parameters are explained 
in Table 6.5. 
 
 
 
Parameter 
 
 
Good Outcome 
(CPC 1-2) 
 
 
Bad Outcome 
(CPC 3-5) 
 
p-value◊ 
 
 
Male:Female Ratio 14:7 12:4 ---- 
Age (Years) 57.50 (±12.20) 49.33 (±12.77) 0.06 
Days Ventilated 19.86 (±24.22) 19.81 (±23.35) 0.99 
FV (cm/s) 49.28 (±23.13) 47.31 (±21.00) 0.79 
ABP (mm Hg) 84.44 (±15.86) 83.96 (±14.98) 0.93 
HR (Hz) 1.34 (±0.33) 1.55 (±0.23) 0.46 
TAUs (s) 0.07 (±0.03) 0.04 (±0.03) 0.03 
Mx_a 0.15 (±0.27) 0.37 (±0.17) <0.01 
Waveform 0.96 (±2.31) 2.99 (±2.91) 0.03 
BRS (ms/mm Hg) 12.93 (±12.16) 9.19 (±5.30) 0.26 
HRV_LFHF (Hz) 1.32 (±1.27) 1.16 (±0.85) 0.67 
CrCP (mm Hg) 29.41 (±12.43) 27.05 (±17.57) 0.64 
DCM (mm Hg) 30.86 (±12.43) 34.38 (±17.55) 0.48 
gPI 1.39 (±0.37) 1.33 (±0.42) 0.65 
nICP (mm Hg) 15.69 (±5.15) 15.81 (±5.65) 0.95 
nCPP (mm Hg) 57.39 (±13.55) 57.97 (±13.99) 0.90 
 
 
◊Statistical significance was determined via Mann-Whitney U-tests with an alpha of 0.05 
assigned to entries with p-values below this threshold. 
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6.2.4.  Discussion 
The overall context of this study is to elucidate the feasibility of a multi-modal TCD 
approach for cerebrovascular assessment in critically-ill, comatose patients. The main 
findings from these preliminary results from the “Triple-M” trial underscore the 
importance of utilizing a multi-modal approach to neuromonitoring. Multi-modal 
monitoring approaches aim to provide a highly-accurate gauge of secondary 
neurological complications by balancing the shortcomings of individual techniques (i.e. 
poor probe placement, motion artifacts, intermittent monitoring sessions)(260). In a 2011 
clinical report of advances in neuromonitoring, a focus on the interpretation of 
combined information from invasive (ICP, ABP, CPP, brain tissue oxygenation, and 
brain temperature) and non-invasive probes (i.e. TCD to monitor cerebral blood flow) 
was suggested to have great potential in both the improvement of bedside interventions 
and of outcome(260). With the introduction of TCD and the derived indices from the 
TCD base signal FV to general intensive care, clinicians can gain a more holistic(22,261) 
understanding of cerebral hemodynamic abnormalities that occur as a result of 
relatively common conditions such as cardiac arrest, metabolic encephalopathies, 
sepsis, organ failure, etc. To current knowledge, this study is the first of its kind to 
extend a multi-modal monitoring approach inclusive of TCD to a mixed population of 
general intensive care patients in addition to routine EEG(262), and suggests that TCD is 
able to identify deficient autoregulatory mechanisms(263) in most, if not all, critically-ill 
patients. 
 In particular, the highly significant effect of the TCD-based index Mx_a (the 
correlation coefficient between FV and ABP) on patient outcome prediction in this 
selected population correlates well with similar studies of Mx_a(21,36,264) in patients 
suffering from traumatic brain injuries, which defined this index as a robust descriptor 
of outcome. Mx_a has been cited as an appropriate substitute for quantifying cerebral 
autoregulation in the absence of invasive ICP, and has been validated against Mx (the 
index describing the passivity of changes in mean FV when CPP changes) in outcome-
predictive power(265). Sorrentino et al.(21)  identified lower and upper boundaries for 
Mx_a, with a threshold of 0.05 signifying a likelihood for survival and good outcome, 
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and a threshold of 0.30 signifying a strong association with unfavorable outcome and/or 
mortality. The observations of differences in Mx_a between our general intensive care 
patients with CPC 1-2 (0.15) versus those with CPC 3-5 (0.37) are in keeping with these 
critical thresholds for outcome. 
 Additionally, although not determined to be significant in the analyses, TCD-
derived non-invasive estimators of ICP such as nICP or ICP_FVd have been found to 
closely approximate traditional invasive ICP monitoring in patients with hypoxic 
ischemic brain injuries following resuscitation from cardiac arrest(250). Further, more 
simplistic descriptors of cerebrovascular resistance such as FVd and gPI have been 
demonstrated to dichotomize good and bad outcome in patients after cardiac arrest 
(>1/3 of this cohort), although these parameters did not reach significance(266). 
Autoregulation monitoring indices have been utilized to inform personalized 
treatment following both TBI and cardiac arrest. Non-invasive, multi-modal TCD 
approaches to autoregulation monitoring integrate the information provided by 
invasive measurements (i.e. ABP or ICP) with cerebral hemodynamic activity. For 
instance, the non-invasive identification of potential instances of intracranial 
hypertension is advantageous for all patients with neurological complications; in 
contrast to patients with traumatic brain injuries, general intensive care monitoring 
standards do not routinely incorporate ICP into management protocols. Multi-modal 
monitoring lends itself to the potential for individualized patient management; a variety 
of parameters can be evaluated simultaneously in real time and revisited when 
necessary to redirect and optimize targeted treatment, such as ICP, ABP, or  Mx_a. Non-
invasive ICP monitoring with TCD poses no risk to patients, and the machines can easily 
be connected to bedside monitors to provide clinicians with more insight into the 
dynamic effects of various diseases on the brain that would otherwise be unavailable.  
 
Limitations 
 
 It must be acknowledged that the strength of the results, and therefore 
statistical power, is fundamentally limited by the small sample size of the “Triple-M” 
trial. With a larger cohort, perhaps more parameters would have reached statistical 
significance, and further supported the rationale for multi-modal neuromonitoring in 
general intensive care. However, TCD is primarily viewed as a research tool at the 
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moment, and is treated as an accessory to standard interventions; thus, recordings are 
intermittent in nature, and must be coordinated by dedicated operators at the 
discretion of clinical staff. It is also important to acknowledge that multi-modal 
monitoring data may not be able to be evaluated in time to provide immediate benefits 
to patients(260). However, new state-of-the-art robotic TCD devices are being tested in 
neurocritical care settings to overcome measurement inaccuracies; these advances in 
TCD technology have demonstrated stronger FV signal intensity, which enhances the 
descriptive power of TCD-derived indices such as Mx_a or nICP(267). This initial foray 
into more continuous TCD monitoring can improve the reliability of multi-modal TCD 
parameters in providing personalized treatment targets. 
This paper presented preliminary results only, with exclusive focus on TCD-
based indices and their relationships with patient outcome. In future communications 
of this work, it would be useful to correlate TCD and routine EEG findings to compare 
the two monitoring modalities with respect to outcome. Additionally, patients were not 
separated by condition, it was impossible to observe any cerebral hemodynamic trends 
in particular disease states that could, with further study, become viewed as outcome-
predictive traits.  
 
6.2.5.   Conclusions 
Preliminary results from the “Triple-M” trial indicate that multi-modal 
neuromonitoring increases outcome-predictive power. In particular, TCD-based indices 
such as Mx_a can be applied to general intensive care monitoring to describe patient 
outcome as a dynamic function of cerebral autoregulation
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Chapter 7 
 
Conclusions and Research Outlook 
 
7.1.  Thesis Outcomes in Context 
 
Detailed knowledge and understanding of brain physiology and underlying cerebral 
hemodynamics are essential to the ongoing management of acute brain injury. 
Neuromonitoring techniques such as ICP and TCD monitoring provide clinicians with 
opportunities for the observation and detection of both structural and functional 
abnormalities that can adversely affect patient outcome. Over time, non-invasive TCD-
based parameters have been applied to standard patient monitoring procedures (i.e. FV, 
Mx) to provide surrogate measures of cerebral autoregulation; increased focus on 
cerebral blood flow velocity waveform analysis has enabled these new derived 
parameters to be modified to better approximate their invasive counterparts. The 
expansion of non-invasive neuromonitoring outside of a strict neurocritical care setting 
has immense potential for outcome prediction in general intensive care management; 
these measurement techniques create more holistic patient profiles without any added 
risks.  
 
7.2. Summary of Main Results 
This thesis examined the clinical applications of available neuromonitoring techniques 
in acute brain injury.  
In Chapter 2, the core mechanisms and clinical descriptors of cerebral 
autoregulation were introduced and evaluated in the context of both invasive and non-
invasive neuromonitoring parameters that are used in the prediction of patient 
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mortality following acute brain injury. Chapter 3 outlined methodologies common to 
the work presented in this thesis. 
 In Chapter 4, the clinical indications of elevated intracranial pressure after 
traumatic brain injury were described in several distinct patient populations. The 
direction of ICP management is heavily dependent on ICP measurement accuracy. To 
create the best possible outcomes for patients, “true” ICP should be identified and 
updated continuously to guide treatment options. 
 In Chapter 5, new mathematical models were introduced that describe pulsatile 
cerebral hemodynamics in terms of cerebrovascular resistance and cerebral blood 
volume in both the time and frequency domains. These models are based on TCD 
waveform analysis, and expand the ability of TCD monitoring to provide deeper insight 
into the driving forces behind fluctuations in ICP and CPP that could affect cerebral 
autoregulation and subsequently, outcome.  
 In Chapter 6, non-invasive neuromonitoring techniques such as TCD were 
applied to both create alternatives to invasive monitoring and expand neuromonitoring 
principles to broader patient populations. In a large cohort of TBI patients, TCD-based 
non-invasive estimators of PRx and PAx were found to be robust approximators of PRx 
and PAx, which have been previously demonstrated to correlate with outcome. 
Additionally, TCD monitoring was extended to general intensive care, and was able to 
identify underlying hemodynamic differences between patients who survived versus 
those who did not. 
 
7.2.1. Current Limitations 
 
Several fundamental limitations of all of the clinical research presented in this thesis 
must be addressed prior to the generalization of the results.  
 First, the retrospective patient data for the majority of points evaluated here 
stems from the same large, overlapping clinical monitoring database that is divided into 
subsets to meet the specifications of the comparative study in question. Additionally, 
notes on clinical events or nursing interventions are not consistently present in the 
database, so it is impossible to attribute observable ICP or CPP trends solely to natural 
fluctuations as a result of brain injury rather than to pharmacological or mechanical 
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manipulations that occurred with the aim to treat unstable patients. With respect to the 
prospective data collected from a varied population of general intensive care patients, 
this sample size was much too small to support a universal claim that differences in 
specific cerebral hemodynamic parameters predicate the risk of mortality.  
 Second, TCD monitoring is still largely considered to be a “research tool”, and is 
treated as an accessory to standard patient care management. As a result, continuous 
FV recordings are unavailable, as any TCD monitoring session must be planned in 
advance at the discretion of bedside nursing staff and the availability of dedicated 
research teams to operate the device for data collection and interpretation. TCD 
recordings are intermittent at best, and not every patient within this “Cambridge 
database” was able to receive TCD monitoring. Although it is presumed that all of the 
TCD-based parameters introduced in this thesis are equally sensitive and specific to 
outcome prediction following acute brain injury, it is difficult to generalize the main 
results of this thesis to all patients.  
 Finally, several important monitored variables that could significantly affect 
neuromonitoring indices have not been considered within the scope of this thesis (i.e. 
brain tissue oxygenation, mechanical ventilation, and microdialysis). The interaction of 
these variables with TCD-based parameters and cerebral autoregulation has not been 
evaluated, although these relationships could inform the further development of 
outcome-predictive modeling.  
 
 
7.3.  Research Outlook 
7.3.1. Non-Invasive Markers of Autoregulation and  
   Individualized Treatment Targets 
 
The advancement of non-invasive approximation of “traditional” invasive estimators of 
cerebral autoregulation (i.e. nPRx and PRx, or nICP and ICP) offers the potential to 
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expand neuromonitoring both within and outside of neurocritical care. As these 
parameters can be calculated on the basis of non-invasive TCD waveform analysis, the 
incorporation of TCD into broader hospital settings poses no further risk of infection or 
discomfort to patients, and can quickly provide key information about cerebral 
hemodynamics in real time. If TCD monitoring can be extended to more patients on a 
more regular basis, real-time TCD data could potentially detect and track the evolution 
of hemodynamic or structural asymmetry. Longitudinal FV observation (and that of 
TCD-derived parameters) could then be revisited to inform and individualize patient 
care plans, rather than make assumptions about prognostication on the basis of research 
trends.  
 
7.3.2.  Multi-Modal Monitoring  
 The presentation of preliminary results from the “Triple-M” trial introduced the 
concept of TCD monitoring into a more mainstream care environment. Joint 
consideration of cerebral electrical and circulatory activity is presumed to provide more 
thorough insight into brain health than isolated monitoring modalities. Although not 
evaluated in the scope of this thesis, the comparative analysis of other non-invasive 
neuromonitoring modalities in general intensive care, such as routine EEG and near-
infrared spectroscopy (NIRS) with TCD-based estimators of cerebral autoregulation are 
of great interest to future studies of outcome prediction. 
Appendix A – Non-Linear Regression Between CPP and PI (Plateau Waves) 185 
 
 
Appendix A 
 
Non-Linear Regression Between CPP and PI for 
Individual Patients with Plateau Waves 
 
*Note:   
x-axis = CPP measured in mm Hg 
y-axis = PI (F1/FV); no unit 
 
Coefficients of Determination: 
 
P1 = 0.93 P2 = 0.94 
 P3 = 0.75 P4 = 0.81 
P5 = 0.97 P6 = 0.80 
P7 = 0.87 P8 = 0.92 
P9 = 0.83 P10 = 0.89 
P11 = 0.84 P12 = 0.73 
P13 = 0.56 P14 = 0.92 
P15 = 0.94 P16 = 0.98 
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Appendix B 
 
Non-Linear Regression Between CPP and PI for 
Individual Patients with Unstable MAP 
 
 
*Note:  x-axis = CPP measured in mm Hg, y-axis = PI (F1/FV); no unit 
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Appendix C  
 
Spectral Models of Cerebral Blood Volume Estimation 
 
 
 
 
 
 
 
 
 
 
 
 
 
where: Amp CBFVa represents the fundamental amplitude of cerebral blood flow 
velocity (F1), AmpABP – the fundamental amplitude of AMP (A1), AmpCPP – the 
fundamental amplitude of CPP, AmpCBFVa – the fundamental amplitude of FV, 
AmpICP – the fundamental amplitude of ICP, CVR – the cerebrovascular resistance, HR 
– the heart rate, and ICP – intracranial pressure.  
 
 
 
 
 
𝐴𝑚𝑝𝐶𝑎𝐵𝑉𝑃𝐹𝐹𝐴𝐵𝑃 =
(𝐴𝑚𝑝𝐶𝐵𝐹𝑉𝑎 − (
𝐴𝑚𝑝𝐴𝐵𝑃
𝐶𝑉𝑅 ))
2𝜋 ×  𝐻𝑅
 
            [8] 
             𝐴𝑚𝑝𝐶𝑎𝐵𝑉𝑃𝐹𝐹𝐶𝑃𝑃 =
(𝐴𝑚𝑝𝐶𝐵𝐹𝑉𝑎 − (
𝐴𝑚𝑝𝐴𝐵𝑃 − 𝐴𝑚𝑝𝐼𝐶𝑃
𝐶𝑉𝑅 ))
2𝜋 ×  𝐻𝑅
 
 
        [9] 
 
where: AmpCBFVa represents the fundamental amplitude of cerebral blood flow velocity (F1), AmpABP – 
the fundamental amplitude of ABP (A1), AmpCPP – the fundamental amplitude of CPP, AmpCBFVa – the 
fundamental amplitude of FV, AmpICP – the fundamental amplitude of ICP, CVR – the cerebrovascular 
resistance, HR – the heart rate, and ICP – intracranial pressure. 
[5.10] 
 
 [5.11] 
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Resistors    Capacitors 
 
Ra1 = 
𝐴𝐵𝑃𝑚
𝐹𝑉𝑚
     C1 =   
𝐴𝑚𝑝𝐶𝐴𝐵𝑉𝐶𝐹𝐹
𝐴𝑚𝑝𝐴𝐵𝑃
 
Ra2 = 
𝐴1
𝐹1
    C2 =  
𝐴𝑚𝑝𝐶𝐴𝐵𝑉𝑃𝐹𝐹𝐴𝐵𝑃
𝐴𝑚𝑝𝐴𝐵𝑃
 
Ra3 = 
𝐶𝑃𝑃𝑚
𝐹𝑉𝑚
    C3 =  
𝐴𝑚𝑝𝐶𝐴𝐵𝑉𝑃𝐹𝐹𝐶𝑃𝑃
𝐴𝑚𝑝𝐴𝐵𝑃
 
     
                     [5.12] 
 
 
where: ABPm, CPPm, and FVm each represent the mean value of the respective parameter, 
A1 the fundamental harmonic of ABP, and F1 the fundamental amplitude of the FV 
waveform. 
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where: ABPm, CPPm, and FVm each represent the mean value of the respective parameter, 
A1 the fundamental harmonic of ABP, F1 the fundamental amplitude of the FV waveform, 
CABV1-3S the time-averaged mean values of each CaBV estimation method resolved into 
the spectral domain, and HrHz the fundamental frequency of FV.  
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